Document:

EX-10.13

 Exhibit 10.13 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

LICENSE AGREEMENT 
 This License
Agreement (“Agreement”) is made this 31st day of December, 2006 (the “Effective Date”), by and between Materia, Inc., a Delaware corporation, with a principal
place of business at 60 North San Gabriel Boulevard, Pasadena, California 91107, USA (“Materia”), and Renegade Therapeutics, Inc., with a principal place of business at One Broadway,
14th Floor, Cambridge, Massachusetts, 02142 (“Renegade”). 

Recitals 
 WHEREAS, Materia owns
and has other rights in Materia Technology (as defined below) relating to compositions and uses of certain Catalysts (as defined below) and desires to enable pharmaceutical researchers such as Renegade to carry out research and development,
manufacturing, and commercialization related to pharmaceutically active products using the Catalysts and the Materia Technology; and 
 WHEREAS, by this
Agreement, Renegade desires to obtain a license to the Catalysts and the Materia Technology, all as more specifically set forth herein in accordance with all of the terms of this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and for other consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties agree as follows: 
 ARTICLE I 

DEFINITIONS 
 The following
capitalized terms used in this Agreement shall have the respective meanings ascribed to them below in this Article unless otherwise expressly defined in this Agreement: 

1.1 “Affiliate” shall mean, with respect to a party to this Agreement, any person or entity which now or in the future
is directly or indirectly controlling or controlled by or in common control with such party, where “control” is defined as the ownership of at least fifty percent (50%) of the equity or beneficial interests of such entity, or the
right to vote for or appoint a majority of the board of directors or other governing body of such entity. 
 1.2
“Catalysts” shall mean those olefin metathesis catalyst compositions owned or controlled by Materia during the License Term as further described in the Materia Patent Rights. 

1.3 “Confidential Information” shall have the meaning given to this term in Article 6.1. 

1.4 “Field” shall mean the prevention, diagnosis, treatment or control of any human or animal disease, disorder or
condition. 
 1.5 “Field Inventions” shall mean all inventions, improvements and/or discoveries, patentable
or unpatentable, which are conceived and/or made by Renegade during the License Term that relate primarily to the Field, and which either (a) use or incorporate any Materia Catalyst 

  
 1 

 
or Materia Patent Right or (b) are dominated by the claims of the Materia Patent Rights. By way of example, Field Inventions would include pharmaceutically active compositions, or specific
processes to make pharmaceutically active compositions. 
 1.6 “Know-How” shall mean all confidential information
and data owned or controlled by Materia and disclosed to Renegade pursuant to this Agreement, including, without limitation, instructions, processes, procedures, formulas, drawings, technical and non-technical data, biological materials, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data. 

1.7 “License Term” shall have the meaning given to this term in Article 7.1. 

1.8 “Materia Patent Rights” shall mean issued patents owned or controlled by Materia during the License Term that
claim Catalysts and/or olefin metathesis processes utilizing Catalysts, including any and all corresponding domestic or foreign equivalents within the Territory, continuations, divisionals, continuations-in-part, re-issues, and substitution
applications related to the foregoing. Materia Patent Rights as of the Effective Date are set forth on Exhibit A. Materia Patent Rights expressly excludes any specific compositions or products which are not Catalysts that have been developed or will
be developed by Materia. 
 1.9 “Materia Technology” shall mean the Materia Patent Rights and the Know-How
related thereto but expressly excludes compositions or products which are not Catalysts and which are now or will become owned or controlled by Materia. 

1.10 “Net Sales” shall mean the gross amount billed for the sale of Products covered by a Valid Claim to a Third
Party, less (a) applicable taxes (e.g. sales, excise, or use taxes) incurred to the extent stated on the invoice as a separate item; (b) separately stated charges for transportation or customs clearance; (c) credits for defective or
returned royalty bearing Products, to the extent actually allowed; and (d) discounts, rebates, refunds, marketing allowance or other promotional fees identified on the invoice. Transfer of a Product to a Sublicensee for sale by the Sublicensee
shall not be considered a sale. In the case of such a transfer, the Net Sales price shall be based on the gross billing price of the Product by the Sublicensee as invoiced to its customer, less items (a) through (d) above. In the case of
any other arms length sale or other disposal for value other than exclusively for money, such as barter or counter trade, Net Sales shall be calculated as above on the fair market value of the consideration received. In the case of any sale or other
disposal for value that is not an arms length transaction, Net Sales shall be calculated at the fair market value of the Product as sold in the relevant country of sale or disposal. Product provided at or below cost for bona fide clinical trials,
evaluation, research or development purposes shall not be considered a sale or other disposal for value for purposes of this definition. 

1.11 “Product” shall mean a conformationally-restricted peptide made using ring-closing metathesis. 

1.12 “Renegade Patent Rights” shall mean patents and patent applications owned by Renegade during the License Term
claiming any Field Inventions or Technology Inventions, including any and all corresponding domestic or foreign equivalents within the Territory, continuations, divisionals, continuations-in-part, re-issues, and substitution applications related to
 

  
 2 

 
the foregoing. Renegade Patent Rights expressly excludes any specific compositions, or uses thereof, that are not Catalysts, as well as any methods or processes that do not utilize olefin
metathesis, that have been developed or will be developed by Renegade. 
 1.13 “Sublicensee” shall mean any Third
Party licensed by Renegade pursuant to Section 2.2 to make or sell any Product. 
 1.14 “Technology
Inventions” shall mean all inventions, improvements, and/or discoveries patentable or unpatentable, which are conceived and/or made by Renegade during the License Term that relate primarily and generally to the Materia Patent Rights and not
the Field, and which either (a) use or incorporate any Materia Catalyst or Materia Patent Right or (b) are dominated by the claims of the Materia Patent Rights. By way of example, Technology Inventions would include generic processes to
make a wide variety of compositions. 
 1.15 “Territory” shall mean worldwide. 

1.16 “Third Party” shall mean any entity other than (a) Materia and any of its Affiliates and successors in
interest and assigns or (b) Renegade and any of its Affiliates and successors in interest and assigns. 
 1.17
“United States Dollar” and “USD” will mean the lawful currency of the United States of America. 

1.18 “Universities” shall mean those entities, including Boston College and the California Institute of Technology,
that have licensed certain rights identified on Exhibit A, or that in the future may license such rights to Materia, that are sublicensed hereunder to Renegade. 

1.19 “Valid Claim” shall mean a claim contained in an issued and unexpired patent included within the Materia Patent
Rights which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been rendered
unenforceable through abandonment, reissue, disclaimer or otherwise, and which has not been lost through an interference proceeding. 

ARTICLE II 
 LICENSE
GRANT AND LIMITATIONS 
 2.1 License. Upon payment of the Technology Access Fee set forth in Article 3.1, and upon the terms
and conditions set forth herein, Materia hereby grants to Renegade and Renegade hereby accepts, a non-exclusive license, with the right to authorize and grant sublicenses, under Materia Technology to develop, make, have made, use, sell, offer for
sale, import and export Products in the Territory and in the Field. The foregoing license specifically excludes the manufacture of Catalysts. 

2.2 Sublicenses. Renegade shall provide Materia copies of all agreements (with royalty and other economic terms redacted) with
Sublicensees (“Sublicense Agreements”) within [**] days after execution of such Sublicense Agreements. Such Sublicense Agreements shall only convey the rights to Product(s) that are covered by patent or other intellectual property rights

  
 3 

 
owned or controlled by Renegade, and expressly excludes any naked sublicense of Materia Technology (i.e., the sublicensing of the right to develop Product(s) not covered by Renegade intellectual
property rights). Renegade shall remain responsible for all acts and omissions by any Sublicensee as if they were acts or omissions of Renegade. In the event that this Agreement is terminated, each Sublicense Agreement shall survive, provided that
(i) Materia received a copy of the Sublicense Agreement as provided above, (ii) the Sublicensee is not in breach of its obligations under such Sublicense Agreement as of the date of such termination, and (iii) the Sublicensee agrees
to be bound by all the obligations of Renegade set forth herein. 
 2.3 Rights Sublicensed from Universities. In the event of the
termination of a license agreement between a University and Materia under which Materia obtained certain rights in the Materia Patent Rights (“University Agreement”), the rights and obligations of Renegade under this Agreement derived from
the rights granted Materia under such University Agreement shall remain in effect, and Materia shall undertake the obligations set forth in Section 8.3(vii) to ensure the same. Renegade will assume no obligations of Materia under the University
Agreements other than Renegade’s obligations to Materia under this Agreement as modified in accordance with this Section 2.3. Notwithstanding the foregoing, Renegade acknowledges that certain of the University Agreements may condition the
survival of sublicenses granted by Materia thereunder upon a sublicensee’s obligation to use commercially reasonable efforts to commercialize the Materia Technology licensed under such University Agreements. Further, Renegade acknowledges that
a University shall not assume any obligations under this Agreement beyond the scope of its obligations to Materia under its respective University Agreement, and without limiting the foregoing, such University shall not assume any supply obligations
of Materia under this Agreement. 
 2.4 No Implied License. Except for the license expressly set forth in this Article 2, Materia
retains all right, title and interest in and to the Materia Technology. 
 2.5 Acknowledgement. Except for those rights expressly
granted herein, Renegade acknowledges and agrees that it has no other rights under the Materia Technology. 
 ARTICLE III 

LICENSE FEES 
 3.1
Technology Access Fee. In consideration for the technology access rights provided to Renegade hereunder, within [**] days of the Effective Date, Renegade shall pay Materia the sum of [**] dollars ($[**] USD) (the “Technology Access
Fee”) Failure to pay the Technology Access Fee within such [**] day period will result in the immediate termination of the Agreement. In addition, Renegade shall pay $50,000 to Materia on each anniversary of the Effective Date of the
Agreement (“Renewal Fee”). Such payments shall be non-refundable. 
 3.2 Milestone Payments. Renegade shall make the
following payments to Materia in respect of each Product that achieves a Milestone set forth below; provided, that no Milestone shall be owing for any Product as to which there is no Valid Claim in the applicable country covering the use,
manufacture, sale or importation of such Product at the time of achieving such Milestone. If one or more Products having the same active pharmaceutical ingredient are substituted by 

  
 4 

 
Renegade for another Product for the same indication in the Field, then the milestone payments shall be made only for the first Product to achieve such milestones. 

 

					
	 Milestone
	  	Payment	 
	 Acceptance of IND/CTx by Regulatory Authority
	  	$	50,000	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 [**]
	  	 	[**]	  
	 First time annual sales of a Product reach $[**]
	  	 	[**]	  
	 First time annual sales of a Product reach $[**]
	  	 	[**]	  

 3.3 Royalties. Renegade shall make royalty payments to Materia on the Net Sales of Products by Renegade
and its Sublicensees for each calendar year until the expiration of the last-to-expire patent containing a Valid Claim covering the use, manufacture, sale or importation of such Product on a country-by-country basis. Additionally, in the event that
(a) a Product sold by Renegade or its Sublicensees is not covered at the time of sale by a Valid Claim in the country in which it is sold, (b) there is a pending published patent application comprising the Materia Patent Rights that
contains a patent claim covering the use, manufacture, sale or importation of such Product in that country (“Published Claim”), and (c) that Published Claim subsequently issues and becomes a Valid Claim (“Secondary Valid
Claim”, and the issued Secondary Valid Claim is “substantially identical” to the Published Claim at the time of publication (as provided in U.S.C. 35 Section 154(d)), then Renegade and its Sublicensees shall, on a
country-by-country basis, make (a) retroactive royalty payments on the Net Sales of Products covered by such Secondary Valid Claims in that country, and (b) retroactive Milestone payments (as provided in Section 3.2) for Products
covered by such Secondary Valid Claims, in each case as to those Net Sales and Milestones for such Product that were achieved on or after the first publication date of the Secondary Valid Claim, and to the solely to the extent such royalty payments
or Milestone payments were not previously paid with respect to such Products. The percentage royalty rate will be calculated based on the total Net Sales by Renegade and its Sublicensees made in each calendar year. The royalty rate applied shall be
in accordance with the following schedule. 
  

					
	 Annual Net Sales Volume in Territory Per Product
	  	Rate	 
	 Up to $[**]
	  	 	[**]	  
	 Greater than $[**] to $[**]
	  	 	[**]	  
	 Greater than $[**] to $[**]
	  	 	[**]	  
	 Greater than $[**]
	  	 	[**]	  

 3.4 Anti-stacking. Renegade shall be responsible for the payment of any additional payments payable to
Third Parties; provided however, that Renegade shall be entitled to credit against the royalties otherwise due to Materia up to [**]% of the royalties paid by Renegade under agreements entered into with Third Parties owning or
controlling patent rights, which but for such agreements would be infringed by the import, use, sale, or offer to sell Products in the Territory. In no event shall the cost of such additional Third-Party patent licenses result in royalties to

  
 5 

 
Materia being reduced by more than [**]% as a maximum deduction, i.e. the minimum royalty rates payable shall be as shown in the following schedule. 

 

					
	 Annual Net Sales Volume in Territory Per Product
	  	Rate	 
	 Up to $[**]
	  	 	[**]	  
	 Greater than $[**] to $[**]
	  	 	[**]	  
	 Greater than $[**] to $[**]
	  	 	[**]	  
	 Greater than $[**]
	  	 	[**]	  

 3.5 United States Dollars. All payments due hereunder will be considered to have been made in Pasadena,
California, and will be made in United States Dollars. Renegade will make all such payments according to the payment instructions specified in Article 3.6. No deductions will be made from the amounts due hereunder due to currency conversion fees.
For purposes of determining the amount of royalties due from Renegade, the amount of Net Sales in any foreign currency shall be computed by converting such amount into United States Dollars at the prevailing commercial rate of exchange for
purchasing dollars with such foreign currency as reported in The Wall Street Journal on the last business day of the calendar quarter to which a royalty payment relates. 

3.6 Payment Instructions. Payment hereunder shall be made to Materia, Inc. in immediately available funds delivered by wire transfer to
Materia’s account, ABA No. [**], Account No. [**] at [**], USA (customer service telephone number [**]. Payments for Catalysts shall be due [**] days after receipt of invoice. 

3.7 Payment Dates and Reports. The royalty payments shall be paid by Renegade and Sublicensees on Net Sales within [**] days after the
end of each calendar year in which such Net Sales are made and royalties are owed hereunder. Such payments shall be accompanied by a report showing, for each country in which Products are sold, (i) the number of Products sold by Renegade and/or
its Sublicesensees, (ii) the gross price charged by Renegade and/or it Sublicensees, (iii) the calculation of Net Sales of each Product sold by Renegade and/or its Sublicensees, including a listing of applicable deductions, (iv) the
applicable royalty rate for such Product and (v) a calculation of the total royalty payment due for such calendar year. At Materia’s request, Renegade shall provide to Materia an officer’s certificate certifying that such reports are
true and accurate. 
 3.8 Withholding Taxes. Any tax which Renegade is required to pay or withhold with respect to royalty payments
to be made to Materia under this Agreement shall be deducted from the amount otherwise due; provided, that, in regard to any such deduction, Renegade shall give Materia such assistance as may reasonably be necessary to enable or assist Materia to
claim exemption therefrom or a reduction thereof and shall upon request provide documentation from time to time as to confirm the payment of the tax. 

3.9 Records. Renegade and its Sublicensees shall keep for [**] years from the date of each payment of royalties complete and accurate
records of sales by Renegade and its Sublicensees of each Product, in sufficient detail to allow the accruing royalties to be determined accurately. Materia shall have the right for a period of [**] years after receiving any report or statement with
respect to royalties due and payable to appoint at its expense an independent 

  
 6 

 
certified public accountant reasonably acceptable to Renegade (and any Sublicensee that will be audited) to inspect the relevant records of Renegade and its Sublicensees to verify such report or
statement. Prior to any such review, the accountant shall execute a confidentiality agreement reasonably acceptable to Renegade and any Sublicensee that will be audited. Renegade and its Sublicensees shall each make its records available for
inspection by such independent certified public accountant during regular business hours at such place or places where such records are customarily kept, upon reasonable notice from Materia, solely to verify the accuracy of the reports and payments.
Such inspection right shall not be exercised more than [**] nor more than [**] with respect to sales of any Product in any given period. The accountant shall agree to hold in strict confidence all information concerning royalty payments and reports,
and all information learned in the course of any audit or inspection, and shall only reveal to Materia the amount of any underpayment or overpayment of royalties. The results of each inspection, if any, shall be binding on both parties. Materia
shall pay for such inspections, except that in the event there is any underpayment of royalties by Renegade for the period audited shown by such inspection of more than [**] percent ([**]%) of the amount paid, Renegade shall pay for such inspection.
Materia shall only be entitled to audit a particular royalty period [**]. 
 3.10 Overdue Royalties. Royalties not paid within the
time period set forth in Section 3.7 shall bear interest at a rate of [**] percent ([**]%) per month from the due date until paid in full. In the event that Materia disputes the amount of royalties payable for any calendar year, Materia shall
provide written notice of such dispute to Renegade and within [**] days after receipt of such notice, the parties shall submit the dispute for resolution pursuant to Section 10.16. Failure to pay any accrued royalties and interest within [**]
days after a resolution in favor of Materia shall constitute a breach of this Agreement. 
 ARTICLE IV 

CATALYST SUPPLY; TECHNICAL SUPPORT AND QUALITY CONTROL 

4.1 Catalyst Supply. During the License Term, Materia shall supply Renegade with Catalysts at the prices set forth in Exhibit B.
Renegade shall purchase all of its Catalyst requirements from Materia, unless Materia is unable or unwilling to deliver such Catalysts to Renegade as follows: (a) for Orders of [**] or less: the entire Order by [**] days after the required
delivery date and (b) for Orders of more than [**] but not more than [**]: at least [**] of the Order by [**] days after the required delivery date and the remaining portion of the Order by [**] days after the original delivery date. Each such
occurrence shall be deemed an “Interruption of Supply”. In the event of an Interruption of Supply, Renegade shall be free to procure such Catalysts from Third Parties until such time as Materia can reasonably demonstrate that it has solved
the cause of such Interruption of Supply and so notifies Renegade in writing. Shipping terms are FCA (Incoterms 2000) Renegade’s designated carrier at Materia’s plant. The prices set forth in Exhibit B are subject to change [**] or as
otherwise required due to unexpected changes in Materia’s raw material or other costs. Notwithstanding the foregoing, Materia agrees to provide Catalysts under this Section 4.1 at prices no higher than its standard prices, and on its then-standard terms and conditions. 
 4.2 Forecast and Lead Times. On a quarterly basis, Renegade
shall provide Materia with non-binding rolling [**] month forecasts of the quantities of Catalysts Renegade reasonably and in good faith believes it will require during such period. With respect to the Catalysts listed

  
 7 

 
on Exhibit B (the “Listed Catalysts”), Renegade shall provide Materia with purchase orders of the quantities of Listed Catalysts Renegade desires to purchase (the
“Order”). Each Order shall be placed in advance of the required delivery date (the “Lead Time”) for specified as follows, and shall be binding upon Renegade and Materia upon Materia’s acknowledgement of such
Order: 
  

			
	[**]	  	[**] Days
	[**]	  	[**] Days
	[**]	  	[**] Days.

 Lead Times for Catalysts not listed on Exhibit B shall be determined on a case-by-case basis. In the event of a conflict
between the terms of any Order and the terms of this Agreement, the terms of this Agreement shall control. 
 4.3 Commercial Supply
Agreement. In the event that Renegade desires (or notifies Materia that any Sublicensee desires) to enter into a commercial supply agreement for any Catalysts for the manufacture of Products for clinical development or commercial sale purposes,
Materia shall negotiate in good faith the terms and conditions of a separate supply agreement with such party for the supply of Catalysts on commercially reasonable terms (“Commercial Supply Agreement”). Such terms shall include
lead times, forecasts, pricing and price increases, most favored customer pricing (as set forth below), priority of allocation (as set forth below), and the ability to make or have made Catalysts (as set forth below): 

(a) Most Favored Customer Pricing. In the event that Materia supplies Catalysts to any Third Party, for use in the Field, at prices
lower than those offered for such Catalysts to Renegade under the Commercial Supply Agreement for comparable purchase volumes, during comparable time periods and at comparable specifications, Materia will promptly notify Renegade in writing of such
lower pricing, and the Commercial Supply Agreement shall be deemed to be amended effective immediately as of the date of such lower Catalyst pricing, and Materia shall adjust all prices to such lower prices for all future Renegade orders and all
outstanding orders not yet shipped. At Renegade’s request, Materia shall provide to Renegade an officer’s certificate certifying its compliance with the foregoing. 

(b) Priority of Allocation. Materia agrees to give Renegade priority in allocation in the event of any Catalyst scarcity in the
proportion of the Catalyst quantities ordered in Renegade’s purchase orders for scarce Catalysts to the total quantities ordered in all of Materia’s customers’ purchase orders for such Catalysts as of the date of Renegade’s
purchase order. 
 (c) Catalyst Supply. In the event Materia is unable or unwilling to meet the volume or lead times for Catalysts
set forth in the Commercial Supply Agreement, Materia shall grant to Renegade a license under the Materia Patent Rights to make and have made such Catalysts solely for the purpose of Renegade’s and its Sublicensees’ exercise of the license
rights under Section 2.1, provided that Renegade and its Sublicensees shall not have the right to sell such Catalysts to Third Parties (other than Renegade’s provision of such Catalysts to its Sublicensees solely for their exercise
of their sublicense rights under Section 2.2) (“Catalyst Supply License”). The Catalyst Supply License shall be granted upon the execution of the Commercial Supply Agreement, but shall not be exercisable until and unless
Materia is unable or unwilling to meet the volume or lead times for Catalysts set forth in the Commercial Supply Agreement. Such Catalyst 

  
 8 

 
Supply License shall be in effect only until such time as Materia can reasonably demonstrate its ability to deliver such Catalysts to Renegade on the volume and lead times set forth in the
Commercial Supply Agreement and so notifies Renegade in writing. 
 4.4 Acknowledgement. Renegade acknowledges and agrees that
Catalysts offered hereunder may be developmental in nature, may not be listed on the EPA’s TSCA inventory, and may comprise materials whose chemical, physical, and toxicological properties have not been fully determined. 

4.5 Technical Support. During the term of this Agreement, Materia shall (a) provide Renegade with reasonable amounts of telephone
or e-mail technical support by Materia personnel regarding the Materia Technology, (b) invite Renegade to attend, at its own expense, but free of charge, an annual Materia Technology update meeting at Materia’s offices, and (c) send a
Materia technical representative to each Renegade site for [**] to present technology updates and/or otherwise provide technical support. 

ARTICLE V 

INTELLECTUAL PROPERTY 

5.1 Patent Prosecution. Materia retains all rights to control the preparation, filing, prosecution and maintenance (including
conducting interferences, re-examinations, reissues, oppositions and requests for patent term extensions) with respect to the Materia Patent Rights, in the United States and such other countries where Materia deems patent protection would be
beneficial or appropriate at its sole expense. Nothing contained in this Agreement, however, shall be construed as an obligation upon Materia to prepare, file, prosecute, or maintain any patent, patent application, or any other intellectual property
right. 
 5.2 Enforcement. Materia and Renegade each agree to notify the other of any material infringement of the Materia
Patent Rights in the Field that infringe the rights granted to Renegade in Section 2.1 (“Renegade Product Rights”) of which it becomes aware (provided that neither party shall have any affirmative duty to undertake any investigation
to learn of any infringement), and shall confer to discuss in good faith an appropriate course of action to enforce the Renegade Product Rights. Materia shall have the sole right (but not the obligation) to enforce the Renegade Product Rights, or to
defend any declaratory judgment action with respect thereto, at its expense, and any recovery by Materia received as a result of any such claim, suit or proceeding shall be retained by Materia; provided, however, that if Materia does
bring such action, Renegade at its option may elect to join in any such action at Renegade’s expense, and the parties shall agree on a reasonable allocation of any damages recovered pursuant to such action to reflect any lost sales or other
injury to Renegade arising from the infringement of the Renegade Product Rights. Materia agrees that if it grants any license to an alleged infringer of the Renegade Product Rights (a “Settlement License”) on financial terms that,
in their totality, are more favorable than those set forth in Article III of this Agreement, then Materia shall promptly notify Renegade of such financial terms. Upon written notice from Renegade, this Agreement shall be deemed amended by
substituting the same financial terms set forth in the Settlement License for those set forth in Article III of this Agreement. For purposes of clarity, any cross-license in which Materia obtains, and sublicenses to Renegade, a royalty-free license
under all of an alleged infringer’s patents to make, use, sell, offer for sale and import Products shall not be a Settlement License. Nothing  

  
 9 

 
contained in this Agreement shall be construed as an obligation upon Materia to institute any suit or action or to defend any suit or action regarding infringement or validity of the Materia
Patent Rights or any other intellectual property right. 
 5.3 Renegade Inventions. Renegade retains full ownership of the Renegade
Patent Rights. At Renegade’s sole cost and discretion, Renegade may file patent applications and obtain patents comprising the Renegade Patent Rights in the United States or any country throughout the world in which it deems appropriate to
protect its inventions, except that such Renegade Patent Rights shall be subject to the following terms. 
 (a) Field Inventions.
Renegade retains full ownership of the Field Inventions. 
 (b) Technology Inventions. Subject to the license granted to Materia in
this Section 5.3(b), Renegade retains full ownership of the Technology Inventions. In consideration of the rights granted herein and subject to the terms and conditions of this Agreement, Renegade hereby grants to Materia, and Materia hereby
accepts, an irrevocable (except in the event of a termination of this Agreement by Renegade for a breach by Materia), worldwide, fully paid-up, royalty-free, sub-licensable, non-exclusive license under the Renegade Patent Rights to make, have made,
sell, offer to sell, export, import, and use any and all Technology Inventions for any uses outside of the Field. Nothing in this Agreement shall constitute any obligation on Renegade to make any disclosure of Technology Inventions to Materia or any
Materia sublicensee. Notwithstanding the foregoing, in the event that Renegade elects to file a patent application on a Technology Invention, Renegade shall provide Materia with notice of such filing within [**] days after the publication date of
such filing. 
 (c) Patent Prosecution. Renegade retains all rights to control the preparation, filing, prosecution and maintenance
(including conducting interferences, re-examinations, reissues, oppositions and requests for patent term extensions) with respect to the Renegade Patent Rights, in the United States and such other countries where Renegade deems patent protection
would be beneficial or appropriate at its sole expense. Nothing contained in this Agreement, however, shall be construed as an obligation upon Renegade to prepare, file, prosecute, or maintain any patent, patent application, or any other
intellectual property right. 
 (d) Enforcement. Renegade shall have the right (but not the obligation) to enforce the Renegade
Patent Rights, or to defend any declaratory judgment action with respect thereto, at its expense. Any recovery by Renegade received as a result of any such claim, suit or proceeding shall be retained by Renegade. Nothing contained in this Agreement
shall be construed as an obligation upon Renegade to institute any suit or action or to defend any suit or action regarding infringement or validity of the Renegade Patent Rights or any other intellectual property right. 

ARTICLE VI 

CONFIDENTIALITY 

6.1 Confidential Information. The parties acknowledge that it may be necessary for one party to disclose to the other party certain
confidential or proprietary information in connection with the performance of this Agreement (the “Confidential Information”). Such 

  
 10 

 
Confidential Information includes: (i) the technical information of a party (including any information relating to product plans, designs, product names, research, development, Know-How, and
other information of a proprietary or confidential nature) which is disclosed hereunder and designated by the disclosing party as “confidential” or “proprietary” or which, if disclosed orally, is identified as confidential at the
time of the disclosure and confirmed in a writing delivered to the receiving party within [**] days of the date of disclosure; and (ii) the terms and conditions of this Agreement. 

6.2 Exclusions. Confidential Information shall not include information that: (i) is now in the public domain or which becomes
generally available to the public through no fault of, or facilitating action by, the receiving party; (ii) is already known to, or in the possession of, the receiving party prior to disclosure by the disclosing party as can be demonstrated by
documentary evidence; (iii) is disclosed on a non-confidential basis from a Third Party having the right to make such a disclosure; or (iv) is independently developed by the receiving party without the use of or reference to the disclosing
party’s Confidential Information, as can be demonstrated by documentary evidence. 
 6.3 Confidentiality Obligations. Each party
agrees to take all measures reasonably required in order to maintain the confidentiality of all Confidential Information in its possession or control, which will in no event be less than the measures used to maintain the confidentiality of its own
information of equal importance from the date of disclosure until [**] years after the termination or expiration of this Agreement. It is understood and agreed that a receiving party may only use Confidential Information received from a disclosing
party solely as permitted under this Agreement, or otherwise as mutually agreed upon by the parties in writing. The receiving party will not disclose the Confidential Information of the disclosing party to any Third Party, except that the receiving
party may disclose the Confidential Information of the disclosing party to its employees, consultants, existing and prospective Sublicensees and agents who have a need-to-know to use the Confidential Information as permitted under this Agreement and
who have entered into a written agreement with the receiving party containing provisions at least as protective of the disclosing party’s Confidential Information as those set forth herein. 

6.4 Permitted Disclosures. Notwithstanding the foregoing, Confidential Information may be disclosed under the following circumstances:

 (a) The parties may disclose Confidential Information of the other party in the course of complying with applicable governmental
regulations or submitting information to tax or other governmental authorities, provided that if a party is required to make any such disclosure of the other party’s Confidential Information, to the extent it may legally do so, it will give
reasonable advance notice to the other party of such disclosure in order to allow the other party an opportunity to secure confidential treatment of its Confidential Information prior to its disclosure; 

(b) Each party may disclose the existence of this Agreement, a summary of the rights granted hereunder and certain terms and conditions of the
Agreement as follows: 
 (i) any reasonably relevant portions of the Agreement may be disclosed to actual Sublicensees as well as to actual
and potential investors attorneys, financial advisors, accountants, employees, and contractors who are bound by written agreements with the receiving party containing provisions at least as protective of the disclosing party’s Confidential
Information as those set forth herein; 

  
 11 

 (ii) the royalty rates set forth in the Agreement and any reasonably relevant non-economic
portions of the Agreement may be disclosed to potential Sublicensees who are bound by written agreements with the receiving party containing provisions at least as protective of the disclosing party’s Confidential Information as those set forth
herein. 
 (c) Either party may disclose the terms and conditions of this Agreement to the Universities. 

6.5 Injunctive Relief. The receiving party acknowledges that the disclosure of the disclosing party’s Confidential Information may
cause substantial and irreparable harm to the disclosing party that cannot be remedied by the payment of damages alone. Accordingly, the parties agree that a disclosing party may be entitled to seek preliminary and permanent injunctive relief and
other equitable relief for any material breach of this Article VI. 
 ARTICLE VII 

TERM AND TERMINATION 

7.1 Term. The Agreement shall remain in effect until the expiration of Renegade’s obligation to pay royalties in the
Territory (the “License Term”), unless earlier terminated under Article 7.2 of this Agreement. Upon any expiration of this Agreement, Renegade’s license under Materia Know-how shall become irrevocable, perpetual and
royalty-free. 
 7.2 Termination for Cause. Except for any failure to pay the Technology Access Fee as set forth in
Section 3.1, if either party breaches any material provision of this Agreement, the other party may give written notice to the breaching party. If the default is not cured within [**] days of the date of such notice, the non-defaulting party
shall have the right to terminate this Agreement, unless on or before such date the party in default is diligently undertaking substantive and progressive efforts to cure such breach and such breach is in fact cured as soon as reasonably possible,
but no later than [**] days after the expiration of such [**] day period. In the event that either party should dispute in good faith the existence of an alleged material breach under this Section 7.2, such dispute shall be resolved pursuant to
Section 10.16, provided that, such dispute resolution process must be initiated within the initial [**] day cure period, and further provided that, in the event of such disputed material breach, the initial [**] day cure period shall be tolled
and thereafter shall not commence until the existence of such material breach is finally determined in accordance with Section 10.16. Additionally and subject to the foregoing, in the event that Materia materially breaches the Agreement and
fails to cure such default within the cure period (a “Materia Breach”), (a) Renegade shall be entitled to terminate the Catalyst Supply portion of this Agreement (Sections 4.1), (b) Materia hereby grants to Renegade a
royalty-bearing license (which royalties shall be limited to the pass-through royalties that Materia would owe under the applicable University Agreements from Renegade’s exercise of its rights herein) under the Materia Patent Rights,
exercisable only in the event of such Materia Breach, to make and have made any Catalysts solely for the purpose of Renegade’s and its Sublicensees’ exercise of the license rights under Section 2.1, provided that Renegade and
its Sublicensees shall not have the right to sell such Catalysts to Third Parties (other than Renegade’s provision of such Catalysts to its Sublicensees 

  
 12 

 
solely for their exercise of their sublicense rights under Section 2.2), and (c) Renegade’s license grant under Section 2.1 shall continue, provided that, Renegade continues
to pay the annual Renewal Fee. Failure to pay such Renewal Fee shall be a material breach by Renegade and Materia may terminate the license pursuant to this Article 7.2. 

7.3 Termination by Renegade for Convenience. Renegade may terminate this Agreement at any time, with or without cause, upon at least
sixty (60) days’ prior written notice to Materia. 
 7.4 Effect of Breach or Termination. Upon any termination of this
Agreement by Materia pursuant to Section 7.2, all licenses and sublicenses granted by Materia to Renegade hereunder shall immediately terminate. Termination of this Agreement for any reason shall not release any party hereto from any liability
which, at the time of such termination, has already accrued to such party or which is attributable to a period prior to such termination, nor shall it preclude either party from pursuing all rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement. 
 7.5 Survival. All indemnification obligations set forth in this Agreement,
and all terms and provisions hereof intended to be observed and performed by the parties after the termination hereof shall survive such termination and continue thereafter in full force and effect, subject to applicable statute of limitations. Upon
any termination, Sections 2.2, 2.4, 2.5, 3.9, Article V, Article VI, Sections 7.2, 7.4, 7.5, Article IX, and Article X shall survive such termination. 

ARTICLE VIII 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations by Materia. Materia represents and warrants to Renegade that Materia has the right and authority to enter into this
Agreement and to perform its other obligations herein. Materia hereby represents, warrants and covenants that, (i) as of the Effective Date, Materia has the right to grant the licenses granted to Renegade hereunder; (ii) as of the
Effective Date, Materia has not granted, and shall not during the term of this Agreement grant, any right, license, covenant, consent or privilege to any Third Party or Affiliate with respect to the Materia Technology or otherwise undertake any
action which would conflict in any respect with the rights granted to Renegade set forth in this Agreement; (iii) except as indicated in Exhibit A, no Third Party has made any claim or allegation to Materia, and Materia is not aware of any
claim by a Third Party or Affiliate, that such Third Party or Affiliate has any right or interest in or to the Materia Technology or that any of the Materia Patent Rights are invalid or unenforceable; and (iv) except as indicated in Exhibit A,
to the best of its knowledge the Materia Patent Rights are valid and enforceable, and have not been misused. 
 8.2 Representations by
Renegade. Renegade represents and warrants to Materia that (i) Renegade has the right and authority to enter into this Agreement and to perform its other obligations herein and (ii) during the License Term Renegade shall not
disassemble, decompile, reengineer, reverse engineer, translate or otherwise attempt to replicate any Catalyst compositions covered by any Valid Claim. 

  
 13 

 8.3 Representations regarding University Agreements. Materia represents and warrants that:

 (i) none of the University Agreements has, as of the Effective Date, been terminated by either Materia or the respective University;

 (ii) Materia has not, as of the Effective Date, received nor given notice of termination for breach of a University Agreement; 

(iii) Materia is not currently in default or breach of any University Agreement; 

(iv) Materia will use commercially reasonable efforts to maintain the University Agreements and the exclusive and nonexclusive licenses
granted to Materia therein in full force and effect, which shall include, without limitation, (a) complying with its obligations to pay the royalties and other amounts owed each University pursuant to a University Agreement, and complying with
all due diligence and commercialization obligations and milestones set forth in the University Agreements, (b) refraining from entering into any modification of or amendment to any University Agreement that would adversely affect the rights
under the Materia Patent Rights granted Renegade hereunder, (c) not knowingly taking any action or making any omission which will cause a University to have the right to terminate a University Agreement pursuant to its terms, and
(d) taking no action to terminate any University Agreement; 
 (v) Materia will notify Renegade in the event it becomes aware of any
claim by a University Materia has breached a University Agreement, or that a University desires to terminate a University Agreement; 

(vi) Materia has the right under the University Agreements to grant to Renegade the rights and licenses granted herein; and 

(vii) should any University Agreement be terminated or rendered non-exclusive by a University, Materia shall take all steps necessary to
preserve Renegade’s sublicense rights under that University Agreement (including executing any required assignments or other documents). 

8.4 WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH HEREIN, MATERIA EXPRESSLY DISCLAIMS ANY WARRANTIES AND REPRESENTATIONS, EXPRESS
OR IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE MATERIA TECHNOLOGY OR THE MATERIA CONFIDENTIAL INFORMATION AND OTHER MATTERS CONTEMPLATED BY THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS
FOR A PARTICULAR PURPOSE, VALIDITY OF TECHNOLOGY, PATENTED OR UNPATENTED, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, MATERIA DOES NOT WARRANT OR GUARANTEE THE OUTCOME
OF ANY RESEARCH ACTIVITY OF RENEGADE BASED ON THE MATERIA TECHNOLOGY, AND MATERIA SHALL HAVE NO OBLIGATION TO PROVIDE ANY SUPPORT OR TECHNICAL ASSISTANCE UNDER THIS AGREEMENT 

  
 14 

 
EXCEPT AS OTHERWISE EXPRESSLY STATED HEREIN. ALL MATERIA TECHNOLOGY IS LICENSED HEREUNDER ON AN “AS IS” BASIS AND EXCEPT AS EXPRESSLY SET FORTH HEREIN, TO THE FULLEST EXTENT PERMITTED
BY LAW, MATERIA WILL HAVE NO LIABILITY FOR ANY LOSS OR DAMAGE RELATING TO OR RESULTING FROM THE MANUFACTURE, USE, SALE OR IMPORTATION OF ANY PRODUCTS BY OR ON BEHALF OF RENEGADE OR ANY SUBLICENSEE. 

ARTICLE IX 
 DAMAGES,
INDEMNIFICATION, AND LIMITATION OF LIABILITY 
 9.1 Responsibilities of Renegade. Renegade assumes all responsibility for,
and hereby agrees to use its reasonable efforts to ensure, the safe use of the Catalysts and the Materia Technology by its employees, agents, contractors, and subcontractors including, but not limited to, compliance and/or qualification with respect
to all safety laws, regulations, and agency approvals and compliance with all safety instructions provided by Materia. Renegade acknowledges that its research is experimental in nature and that Materia cannot know or anticipate Renegade’s
intended uses of the Materia Technology and that Renegade’s use or misuse of the Materia Technology could result in property damage and/or bodily injury, including death. 

9.2 Indemnity. 
 (a) Of
Materia by Renegade. Renegade shall defend, indemnify and hold harmless the Universities, their officers, employees and agents and Materia and Materia’s directors, officers, employees, and Affiliates (and such Affiliates’ directors,
officers, and employees) from and against any liability, losses, damages, claims, costs and expenses (including reasonable fees of attorneys and other professionals and court costs) claimed by a Third Party arising from a product liability,
bodily-injury, or property damage claim, or any other action or cause of action by any Third Party arising from (i) Renegade’s research activities utilizing Materia Technology, or (ii) Renegade’s (or its Affiliates’ or
Sublicensees”) activities related to making, using or selling Products, or otherwise practicing its Field Inventions or Technology Inventions, including, but not limited to, claims of infringement or inducement of infringement by a Third Party
(but not including claims of infringement or inducement of infringement by a Third Party relating to a patent, trade secret, copyright or trademark expressly licensed herein), or (iii) Renegades’ breach of any of its representations and
warranties under Article VIII of this Agreement, in each case except to the extent caused by the gross negligence or willful misconduct of Materia, or Materia’s breach of this Agreement. 

(b) Of Renegade by Materia. Materia shall defend, indemnify and hold harmless Renegade and its Sublicensees, and their respective
directors, officers, employees, and Affiliates (and such Affiliates’ owners, directors, officers, and employees) from and against any liability, losses, damages, claims, costs and expenses (including reasonable fees of attorneys and other
professionals and court costs) claimed by a Third Party arising from (i) Materia’s breach of any of its representations and warranties under Article VIII of this Agreement, or (ii) Materia’s activities related to making, using or
selling products, or otherwise practicing Technology Inventions, including, but not limited to, claims of infringement or inducement of infringement by a Third Party, in each case except to the extent caused by the gross negligence or willful
misconduct of Renegade, or Renegade’s breach of this Agreement. 

  
 15 

 9.3 Procedure. Each party’s indemnification obligations shall be subject to the
following: A party (the “Indemnitee”) that intends to claim indemnification under this Article IX will (a) promptly notify the other party (the “Indemnitor”) in writing of any loss, claim, damage, liability or
action in respect of which the Indemnitee intends to claim indemnification (each, a “Claim”), and (b) the Indemnitor will have the sole right to participate in, assume the defense thereof and settle any such Claim, and (c) the
Indemnitee, its employees and agents will cooperate fully with the Indemnitor and its legal representatives in the investigation of any action, claim or liability covered by this indemnification and provide full information with respect thereto. An
Indemnitee will have the right to retain its own counsel, with the reasonable fees and expenses to be paid by the Indemnitor, if representation of the Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual conflict
of interests between the Indemnitee and any other party represented by the counsel in the proceeding, as mutually agreed upon by the parties in their reasonable discretion. The failure to deliver written notice to the Indemnitor within a reasonable
time after the commencement of any the action, if prejudicial to its ability to defend the action, will relieve the Indemnitor of any liability to the Indemnitee under this Article IX to the extent Indemnitor is prejudiced thereby. 

9.4 LIMITATION ON LIABILITY. EXCEPT FOR THE PARTIES INDEMNITY OBLIGATIONS SET FORTH HEREIN, AND EXCEPT FOR A BREACH OF ARTICLE VI, IN
NO EVENT WILL THE UNIVERSITIES OR EITHER PARTY OR ANY OF ITS AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES, OR OTHER REPRESENTATIVES BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES, OR DAMAGES FOR LOSS OF PROFITS, BUSINESS INTERRUPTION,
LOSS OF GOODWILL, OR OTHERWISE, ARISING FROM OR RELATING TO THIS AGREEMENT, EVEN IF SUCH PARTY IS EXPRESSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING LIMITATIONS SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED BY LAW, EVEN IF A PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. 
 9.5
Insurance. Prior to such time as Renegade begins human clinical trials of Products, Renegade shall at its sole expense, procure and maintain policies of comprehensive general liability insurance (or have a program of self-insurance) in
amounts not less than $[**] per incident and $[**] in annual aggregate. Such comprehensive general liability insurance shall provide: (a) product liability coverage; and (b) broad form contractual liability coverage for Renegade’s
indemnification of those indemnified under Section 9.2. In the event the aforesaid product liability coverage does not provide for occurrence liability, Renegade shall maintain such comprehensive general liability insurance for a reasonable
period of not less than [**] years after it has ceased commercial distribution or use of any Product. In the event that Renegade ceases to have a program of self-insurance, Renegade shall procure and maintain policies of comprehensive general
liability insurance as set forth above and provide documentation of such change in coverage to Materia within fifteen days after such change. Thereafter, Renegade shall provide Materia with at least [**] days advance notice of any cancellation or
material adverse change in policies of comprehensive general liability insurance provided for above. If Renegade does not obtain replacement insurance providing comparable coverage within [**] days of such cancellation, non-renewal or material
adverse change, then Renegade shall be deemed to be in breach of a material provision of this Agreement under Section 7.2, unless Renegade at such time has reinstated a program of self-insurance. 

  
 16 

 ARTICLE X 

GENERAL PROVISIONS 

10.1 Entire Agreement. This Agreement, together with all the schedules hereto, constitutes the entire agreement of the parties with
respect to the subject matter of this Agreement and supersedes all previous proposals or agreements, oral or written, and all negotiations, conversations or discussions heretofore had between the parties related to the subject matter of this
Agreement. 
 10.2 Governing Law. This Agreement will be deemed to have been entered into and governed by and construed in accordance
with the laws of the United States and the State of California, without reference to principles of conflicts of law. 
 10.3
Jurisdiction. Any action or proceeding brought by any party against another party arising out of or related to this Agreement will be brought in a state or federal court of competent jurisdiction located in Los Angeles, California and each
party hereby irrevocably consents to the jurisdiction and venue of these courts. 
 10.4 Waiver, Discharge, etc. This Agreement may
not be changed or modified in any manner, except by an instrument in writing signed on behalf of each of the parties to this Agreement by their duly authorized representatives. The failure of either party to enforce at any time any of the provisions
of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part of it or the right of either party after any such failure to enforce each and every such
provision. No waiver of any breach of or right under this Agreement shall be held to be a waiver of any other or subsequent breach or exercise of such right. 

10.5 Execution in Counterparts. This Agreement may be executed in one or more counterparts, including by facsimile, all of which shall
be considered one and the same agreement, and which shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. 

10.6 Titles and Headings. The titles and headings to the Articles herein are inserted for the convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement. 
 10.7 Benefit. Except as expressly stated
nothing in this Agreement is intended to confer on any person other than the parties to this Agreement or their respective successors or assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement. 

10.8 Notices. All notices required or permitted under this Agreement will be in writing and will be deemed given when:
(a) delivered personally; (b) sent by confirmed telex or facsimile; (c) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one (1) business
day after deposit with a commercial overnight carrier specifying next day delivery, with written verification of receipt. All 

  
 17 

 
communications will be sent to the respective addresses set forth below or to such other address as may be designated by a party by giving written notice to the other party pursuant to this
Article 10.8. 
  

			
	If to Renegade:	  	Renegade Therapeutics, Inc.
		  	One Broadway, 14th Floor
		  	Cambridge, MA 02142
		  	Attn: Chief Executive Officer
		  	FAX: [**]
		
	If to Materia:	  	Materia, Inc.
		  	60 North San Gabriel Boulevard
		  	Pasadena, California 91107
		  	Attn: President
		  	FAX: [**]
		
	with a copy to:	  	Nixon Peabody LLP
		  	Gas Company Tower
		  	555 West Fifth Street, 46th Floor
		  	Los Angeles, CA 90013
		  	Attn: Richard M. Jones, Esq.
		  	FAX: [**]

 10.9 Severability. If any provision of this Agreement is held invalid by a court of competent
jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be deemed amended to narrow its application to the extent necessary
to make the provision enforceable according to applicable law and shall be enforced as amended 
 10.10 Publicity. Neither party will
use the name of the other party in any public statements or advertising involving the subject matter of this Agreement without the prior written approval of the other party. 

10.11 Assignment. The Agreement may not be assigned without the prior written consent of the other party, but no consent will be
required for any assignment to an Affiliate, or in connection with any merger, acquisition, reorganization or transfer of all or substantially all of the stock, assets or business of a party to which the Agreement relates. 

10.12 Relationship of the Parties. Each party is an independent contractor with respect to the other, and is not an agent, partner,
joint venture, or employer of the other. Neither party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, that will be binding on the other party. 

10.13 Construction. This is an agreement between parties who are experienced in sophisticated and complex matters similar to the
license transaction contemplated by this Agreement and is entered into by both parties in reliance upon the economic and legal bargains contained herein and shall be interpreted and construed in a fair and impartial manner without regard to such
factors as the party which prepared this Agreement or the relative bargaining powers of the parties. Materia and Renegade were each represented by legal counsel competent in advising them of their obligations and liabilities hereunder. 

  
 18 

 10.14 No Third Party Beneficiaries. Except as set forth in Article IX, no Third Party
including any employee of any party to this Agreement, shall be a Third Party beneficiary of this Agreement or have or acquire any rights by reason of this Agreement. 

10.15 Bankruptcy. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be,
deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 (35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise
all of their respective rights and elections under the Bankruptcy Code. 
 10.16 Dispute Resolution. (a) Any controversy, claim
or dispute (a “Dispute”) arising out of or in connection with, or relating to, this Agreement, its validity, interpretation, performance, or termination shall be submitted to and finally settled by arbitration by a panel of three
(3) arbitrators conducted in accordance with the Arbitration Rules of the American Arbitration Association in effect at the time of arbitration except as modified by mutual agreement of the parties. Each party shall designate one arbitrator;
the third arbitrator shall be designated by the two arbitrators designated by the parties. Any such arbitration shall take place in Chicago, Illinois. Such arbitration shall be conducted in the English language. Except as required by law, the
subject matter, proceedings, evidence, and award in any arbitration shall be treated as Confidential Information of each party subject to the provisions of Article 6. 

(b) For purposes only of enforcing the agreement to arbitrate set forth in this Section, enforcing any arbitration award, or obtaining interim
relief necessary to protect the parties pending arbitration, each party shall have the right to seek injunctive relief in any state or federal court having jurisdiction. 

(Remainder of page intentionally left blank) 

  
 19 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed in the manner appropriate to
each, to be effective on the Effective Date given above. 
  

									
	RENEGADE THERAPEUTICS, INC.	 		 	MATERIA, INC.
					
	By:	 	 /s/ Joseph A. Yanchik III
	 		 	By:	 	 /s/ Mark S. Trimmer

	Name:	 	 Joseph A. Yanchik III
	 		 	Name:	 	Mark S. Trimmer
	Title:	 	 President
	 		 	Title:	 	Executive VP
				
	Date: 12/22/2006	 		 	Date:	 	12/22/2006

  
 20 

 EXHIBIT A 

MATERIA PATENT RIGHTS 

(LAST UPDATED SEPTEMBER 30, 2006) 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of four pages were omitted. [**]. 

Materia Patents and Patent Applications: 
 [**] 

  
 A-1 

 Exhibit B 

CATALYST PRICING 

(EFFECTIVE THROUGH 12/31/2007) 
  

					
	Catalyst	 	Order Quantity	 	Price/g (USD)

 [**] 
 Other Catalysts can be
purchased from Materia at a cost of $[**] (minimum [**] purchase quantity of each Catalyst). 

  
 B-1 

 EXHIBIT C 

UNIVERSITY AGREEMENTS SPECIFIED IN SECTION 2.3 

  
 C-1 

 CALTECH - MATERIA LICENSE AGREEMENT 

THIS AGREEMENT is effective as of the      day of
            , 2001 (the “Effective Date”), between CALIFORNIA INSTITUTE OF TECHNOLOGY, 1200 East
California Boulevard, Pasadena, California 91125 (“Caltech”) and Materia, Inc., having a principal place of business at 2531 Nina Street, Pasadena, CA 91107 (“Licensee”). 

WHEREAS, Caltech has been engaged in basic research in the field of olefin metathesis chemistry catalyzed by
well-defined metal complexes; and 
 WHEREAS, this Caltech research led to the United States
patents, patent applications and other inventions listed in Exhibit A, in addition to patents that were donated to Caltech and are also listed in Exhibit A, all of which are owned by Caltech; and 

WHEREAS, Caltech has granted certain rights to third parties designated in Exhibit A and described in
Exhibit B; and 
 WHEREAS, Caltech has granted Licensee four Option Agreements ([**], which are
appended as Exhibit C) effective April 7, 2000 to acquire a license to Inventions, Licensed Patents and Technology; and 

WHEREAS, Licensee is desirous of obtaining, and Caltech wishes to grant to Licensee, an exclusive license to the
Licensed Patent Rights (as listed in Exhibit A and defined in Paragraph 1.5) and Improvements thereof in the Field (as defined in Paragraphs 1.2 and 1.11) and a nonexclusive license to the Technology (as defined in Paragraph 1.7). 

  

					
		  	- 1 -	  	

 NOW, THEREFORE, the parties agree as
follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1
“Licensed Product” means any product, device, service or system in the Field which is covered by, or is made by a process covered by, any Valid Claim of any Licensed Patent Rights or a patent claiming an Improvement, or which
utilizes the Technology in material part. 
 1.2 “Field” means all fields of use; including but not limited
to, olefin metathesis technology, including compositions of matter and methods of preparation of olefin metathesis catalyst complexes and their use to effect a wide variety of olefin metathesis chemistries including, but not limited to, ring-opening
metathesis polymerization (ROMP), ring-closing metathesis (RCM), metathesis depolymerization, cross-metathesis, acyclic diene metathesis polymerization (ADMET), and metathesis coupling, all of which are useful for the preparation of chemical and
material products including, but not limited to, resins, polymers, functional polymers, telechelic polymers, segmented polymers, block copolymers, substituted polymers, and oligomers, adhesives, pheromone chemicals, pharmaceutical intermediates,
flavor and fragrance chemicals, fine chemicals, specialty intermediates, performance chemicals, etc.; except as reserved by Caltech and limited by third party licenses granted to U. S. Government, [**]. Limitations to the Grant and Field of this
License Agreement are delineated by a listing of the grant, field and term of third party licenses in Exhibit B. 
 1.3
“Deductible Expenses” means the following items of expense incurred in connection with sales of Licensed Products to the extent paid or allowed by Licensee or an Affiliate and included in accordance with generally accepted
accounting principals (GAAP) in the gross sales price billed: (i) sales, use or turnover taxes; (ii) excise, value added or other taxes, custom duties or consular fees; (iii) transportation, freight, and handling charges, and
insurance on shipments to customers; (iv) trade, cash or quantity discounts or rebates to the extent actually granted (including Medicaid and other government-mandated rebates); (v) agent fees or commissions; (vi) rebates, refunds,
and credits for any rejected or returned Licensed Products or because of retroactive price reductions, rebates or chargebacks; and (vii) uncollected accounts receivable attributable to sales of Licensed Products. 

  

					
		  	- 2 -	  	

 1.4 “Affiliate” means any corporation, limited liability company or other
legal entity directly or indirectly controlled by Licensee or its successors or assigns, or any successor or assign of such an entity. For the purpose of this Agreement, “control” shall mean the direct or indirect ownership of at least
fifty-one percent (51%) of the outstanding shares on a fully diluted basis or other voting rights of the subject entity to elect directors, or if not meeting the preceding, any entity owned or controlled by or owning or controlling at the
maximum control or ownership right permitted in the country where such entity exists. 
 1.5 “Licensed Patent
Rights” means (a) rights under all domestic and foreign patents and patent applications listed in Exhibit A attached hereto, and all patents and patent applications that describe and claim inventions set forth in the invention
disclosures listed in Exhibit A; any patents which issue on the applications listed in Exhibit A or any applications that claim inventions set forth in the invention disclosures set forth on Exhibit A; all reissues, reexaminations, renewals,
extensions, divisionals, continuations, and continuations-in-part of the foregoing patents and patent applications; and any foreign counterparts and any other forms of protection directed to the inventions covered by the patents or patent
applications and invention disclosures listed in Exhibit A, and (b) all patent applications hereafter filed and owned by Caltech which claim an Improvement, together with any and all patents that issue therefrom, and all related divisionals,
continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patents and patent applications. 

1.6 “Caltech Technology” means the Licensed Patent Rights, Improvements and the Technology. 

1.7 “Technology” means all proprietary information, know-how, procedures, methods, prototypes, designs, technical data
and reports owned by Caltech that are necessary or useful in the development of Licensed Products and which relate to the Licensed Products, but which are not the subject of the Licensed Patent Rights. Subject to the foregoing, inventions which
(i) are the subject of applications for patents listed in Exhibit A or applications that claim Improvements, or applications which claim priority from such applications, and (ii) are not claimed in an issued patent included in the Licensed
Patent Rights shall be considered to be Technology. 

  

					
		  	- 3 -	  	

 1.8 “Net Revenues” means the combined amount received by Licensee and
Affiliates from the sale to unrelated third parties of Licensed Products, less Deductible Expenses. 
 1.9 “Valid
Claim” means (a) an issued claim of an issued patent within the Licensed Patent Rights or a patent claiming an Improvement thereof, which has not (i) expired or been canceled, (ii) been declared invalid by an unreversed and
unappealable decision of a court or other appropriate body of competent jurisdiction, (iii) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, and/or (iv) been abandoned in accordance with or as
permitted by the terms of this Agreement or by mutual written agreement; or (b) a claim included in a pending patent application within the Licensed Patent Rights that is being actively prosecuted in accordance with this Agreement and which has
not been (i) canceled, (ii) withdrawn from consideration, (iii) finally determined to be unallowable by the applicable governmental authority (and from which no appeal is or can be taken), and/or (iv) abandoned in accordance with
or as permitted by the terms of this Agreement or by mutual written consent. 
 1.10 “Sublicensee” shall mean, with
respect to a particular Licensed Product, a third party to whom Licensee has granted a license or sublicense under the Caltech Technology to develop, make, have made, use and sell such Licensed Product. 

1.11 “Improvements” [**]. 

1.12 “Confidential Information” shall mean technical, business, or other information provided to one party by the
other party under Article 10 of this Agreement, that is in written form and that is marked as Confidential Information. 

  

					
		  	- 4 -	  	

 ARTICLE 2 

PATENT LICENSE GRANT 

2.1 Caltech hereby grants to Licensee the following licenses: 

(a) an exclusive, royalty-bearing license under Licensed Patent Rights, as listed in Exhibit A, and Improvements thereof, to research,
develop, make, have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Licensed Products in the Field throughout the world; and 

(b) a nonexclusive, royalty-bearing worldwide license to the Technology to make, have made, import, have imported, use, have used,
sell, have sold, offer for sale, have offered for sale, and otherwise exploit Licensed Products in the Field throughout the world. 
 2.2
These licenses are subject to: (a) the reservation of Caltech’s right to make, have made, and use Licensed Products for noncommercial educational and research purposes, but not for sale or other distribution to third parties; and
(b) the rights of the U.S. Government under Title 35, United States Code, Section 200 et seq., including but not limited to the grant to the U.S. Government of a nonexclusive, nontransferable, irrevocable, paid-up license to practice or
have practiced any invention conceived or first actually reduced to practice in the performance of work for or on behalf of the U.S. Government throughout the world. These licenses are not transferable by Licensee except as provided in Paragraph
16.4, but Licensee shall have the right to grant nonexclusive or exclusive sublicenses hereunder, provided that: 
 (a)
Licensee shall include all its sublicensing income in Licensee’s reports to Caltech, as provided in Paragraph 9.2, and Licensee shall pay royalties thereon to Caltech pursuant to Paragraph 4.1; and 

(b) Licensee shall furnish Caltech within [**] days of the execution thereof, a true and complete copy of each sublicense and any
changes or additions thereto; and 
 (c) Licensee may grant sublicenses of no greater scope than the license granted under
Section 2.1; and 

  

					
		  	- 5 -	  	

 (d) Each sublicense granted by Licensee shall include provisions similar in all material
respects to those of Articles 6, 12, 15, 16 and Section 2.2. 
 The license grants shall continue for the term of this Agreement as set forth in
Article 12; provided, however, that if this Agreement expires pursuant to the first sentence of Paragraph 12.1, Licensee shall retain a nonexclusive, perpetual, royalty-free, worldwide license, with the right to sublicense, under the Caltech
Technology, to research, develop, make, use, sell, offer for sale and import Licensed Product 
 2.4 Licensee shall have the right to
acquire all additional rights from license grants by Caltech to any third party under Licensed Patent Rights, that either lapse, terminate, are reduced to non-exclusive, or that are further reduced in their grant, field or territory; and Licensee
shall assume a share of patent costs, as well as other fees and royalties, on proportionate basis to such costs, fees and royalties paid by any third party under the additional rights granted to Licensee. 

ARTICLE 3 
 FINANCING

 Licensee hereby certifies that it has closed on a round of equity financing in the amount of XXXXXXXXXXXXXXXXXXXXXX on August 3,
2000, and is organized as a Delaware C Corporation. 
 ARTICLE 4 

ROYALTIES 
 4.1
Licensee shall pay Caltech XXXXXXXXXXX of the royalties or other license revenues that Licensee receives from Sublicensees, other than to Affiliates, for the sale of Licensed Products in the Field or the conduct of services which are Licensed
Products (as defined herein). Such royalties or other revenues specifically shall not include payments made by a Sublicensee (i) in consideration of equity or debt securities of Licensee; (ii) to support research or development activities
to be undertaken by Licensee; (iii) upon the achievement by Licensee or Sublicensee of specified milestones or benchmarks relating to the development of Licensed Products; (iv) in connection with pilot studies; (v) with respect to
performance based milestones;  

  

					
		  	- 6 -	  	

 
(vi) in consideration for the license or sublicense of any intellectual property other than Caltech Technology; (vii) with respect to products other than Licensed Products, or (viii) as
reimbursement for patent or other expenses. 
 4.2 In any country where the sale or use of Licensed Products is covered by a patent
or patent application within the Licensed Patent Rights, if Licensed Products are sold by or for Licensee or Affiliate in the Field in such country, Licensee shall pay Caltech XXXXXXXXXXXXXX of Net Revenues from the sale of Licensed Products or for
the conduct of services which are Licensed Products. 
 4.3 In any country where the sale or use of Licensed Products is not
covered by a patent or patent application within the Licensed Patent Rights but the use or sale of such Licensed Product utilizes the Technology in material part, Licensed Products are sold by or for Licensee or Affiliate in the Field or used to
provide services to third parties, Licensee shall pay Caltech XXX XXXXXXXXXXXXXX of Net Revenues from the sale of Licensed Products or for the conduct of such services for a period of XXXXXXXXXXX from the first commercial sale of a Licensed Product
in such country. 
 4.4 In the event that Licensed Products are sold in combination with one or more other products or
services which are not Licensed Products, Net Revenues for such combination products will be calculated on a country-by-country basis by multiplying actual net sales of such combination products by the fraction A/(A+B) where A is the average invoice
price during the period of the Licensed Product when sold separately, and B is the average invoice price of any other product(s) or services in the combination when sold separately by Licensee or Affiliate. If the products or services in the
combination that are not Licensed Products are not sold separately by Licensee or Affiliate, Net Revenues shall be calculated by multiplying actual net sales of such combination products by the fraction A/C where A is the average invoice price of
the Licensed Product when sold separately and C is the average invoice price of the combination product. If neither the Licensed Product nor the combination product is sold separately by Licensee or Affiliate, Net Revenues shall be calculated as
above except that A shall be the total manufacturing cost of Licensed Product and C shall be the total manufacturing cost of the combination. 

  

					
		  	- 7 -	  	

 4.5 If, in any [**] period commencing on the second anniversary of the Effective Date or
any subsequent anniversary thereof, Licensee does not pay a minimum of XXXXXXXXXXXXXXXXXXXX in royalties under Paragraphs 4.1, 4.2 or 4.3, or pay an additional royalty equal to the difference between XXXXXXXXXXXXXXXXXXXXXX and any lower amount paid
under Paragraphs 4.1, 4.2 or 4.3, then Licensor shall have the right to terminate this Agreement, provided, however, that Licensee may, at its election, pay to Licensor from any other revenues the XXXXXXXXXXXXXXXXXXXX minimum annual royalty and in
such event Licensor may not terminate this Agreement. 
 4.6 If Licensee or Affiliate is required to make any payment
(including, but not limited to, royalties or other license fees) to one or more third parties to obtain a license or similar right in the absence of which it could not legally make, import, use, sell, or offer for sale Licensed Products in any
country, and Licensee provides Caltech with reasonably satisfactory evidence of such third-party payments, such third-party payments shall be fully creditable against royalties owed to Caltech hereunder, provided that in no one year shall such
expenses be credited against more than XXXXXXXXXXXXXXXXX of royalty payments to Caltech. Any greater amount of such expenses may be carried over and credited against royalties owed in future years. 

4.7 For the purpose of determining royalties payable under this Agreement, any royalties or other revenues Licensee receives from
Sublicensees in currencies other than U.S. dollars and any Net Revenues denominated in currencies other than U.S. dollars shall be converted into U.S. dollars according to Licensee’s reasonable standard internal conversion procedures, including
Licensee’s standard internal rates and conversion schedule. 
 4.8 Any sublicenses granted by Licensee, including,
without limitation, any nonexclusive sublicenses, shall remain in effect and be assigned to Caltech in the event this license terminates pursuant to Article 12; provided, the financial obligations of each Sublicensee to Caltech shall be limited to
the amounts Licensee shall be obligated to pay to Caltech for the activities of such Sublicensee pursuant to this Agreement. In such event and subject to the preceding sentence, Caltech shall assume all the rights and obligations of Licensee.

 4.9 No more than one royalty payment shall be due with respect to a sale of a particular Licensed Product. No multiple
royalties shall be payable because any Licensed Product, or its  

  

					
		  	- 8 -	  	

 
manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty shall be payable under this Article 4 with respect to Licensed Products distributed for use in
research and/or development or as promotional samples or otherwise distributed without charge to third parties. 
 4.10 Royalties due
under this Article 4 shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis until the expiration of the last-to-expire issued Valid Claim covering such Licensed Product in such country, or if no such patent has
previously issued in a country, until the XXXXXX anniversary of the first commercial sale of Licensed Product in such country. 

4.11 Notwithstanding the provisions of this Article 4, no royalty shall be payable to Licensor with respect to any sales of Licensed
Products to the U.S. Government on sales made solely to permit the U.S. Government to practice or have practiced or sue on its behalf any invention or process covered by Caltech Technology. 

ARTICLE 5 
 LICENSEE
EQUITY INTEREST 
 5.1 Licensee agrees to issue to Caltech, in consideration of Licensee’s receipt of the intangible
property rights granted under this Agreement, XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXX shares of Licensee’s common stock, pursuant to the terms of Licensee’s stock restriction and cosale agreement. 

5.2 Caltech agrees that, in the event of any underwritten or public offering of securities of Licensee or Affiliate, Caltech shall
comply with and agree to any reasonable restriction on the transfer of equity interest, or any part thereof, imposed by an underwriter, and shall perform all acts and sign all necessary documents required with respect thereto. The provisions of this
Paragraph 5.2 shall survive termination of this Agreement. 

  

					
		  	- 9 -	  	

 ARTICLE 6 

DUE DILIGENCE 
 6.1
Licensee shall have discretion over the commercialization of Licensed Products. However, Licensee agrees to use commercially reasonable efforts to introduce commercial Licensed Product(s) in the United States as soon as practical, consistent
with sound and reasonable business practices and judgments. Licensee shall be deemed to have satisfied its obligations under this Paragraph if Licensee has an ongoing and active research program or marketing program, as appropriate, directed toward
production and use of one or more Licensed Products. Any efforts of Licensee’s Sublicensees shall be considered efforts of Licensee for the sole purpose of determining Licensee’s compliance with its obligation under this Paragraph.

 6.2 After the first year from the Effective Date, Caltech shall have the right, no more often than once each year, to require
Licensee to report to Caltech in writing on its progress in introducing commercial Licensed Product(s) in the United States. 

6.3 If Licensee is not fulfilling its obligations under Paragraph 6.1 with respect to the Field and Caltech so notifies Licensee in
writing, Caltech and Licensee shall negotiate in good faith any additional efforts to be taken by Licensee. If the parties do not reach agreement within [**] days, the parties shall submit the issue to arbitration as provided in Article 14 to
determine whether any additional efforts shall be required of Licensee. If subsequent to the conclusion of such arbitration proceedings Licensee then fails to make any required efforts, and does not remedy that failure within [**] days after
further written notice to Licensee, Caltech may convert the license granted in Paragraph 2.1 to a nonexclusive license in any part of the Field in which Licensee is not fulfilling its obligations under Paragraph 6.1, and the royalties payable under
this Agreement shall be reduced by XXXXXXXXXXXX for Licensed Products in the Field sold under such a nonexclusive license. 
 ARTICLE 7

 INFRINGEMENT BY THIRD PARTY 

7.1 Licensee shall at its expense, have the first right but not the obligation to protect the Licensed Patent Rights from infringement
and prosecute infringers when, in its sole judgment, such action may be reasonably necessary, proper and justified. Notwithstanding the foregoing, Licensee shall have the right to sublicense any alleged infringer pursuant to Paragraph 2.1. 

  

					
		  	- 10 -	  	

 7.2 If Caltech shall have supplied Licensee with evidence of infringement of Licensed
Patent Rights or patents claiming an Improvement by a third party, Caltech may by notice request Licensee to take steps to enforce the Licensed Patent Rights. If Caltech does so, and Licensee does not, within three (3) months of the receipt of
such notice, either (i) cause the infringement to terminate or (ii) initiate a legal action against the infringer, Caltech may, upon notice to and approval of Licensee, initiate an action against the infringer at Caltech’s expense,
either in Licensee’s name or in Caltech’s name if so required by law. Caltech shall have sole control of the action. 

7.3 If a declaratory judgment action alleging invalidity, unenforceability or noninfringement of any of the Licensed Patent Rights or
patents claiming an Improvement is brought against Licensee and/or Caltech, Licensee may elect to have sole control of the action, and if Licensee so elects it shall bear all the costs of the action. 

7.4 In the event one party shall institute or carry on a legal action pursuant to Paragraphs 7.1, 7.2 or 7.3, the other party shall
fully cooperate with and supply all assistance reasonably requested by the party instituting or carrying on such action, including by using commercially reasonable efforts to have its employees testify when requested and to make available relevant
records, papers, information, samples, specimens, and the like. A party controlling an action pursuant to Paragraphs 7.1, 7.2 or 7.3 shall bear the reasonable expenses incurred by said other party in providing such assistance and cooperation as is
requested pursuant to this Paragraph. A party instituting or carrying on such an action shall keep the other party informed of the progress of such action, and said other party shall be entitled to be represented by counsel in connection with such
action at its own expense. To the extent not reimbursed by Caltech, Licensee’s reasonable and customary expenses for such action (including attorneys’ fees and expert fees) shall be fully creditable against royalties owed to Caltech
hereunder, provided that in no one year shall such expenses to be credited against more than [**] of royalty payments to Caltech. Any remaining expenses may be carried over and credited against royalties owed in future years. 

  

					
		  	- 11 -	  	

 7.5 The party controlling any action referred to in this Article 7 shall have the right to
settle any claims, but only upon terms and conditions that are reasonably acceptable to the other party hereto. Should either party elect to abandon such an action other than pursuant to a settlement with the alleged infringer that is reasonably
acceptable to the other party, the party controlling the action shall give timely notice to the other party who, if it so desires, may continue the action; provided, however, that the sharing of expenses and any recovery in such suit shall be as
agreed upon between the parties. 
 7.6 Any amounts paid to a party by third parties as the result of such an action (such as
in satisfaction of a judgment or pursuant to a settlement) shall first be applied to reimbursement of the unreimbursed expenses (including attorneys’ fees and expert fees) incurred by each party and then to the payment to Caltech of any
royalties against which were credited expenses of the action in accordance with Paragraph 7.4. Any remainder shall be divided between the parties as follows: 

(a) To the extent the amount recovered reflects lost profits, Licensee shall retain the remainder, less the amount of any royalties
that would have been due Caltech on sales of Licensed Product lost by Licensee as a result of the infringement had Licensee made such sales, provided that Licensee shall in any event retain at least XXXXXXXXXXXXXXXX of the remainder; and
(ii) Caltech shall receive an amount equal to the royalties it would have received if such sales had been made by Licensee, provided such amount shall in no event exceed XXXX XXXXXXXXX of the remainder; or 

(b) To the extent the amount recovered does not reflect lost profits, XXXXXX XXXXXXXX shall be paid to the party initiating the action
and XXXXXXXXXXX to the other party. 
 7.7 If an infringement or infringements by third parties of Licensed Patent Rights is on a
scale that significantly affects sales of Licensed Products, and neither Caltech nor Licensee elect to bring an infringement suit against the infringers, the royalties hereunder payable by Licensee pursuant to Article 4 shall be reduced by
XXXXXXXXXXXXXXXXXXX of the sums otherwise payable if Licensee presents information to Caltech that such infringer has refused to enter into a royalty-bearing, sublicensing agreement with Licensee on terms reasonably acceptable to Licensee.

  

					
		  	- 12 -	  	

 7.8 The allowed reductions set forth in Paragraph 7.7 and Paragraph 4.6 shall not exceed,
in the aggregate, XXXXXXXXXXXXXX of the sums otherwise payable during any year. 
 ARTICLE 8 

BENEFITS OF LITIGATION, 

EXPIRATION OR ABANDONMENT 

8.1 General. In a case where one or more patents or particular claims thereof within the Licensed Patent Rights expire, or are
abandoned, or are declared invalid or unenforceable or otherwise construed by a court of last resort or by a lower court from whose decree no appeal is taken, or certiorari is not granted within the period allowed therefor, then the effect thereof
hereunder shall be: 
 (a) that such patents or particular claims shall, as of the date of expiration or abandonment or final
decision as the case may be, cease to be included within the Licensed Patent Rights for the purpose of this Agreement; and 
 (b)
that such construction so placed upon the Licensed Patent Rights by the court shall be followed from and after the date of entry of the decision, and royalties shall thereafter be payable by Licensee only in accordance with such construction; and

 (c) in the event that Licensee challenges the validity of Licensed Patent Rights, Licensee may not cease paying royalties as of
the date that the validity of the claims in issue are challenged, but rather may cease paying royalties as to those claims only after a final adjudication of invalidity of those claims. 

8.2 Adjustment. In the event that any of the contingencies provided for in Paragraph 8.1 occurs, Caltech agrees to renegotiate in good
faith with Licensee a reasonable royalty rate under the remaining Licensed Patent Rights which are unexpired and in effect and under which Licensee desires to retain a License. 

  

					
		  	- 13 -	  	

 ARTICLE 9 

RECORDS, REPORTS AND PAYMENTS 

9.1 Licensee shall keep records and books of account in respect of all Licensed Products made and sold by Licensee or its Affiliates
under this Agreement and of royalties or other revenues Licensee receives from Sublicensees other than Affiliates for the sale of Licensed Products. Caltech shall have the right, during business hours, no more often than annually, to examine, or to
have its designated auditors examine, such records and books. Licensee shall keep the same for at least [**] years after it pays Caltech the royalties due for such Licensed Products and require its Affiliates to do the same. Caltech shall not
disclose to any third party any confidential information learned through an examination of such records and books, nor shall Caltech use any such information for any purpose other than determining and enforcing its rights under this Agreement. 

9.2 Following the first commercial sale of a Licensed Product, on or before the last day of each February, May, August and November for
so long as royalties are payable under this Agreement, Licensee shall render to Caltech a report in writing, setting forth Net Revenues and the number of units of Licensed Products sold during the preceding calendar quarter by Licensee and its
Affiliates, and the royalties or other revenues Licensee received from Sublicensees other than Affiliates during the preceding calendar quarter for the sale of Licensed Products. Each such report shall also set forth an explanation of the
calculation of the royalties payable hereunder and be accompanied by payment of the royalties shown by said report to be due Caltech. Notwithstanding the foregoing, if (i) Caltech materially breaches this Agreement, (ii) Licensee gives
Caltech written notice of the breach, and (iii) Caltech has not cured the breach by the time a payment is due under this Paragraph, then Licensee may make the required payment into an interest bearing escrow account to be released when the
breach is cured, less any damages that may be payable to Licensee by virtue of Caltech’s breach. 
 ARTICLE 10 

CONFIDENTIALITY 
 10.1
Dr. Robert H. Grubbs shall provide to Licensee copies of any proposed presentation or publication or abstract which is an Improvement to Caltech Technology prior to the  

  

					
		  	- 14 -	  	

 
submission of such documents. Proposed publications and abstracts shall be supplied at least [**] days in advance of submission to a journal, editor, or third party. In addition, if
Dr. Grubbs submits a copy of the proposed publication to Licensee less than [**] days prior to submission for publication, then Licensee can request Caltech to file, at Caltech’s expense, a provisional patent application enabling the
technology disclosed in the proposed publication at the United States Patent and Trademark Office, and shall provide Licensee with evidence of the filing of such provisional patent application. Licensee may request reasonable changes and/or
deletions be made in any proposed publication. Dr. Grubbs will consider such changes but retains the sole right to determine whether such changes or deletions will be made; but Dr. Grubbs agrees that he will honor Licensee’s
reasonable requests to remove any confidential information of Licensee included in any such public disclosure. If Licensee believes that the subject matter to be disclosed or published warrants patent protection, it will identify the subject matter
requiring protection and notify Caltech. Caltech agrees to use commercially reasonable efforts to cooperate in the filing of a U.S. patent application as provided in Paragraph 11.4 thereon prior to any date that would result in preventing the
obtaining of valid patent rights throughout the world when Licensee so identifies subject matter requiring patent protection from a review of the planned publication. 

10.2 All reports provided to Caltech pursuant to this Agreement shall be Confidential Information of Licensee and shall not be
disclosed to any third party without the prior written consent of Licensee. 
 10.3 Except as expressly provided herein, each
party agrees not to disclose any terms of this Agreement to any third party without the consent of the other party; provided, however, that disclosures may be made as required by securities or other applicable laws, or to actual or prospective
investors or corporate partners, or to a party’s Directors, accountants, attorneys and other professional advisors. 
 ARTICLE
11 
 PAYMENT OF PATENT COSTS 

11.1 Starting XXXXXXXXXXXXXXXXX from the Effective Date, Licensee shall, in connection with the preparation, filing, and prosecution,
issuance and maintenance of the Licensed Patent Rights both in the United States and foreign jurisdictions: 
  

	 	(a)	 pay its proportional share, with respect to the cumulative share of third party licensees, of all reasonable attorney fees for services
performed to 

  

					
		  	- 15 -	  	

	 	
obtain the issuance of the Licensed Patent Rights, and all patent and government fees for services performed after the issuance of Licensed Patent Rights, and 

 

	 	(b)	pay its proportional share, with respect to the cumulative share of third party licensees, of all Patent and Trademark Office maintenance fees; and 

 

	 	(c)	such proportional share shall be established by a mutual determination of the parties with respect to the relative value of Licensed Patent Rights with respect to other third party rights; except that

  

	 	(d)	Licensee’s share shall not be greater than XXXXXXXXXXXXXXXXX of patent costs for shared rights in any jurisdiction. 

11.2 XXXXXXXXXXXXX of the amounts expended by Licensee in connection with U.S. patent costs shall be creditable against earned
royalties due Caltech; XXXXXXXXXXXXX XXXXXX of patent expenses paid by Licensee in conjunction with foreign patent costs shall be creditable against earned royalties due Caltech in the respective territory covered by the patent or patents that are
foreign filed. 
 11.3 Payment shall be made to Caltech within thirty (30) days following receipt by Licensee from Caltech of
(i) an invoice covering such fees (including copies of invoices for legal fees describing the legal services performed in reasonable detail) and (ii) reasonably satisfactory evidence that such fees were paid. To the extent that Licensee
terminates this Agreement pursuant to Paragraph 12.3 with respect to any patent application or patent, Licensee shall have no further liability under Paragraph 11.1 for fees relating to applications or patents affected by the termination. 

11.4 Licensee shall have the right to apply for, prosecute and maintain during the term of this Agreement, the Licensed Patent Rights.
Caltech shall provide Licensee with timely disclosures regarding Improvements and potential Improvements developed in the laboratory of Dr. Robert H. Grubbs at Caltech. The application filings, prosecution, maintenance and payment 

  

					
		  	- 16 -	  	

 
of all fees and expenses, including legal fees, relating to such Licensed Patent Rights shall be the responsibility of Licensee, provided that Licensee shall pay for all reasonable fees and
expenses, including reasonable legal fees, incurred in such application filings, prosecution and maintenance. Caltech shall provide Licensee with all information necessary or useful for the filing and prosecution of such Licensed Patent Rights and
shall cooperate fully with Licensee so that Licensee may establish and maintain such rights. Patent attorneys chosen by Licensee shall handle all patent filings and prosecutions, on behalf of Caltech, provided, however, Caltech and Dr. Grubbs
shall be entitled to review and comment upon and approve all actions undertaken in the prosecution of all patents and applications. Caltech and Dr. Grubbs shall provide any comments or approvals hereunder promptly. In the event Licensee
declines to apply for, prosecute or maintain any Licensed Patent Rights, Caltech shall have the right to pursue the same at Caltech’s expense and Licensee shall have no rights under Caltech’s interest therein. If Licensee decides not to
apply for, prosecute or maintain any Licensed Patent Rights, Licensee shall give sufficient and timely notice to Caltech so as to permit Caltech to apply for, prosecute and maintain such Licensed Patent Rights. In such event, Licensee shall provide
Caltech with all information necessary or useful for the filing and prosecution of such Licensed Patent Rights and shall cooperate fully with Caltech so that Caltech may establish and maintain such rights. 

ARTICLE 12 
 TERMINATION

 12.1 The term of this Agreement shall commence upon the Effective Date and expire upon the date of expiration of all royalty
obligations in all countries as provided in Paragraph. Caltech shall have the right to terminate this Agreement prior to the date it would otherwise expire, pursuant to this Paragraph 12.1, if Licensee fails to make any payment due hereunder and if
Licensee continues to fail to make the payment, either to Caltech directly or by placing any disputed amount into an interest bearing escrow account to be released when the dispute is resolved, for a period of [**] days after receiving notice
from Caltech specifying Licensee’s failure. Upon any such termination, (i) Licensee and Affiliates shall have [**] months to complete the manufacture of any Licensed Products that then are work in progress and to sell their inventory
of Licensed Products, provided Licensee pays the applicable royalties in accordance with Paragraph 9.2, and (ii) Caltech shall accept an assignment by Licensee of any sublicenses granted by Licensee to entities other than Affiliates, and any
sublicense so assigned shall remain in full force and effect. 

  

					
		  	- 17 -	  	

 12.2 If either party materially breaches this Agreement, the other party may elect to give
the breaching party written notice describing the alleged breach. If the breaching party has not cured such breach within [**] days after receipt of such notice, the notifying party will be entitled, in addition to any other rights it may have
under this Agreement, to terminate this Agreement effective immediately; provided, however, that if either party receives notification from the other of a material breach and if the party alleged to be in default notifies the other party in writing
within [**] days of receipt of such default notice that it disputes the asserted default, the matter will be submitted to arbitration as provided in Article 14 of this Agreement. In such event, the nonbreaching party shall not have the right to
terminate this Agreement until it has been determined in such arbitration proceeding that the other party materially breached this Agreement, and the breaching party fails to cure such breach within [**] days after the conclusion of such
arbitration proceeding. 
 12.3 Licensee shall have the right to terminate this Agreement either in its entirety or as to any
jurisdiction or any part of the Licensed Patent Rights or Licensed Patents upon sixty (60) days written notice. If Licensee does so, it shall submit all required reports and make all required payments in accordance with Paragraph 9.2.

 12.4 No termination of this Agreement shall relieve Licensee of the liability for payment of any royalty due for Licensed
Products made prior to the effective date of such termination. 
 12.5 Notwithstanding anything herein to the contrary, in the
event of any termination or expiration of the term of this Agreement, Licensee shall have the right to use or sell Licensed Products on hand on the date of such termination or expiration and to complete Licensed Products in the process of
manufacture at the time of such termination or expiration and use or sell the same, provided that Licensee shall submit the applicable royalty report described in paragraph 9.2, along with the royalty payments required above in accordance with
Article 4 for sale of such Licensed Products. 

  

					
		  	- 18 -	  	

 12.6 Licensee shall have the right to dispose of its existing inventory, whether completed
or in the process of manufacture, for a period of [**] months after termination. 
 12.7 Termination of this Agreement
for any reason shall not release any party hereto from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination, nor preclude either party from
pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination. 

12.8 Paragraphs 4.8, 4.11, 5.2, 9.2 (if Paragraph 12.2 applies), 12.2, 12.4, 12.5 and Articles 9, 10, 14, 15 and 16 of this Agreement
shall survive termination of this Agreement. 
 ARTICLE 13 

WARRANTIES AND NEGATION OF 

WARRANTIES, IMPLIED LICENSES AND AGENCY 

13.1 Caltech represents and warrants that it owns all right, title and interest in and to the Licensed Patent Rights, subject to this
license. 
 13.2 Caltech represents and warrants that it has not granted any third party right or interest in any of the
Licensed Patent Rights or Improvements that is inconsistent with the rights granted to Licensee herein and will not grant any third party such a right during the term of this Agreement. 

13.3 Caltech represents and warrants: (i) it is the sole and exclusive owner of all right, title, and interest in the Caltech
Technology; (ii) it has the right to grant the rights and licenses granted herein, and the Caltech Technology is free and clear of any lien, encumbrance, security interest, or restriction on license; and (iii) there are no threatened or
pending actions, suits, investigations, claims, or proceedings in any way relating to the Caltech Technology. 
 13.4 Nothing
in this Agreement shall be construed as: 
 (a) a representation or warranty of Caltech as to the validity or scope of Licensed
Patent Rights or any claim thereof; or 

  

					
		  	- 19 -	  	

 (b) a representation or warranty that any Licensed Product is or will be free from
infringement of rights of third parties; or 
 (c) an obligation to bring or prosecute actions or suits against third parties for
infringement; or 
 (d) conferring by implication, estoppel or otherwise, any license or rights under any patents of Caltech other
than Licensed Patent Rights, regardless of whether such other patents are dominant or subordinate to Licensed Patent Rights. 
 13.5
CALTECH MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO THE USE, SALE, OR OTHER DISPOSITION BY LICENSEE OF LICENSED PRODUCT(S). 

13.6 Caltech and Licensee are independent parties in this Agreement. Accordingly, there is no agency relationship between Caltech and
Licensee under this Agreement with respect to any products made or sold, or any methods used, by Licensee under this Agreement. 

ARTICLE 14 
 ARBITRATION

 14.1 Any controversy or claim arising out of or related to the parties’ obligations under this Agreement, or the breach
thereof, shall be settled by arbitration conducted in the State of California and, except as otherwise provided in this Paragraph 14.1, shall be conducted in accordance with the Commercial Arbitration Rules of the American Arbitration Association.
Discovery shall be permitted as set forth in the Federal Rules of Civil Procedure with respect to the performance by the Parties of their obligations under this Agreement and such other matters as the arbitrators may determine (it being the intent
of the Parties that full discovery occur with respect to salient facts). Judgment upon an award rendered by the Arbitrator may be entered in any court having jurisdiction thereof. 

  

					
		  	- 20 -	  	

 ARTICLE 15 

PRODUCT LIABILITY 

15.1 Licensee agrees that Caltech shall have no liability to Licensee or to any purchasers or users of Licensed Products made or sold
by Licensee for any claims, demands, losses, costs, or damages suffered by Licensee, or purchasers or users of such Licensed Products, or any other party, which may result from personal injury, death, or property damage related to the manufacture,
use, or sale of such Licensed Products (“Claims”). Licensee agrees to defend, indemnify, and hold harmless Caltech, its trustees, officers, agents, and employees from any such Claims, provided that (i) Licensee is notified promptly of
any Claims, (ii) Licensee has the sole right to control and defend or settle any litigation within the scope of this indemnity, and (iii) all indemnified parties cooperate to the extent necessary in the defense of any Claims. 

15.2 At such time as Licensee begins commercial sales of Licensed Products (other than for the purpose of obtaining regulatory
approvals), Licensee shall at its sole expense, procure and maintain policies of comprehensive general liability insurance in amounts not less than XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX and naming those indemnified under Paragraph 15.1 as additional
insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for Licensee’s indemnification under Paragraph 15.1. In the event the aforesaid
product liability coverage does not provide for occurrence liability, Licensee shall maintain such comprehensive general liability insurance for a reasonable period of not less than five (5) years after it has ceased commercial distribution or
use of any Licensed Product. 
 15.3 Licensee shall provide Caltech with written evidence of such insurance upon request of Caltech.
Licensee shall provide Caltech with notice at least [**] days prior to any cancellation, non-renewal or material change in such insurance, to the extent Licensee receives advance notice of such matters from its insurer. If Licensee does not
obtain replacement insurance providing comparable coverage within [**] days following the date of such cancellation, non-renewal or material change, Caltech shall have the right to terminate this Agreement effective at the end of such
[**] day period without any additional waiting period; provided that if Licensee uses reasonable efforts but is unable to obtain the required insurance at  

  

					
		  	- 21 -	  	

 
commercially reasonable rates, Caltech shall not have the right to terminate this Agreement, and Caltech instead shall cooperate with Licensee to either grant a waiver of Licensee’s
obligations under this Article or assist Licensee in identifying a carrier to provide such insurance or in developing a program for self-insurance or other alternative measures. The previous Article shall survive the expiration or termination of
this Agreement. 
 ARTICLE 16 

MISCELLANEOUS 
 16.1
Licensee agrees that it shall not make any form of representation or statement which would constitute an express or implied endorsement by Caltech of any Licensed Product, and that it shall not authorize others to do so, without first having
obtained written approval from Caltech, except as may be required by governmental law, rule or regulation. Caltech agrees, however, that Licensee may identify Caltech, or California Institute of Technology, and/or Professor Robert H. Grubbs as the
inventor of the Caltech Technology in any advertising or publicity material. 
 16.2 Licensee agrees to mark, whenever
reasonably possible, the appropriate U.S. patent number or numbers on all Licensed Products made or sold in the United States in accordance with all applicable governmental laws, rules and regulations, and to require its Sublicensees to do the
same. 
 16.3 This Agreement sets forth the complete agreement of the parties concerning the subject matter hereof. No claimed
oral agreement in respect thereto shall be considered as any part hereof. No waiver of or change in any of the terms hereof subsequent to the execution hereof claimed to have been made by any representative of either party shall have any force or
effect unless in writing, signed by duly authorized representatives of the parties. 
 16.4 This Agreement shall be binding
upon and inure to the benefit of any successor or assignee of Caltech. This Agreement is not assignable by Licensee without the prior written consent of Caltech, except that Licensee may assign this Agreement without the prior written consent of
Caltech, to any Affiliate, or any successor of, or purchaser of a substantial part of the assets of, the business to which this Agreement pertains. Any permitted assignee shall succeed to all of the rights and obligations of Licensee under this
Agreement. 

  

					
		  	- 22 -	  	

 16.5 This Agreement is subject in all respects to the laws and regulations of the United
States of America, including the Export Administration Act of 1979, as amended, and any regulations thereunder. 
 16.6
Licensee agrees that a Licensed Product which embodies a patented invention or is produced through the use thereof for sale in the United States shall be manufactured substantially in the United States to the extent required by 35 U.S.C. Section
204. 
 16.7 This Agreement shall be deemed to have been entered into in California and shall be construed and enforced in
accordance with California law. 
 16.8 Any notice or communication required or permitted to be given or made under this
Agreement shall be addressed as follows: 
  

			
	Caltech:	  	Office of Technology Transfer
		  	California Institute of Technology
		  	1200 East California Boulevard (MC 210-85)
		  	Pasadena, CA 91125
		  	Fax No.: [**]
		
	Licensee:	  	Materia Inc.
		  	2531 Nina Street
		  	Pasadena, CA 91107
		  	Attn: President
		  	Fax No: [**]

 Either party may notify the other in writing of a change of address or fax number, in which event any subsequent communication
relative to this Agreement shall be sent to the last said notified address or number, provided, however, that the parties shall deliver all material notices under this Agreement by registered mail or overnight delivery service. All notices and
communications relating to this Agreement shall be deemed to have been given when received. 
 16.9 Nothing in this Agreement will
impair Licensee’s right to independently acquire, license, develop for itself, or have others develop for it, intellectual property and technology performing similar functions as the Caltech Technology or to market and distribute products other
than Licensed Products based on such other intellectual property and technology. 

  

					
		  	- 23 -	  	

 16.10 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 
 16.11
Licensor shall indemnify, defend and hold harmless Licensee from and against any and all losses, damages, costs and expenses (including attorneys’ fees) arising out of a material breach by Licensor of its representations and warranties
(“Claims”), provided that (i) Licensor is notified promptly of any Claims, (ii) Licensee has the sole right to control and defend or settle any litigation within the scope of this indemnity, and (iii) all indemnified parties
cooperate to the extent necessary in the defense of any Claims. Licensee shall indemnify, defend and hold harmless Licensor, its trustees, officers, agents and employees from and against any and all losses, damages, costs and expenses (including
attorneys’ fees) arising out of sale of Licensed Products by Licensee, but not involving or relating to a material breach by Licensor of its representations and warranties. 

16.12 Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment
obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo, governmental acts or orders or restrictions, failure of suppliers, or any
other reason where failure to perform is beyond the reasonable control and not caused by the negligence or intentional conduct or misconduct of the nonperforming party, and such party has exerted all reasonable efforts to avoid or remedy such force
majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance. 
 16.13 In
the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. The parties shall in
good faith negotiate a substitute clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the parties in entering this Agreement. 

  

					
		  	- 24 -	  	

 16.14 This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 
 16.15 The headings of the
several Paragraphs are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

16.16 Whenever provision is made in this Agreement for either party to secure the consent or approval of the other, that consent or
approval shall not be unreasonably withheld or delayed, and whenever in this Agreement provisions are made for one party to object to or disapprove a matter, such objection or disapproval shall not be unreasonably exercised. 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed: 

 

							
	Date: 4/24/01	 		 	CALIFORNIA INSTITUTE OF TECHNOLOGY (Caltech)
				
		 		 	By:	 	 /s/ Lawrence Gilbert

		 		 	Name:	 	Lawrence Gilbert
		 		 	Title:	 	Director, Office of Technology Transfer
			
	Date: 4/24/01	 		 	LICENSEE
				
		 		 	By:	 	 /s/ Michael A. Giardello

		 		 	Name:	 	Michael A. Giardello, Ph.D.
		 		 	Title:	 	President and CEO

  

					
		  	- 25 -	  	

 Exhibit A 

Licensed Patent Rights 
  

							
	 Caltech I.D. #
	  	 Appln Serial #/
Issued Patent #
	  	Date	  	 Title

		  		  		  	
		  		  		  	
		  		  		  	

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of seven pages were
omitted. [**]. 

  

					
		  	- 26 -	  	

 Exhibit B 

In addition to rights reserved by Caltech and those granted to U.S. Government under Paragraph 2.2 of this Agreement, the exclusive rights of the Licensee to
Licensed Patent Rights, Technology and Improvements listed in Exhibit A are subject to the third-party rights of [**]. These third-party rights are summarized in Exhibits B.1, B.2, B.3, B.4 and B.5. 

  

					
		  	- 27 -	  	

 Exhibit B.1 
  

			
	Licensee:	  	[**]
		
	Effective Date:	  	 [**]

		
	Grant:	  	 [**]

		
	Field:	  	 [**]

		
	Territory:	  	 [**]

		
	Term:	  	 [**]

		
	Licensed Patent Rights:	  	 [**]

  

					
		  	- 28 -	  	

 Exhibit B.2 
  

			
	Licensee:	  	[**]
		
	Effective Date:	  	 [**]

		
	Licensed Product:	  	 [**]

		
	Grant:	  	 [**]

		
	Field:	  	 [**]

		
	Territory:	  	 [**]

		
	Term:	  	 [**]

		
	Licensed Patent Rights:	  	 [**]

  

					
		  	- 29 -	  	

 Exhibit B.3 
  

			
	Licensee:	  	[**]
		
	Effective Date:	  	 [**]

		
	Licensed Product:	  	 [**]

		
	Grant:	  	 [**]

		
	Territory:	  	 [**]

		
	Term:	  	 [**]

		
	Licensed Patent Rights:	  	 [**]

  

					
		  	- 30 -	  	

 Exhibit B.4 
  

			
	Licensee:		[**]
		
	Effective Date:		[**]
		
	Licensed Products:		 [**]

		
	Grant:		 [**]

		
	Field:		 [**]

		
	Territory:		 [**]

		
	Term:		 [**]

		
	Licensed Patent Rights:		 [**]

  

					
			- 31 -		

 Exhibit B.5 
  

			
	Licensee:		[**]
		
	Effective Date:		 [**]

		
	Licensed Products:		 [**]

		
	Grant:		[**]
		
	Field:		 [**]

		
	Territory:		 [**]

		
	Term:		 [**]

		
	Licensed Patent Rights:		 [**]

  

					
			- 32 -		

 AMENDMENT TO LICENSE AGREEMENT 

This Amendment is effective as of the 6th day of May, 2002 (the “Effective
Date”), between California Institute of Technology, 1200 E. California Blvd., Pasadena, CA 91125 (“Caltech”) and Materia, Inc., having a principal place of business at 2532 Nina Street, Pasadena, CA 91107 (“Materia”). 

Whereas, Caltech and Materia entered into a License Agreement on or about April 24, 2001 (the “License Agreement”) regarding,
inter alia, U.S. Patents No. [**]; and 
 Now, therefore, the parties agree as follows: 

In addition to the rights granted, Caltech grants to Materia a non-exclusive right to make, have made and sell licensed products under U.S.
Patent No. [**]. 
 This Agreement may be executed in counterparts by each of the parties, such counterparts being as effective as a single
document. 
 In Witness Whereof, the parties have caused this Agreement to be executed: 

 

			
	California institute of Technology
		
	By:	 	 /s/ Lawrence Gilbert

		 	Larry Gilbert
		 	Director, Office of Technology Transfer
	
	Materia. Inc.
		
	By:	 	 /s/ Mark Trimmer

		 	Mark Trimmer,
		 	Executive Vice President

 LICENSE AGREEMENT 

BETWEEN 
 BOSTON COLLEGE

 AND 
 MATERIA,
Inc. 

 THIS AGREEMENT dated July 11, 2003 (the “Effective Date”) is made between: 

BOSTON COLLEGE whose administrative offices are at LCOB 550, 140 Commonwealth Avenue, Chestnut Hill, MA 02167-3807, USA (“BC”) and
Materia, Inc. a Delaware corporation with a principal place of business at 60 North San Gabriel Boulevard, Pasadena, CA 91107, USA (“MATERIA”). 
  

	1.	SUBJECT MATTER 

 This Agreement relates to the following-(collectively “the
Technology”): 
 The pending U.S. Patent Application No. [**] entitled “[**]” filed [**] and all derived US and foreign
patent applications including substitutions, divisions, continuations, and continuations-in-part applications of such applications and any patents issuing on any of the preceding, including without limitation, reissues, reexaminations, or extensions
or confirmations, registrations, revalidations, or additions and, to the extent that BC is legally and contractually able, patents (“Improvements”) for inventions developed in the laboratory of Dr. Amir Hoveyda at BC that are
dominated by the patents subject to this Agreement (collectively the “PATENT RIGHTS”). 
  

	2.	EXCLUSIVE LICENSING 

 BC grants to MATERIA an exclusive license, with the right to
sub-license, under the PATENT RIGHTS to use the Technology, world-wide in the production, sale, leasing and other commercial exploitation of products in all fields of use (“the Products”), an expression which shall be taken to mean and
include any products entirely or partially produced by means of or with the use of the Technology, or covered by the PATENT RIGHTS filed to protect the Technology. BC reserves the right to retain a non-exclusive license to the foregoing, with the
right to grant sub-licenses, for research purposes only. The rights of the United States of America as set forth under Public Laws 96-517 and 98-620 are specifically reserved. 

 

	3.	UNDERTAKING BY BC 

  

	 	3.1	BC will not share the Technology in the fields of use covered by this Agreement with any third parties, except for purposes related to a non-exclusive license for research purposes as defined in clause 2 above.

  
 - 2 - 

	 	3.2	BC grants to MATERIA the right to grant an exclusive license (subject to the exceptions defined in clause 2) to a sub-licensee. 

  

	4.	UNDERTAKINGS BY MATERIA 

  

	 	4.1	Payment of Patent Expenses. Materia shall be responsible for all direct expenses incurred by BC and associated with the drafting, filing and prosecution for US and PCT applications that are subject to this
Agreement. BC shall invoice MATERIA for such expenses and within [**] days after BC invoices MATERIA, MATERIA shall reimburse BC for [**] (including [**]) incurred by BC during the term of this Agreement in connection with obtaining or
maintaining the PATENT RIGHTS. 

 MATERIA may elect to have BC file foreign patent applications corresponding to the PATENT
RIGHTS in such countries as MATERIA may select by written notice, and such foreign filings shall be added to PATENT RIGHTS and shall be included in the definition of PATENT RIGHTS. MATERIA shall reimburse BC for [**] (including [**]) incurred by BC
during the term of this Agreement in connection with obtaining or maintaining such foreign PATENT RIGHTS. 
 BC will manage the prosecution
of the PATENT RIGHTS and will be solely responsible for the content of patent applications related thereto, however BC shall permit MATERIA to submit input into the preparation and prosecution and BC shall give full consideration to such input. 

To the extent that MATERIA terminates this Agreement pursuant to Paragraph 7.4 with respect to any patent application or patent, MATERIA shall
have no further liability under this paragraph 4.1 for fees relating to applications or patents affected by the termination and such patents and patent applications shall be removed from the PATENT RIGHTS. 

 

	 	4.2	 MATERIA is free to grant sub-licenses to make, use and sell the Products and may disclose to sub-licensees such of the Technology as is necessary for
the exercise of the rights sub-licensed under appropriate provisions of confidentiality. Immediately following the grant of each sub-license and sub-sub-license, 

  
 - 3 - 

	 	
MATERIA will forward to BC in writing a note of the name and address of the sub-licensee or sub-sub-licensee, a description of the technology sub-licensed and its intended applications, and
confirmation of the duration of the sub-license or sub-sub-license. By controlling the wording of its contracts with sub-licensees, MATERIA will ensure that obligations and conditions matching those recorded in this Agreement, and sufficient to
protect the security of the Technology, the intellectual property rights in the Technology, and the interests of BC are imposed on every sub-licensee and sub-sub-licensee; and that in no circumstances do the terms of any sub-license or sub-sub
license in force from time to time conflict with the terms of this Agreement. 

  

	 	4.3	MATERIA will be responsible for the design and construction of the Products and BC shall have no responsibility or liability in that respect. 

 

	 	4.4	MATERIA will ensure that the Products and the packages associated with them are marked suitably with any relevant patent or patent application numbers to satisfy the laws of each of the countries in which the Products
are sold or supplied and in which they are covered by the claims of any patent or patent application, to the intent that BC shall not suffer any loss of damages in any infringement action. 

 

	5.	INFRINGEMENT 

  

	 	5.1	In the event that either party becomes aware of any infringement of any patent contained within the PATENT RIGHTS, it shall promptly notify the other party in writing of the infringement and provide all available
information regarding the identity of the infringer and the nature of the infringing activity, including the identity of any products being sold by the infringer, and the uses for which the infringing products, or products of an infringing process,
are being sold. MATERIA shall have the right to bring an action at the expense of MATERIA and in the name of MATERIA or both MATERIA and BC, against the infringer(s). 

 

	 	5.2	If MATERIA fails to bring suit against an infringer within [**] days after either party has provided written notice to the other under paragraph 5.1 hereof identifying such infringer, then BC shall be entitled to
bring an action at the expense of BC against the alleged infringer in the name of BC or both BC and MATERIA. 

  
 - 4 - 

	 	5.3	In any action brought by a party hereto under either of paragraphs 5.1 or 5.2 hereof, the party bringing the action shall be entitled to retain any damages, costs, attorneys’ fees or other compensation awarded to
it by the court in such action; provided, however, that if the party bringing the action obtains a recovery in damages, increased damages, punitive damages, costs, expenses, attorneys’ fees or other matters of value which exceeds the sum of its
reasonable attorneys’ fees, costs and expenses in prosecution of the action, it shall pay over to the other party [**] of the total amount of such excess. The party not bringing such action agrees to fully co-operate with the party bringing any
such action, including the provision of documents, testimony and other evidence relevant to issues in the cause. In any action brought by either party under paragraph 5.1 or 5.2 hereof, the other party shall be entitled to be represented by its own
counsel at its own expense. In the event of a joint BC/MATERIA action being taken and succeeding, any damages granted to BC/MATERIA shall be equally apportioned by BC and MATERIA after reduction of the costs of each party in bringing such successful
action. 

  

	 	5.4	In any action brought solely by MATERIA under paragraph 5.1 hereof and wherein judgment in such action is rendered in favor of MATERIA, MATERIA may offset [REDACTED] of the legal costs to MATERIA that are not
recoverable from such infringement suits against that portion of royalties due to BC which exceed the Minimum Royalties due in the year the legal costs are incurred up to a maximum of [REDACTED] of total royalties due to BC in the year the legal
costs are incurred. 

  

	6.	FEES and ROYALTIES 

  

	 	6.1	MATERIA agrees to pay BC the following fees: 

 Issue Fee. Materia shall pay to BC a
nonrefundable issue fee of US [REDACTED] dollars [REDACTED] within [**] days of the Effective Date. 

  
 - 5 - 

 Minimum Annual Payments. MATERIA agrees to pay to BC the following non-refundable
payments; each such payment to be creditable against the Payments that are due under Section 6.2, below, with respect to the period beginning on the due date of that payment and ending with the day before the due date of the next following
payment: 
  

			
	 Due Date
	  	Payment Amount
	 January 1, 2004
	  	[REDACTED]
	 January 1, 2005
	  	[REDACTED]
	January 1, 2006 and each January 1 thereafter	  	

  

	 	6.2	MATERIA agrees to make the following royalty payments (“Payments”) to BC on each Product: 

Earned Royalties 

MATERIA shall pay to BC tiered based royalties on cumulative sales made by MATERIA and or its Affiliates of Products covered by one or more
valid claims of the PATENT RIGHTS with this royalty rate on the Net Sales (as defined below in Paragraph 6.4) thereof: 
 [REDACTED] of Net
Sales 
 [REDACTED] of Net Sales 

[REDACTED] of Net Sales. 
 If
the Products sold by MATERIA are covered by a claim in a pending patent application but not an issued patent contained within the PATENT RIGHTS, then MATERIA shall pay a discounted royalty to BC during the Provisional Rights Period (as defined in
Section 12 below). Such discounted royalty rate shall be [REDACTED] of the applicable royalty rate listed above. 
 Sub-licensee
Royalties and Income 
 MATERIA shall pay BC [REDACTED] of the Sub-licensee Revenues (as defined in Section 12) that it receives
from its sub-licensees. Such Sublicensee Revenues specifically shall not include payments made by a sub-licensee (i) in consideration of equity or debt securities of MATERIA; (ii) to support research or development activities to be
undertaken by MATERIA; (iii) upon the achievement by MATERIA or sublicensee of specified milestones or benchmarks relating to the 

  
 - 6 - 

 
development of Products; (iv) with respect to performance based milestones; (v) in consideration for the license or sublicense of any intellectual property other than the PATENT RIGHTS;
(vi) with respect to products other than Products, or (vii) as reimbursement for patent or other expenses. However, if MATERIA should accept research and development payments in exchange for the transfer of Products for commercial use by a
sub-licensee, those Products shall be subject to a royalty payment by MATERIA to BC in an amount equal to a royalty that would be due for an arms length transaction involving the same Products. 

If the Sub-licensee Revenues received by MATERIA are covered by a claim in a pending patent application but not an issued patent contained
within the PATENT RIGHTS, then MATERIA shall pay to BC [REDACTED] of such Sub-licensee Revenues during the Provisional Rights Period. 

Offset for Third Party Royalties 

If MATERIA must pay royalties to one or more third parties (“Third Party Payments”) for intellectual property related to the sale or
other utilization of Products, the Payments paid to BC shall be reduced by an amount equal to [REDACTED] of Third Party Payments, prior to the application of like offsets to third parties for such Payments, up to a maximum of [REDACTED] offset of
Payments to BC for such Third Party Payments that MATERIA is required to pay, in order to deliver products and services covered by both BC patents and third party patents. 

Treatment of Combination Products 

In the event that Products are sold or sub-licensed in combination with one or more other products or services which are not Products,
Payments for such combination products will be calculated on a country-by-country basis by multiplying the value of such combination products by the fraction A/(A+B) where A is the average invoice price during the period of the Product when sold
separately, and B is the average invoice price of any other product(s) or services in the combination when sold separately by MATERIA or an Affiliate. If the products or services in the combination that are not Products are not sold separately by
MATERIA or an Affiliate, Payments shall be calculated by multiplying the value of such 

  
 - 7 - 

 
combination products by the fraction A/C where A is the average invoice price of the Product when sold separately and C is the average invoice price of the combination product. If neither the
Product nor the combination product is sold separately by MATERIA or an Affiliate, Payments shall be calculated as above except that A shall be the total manufacturing cost of Product and C shall be the total manufacturing cost of the combination.

  

	 	6.3	MATERIA shall provide BC within [**] days after the close of each calendar quarter with; 

a) A royalty report for each Product marketed and for each Product brought into use by or within the groups of MATERIA. Each report shall
state the Net Sales and provide a calculation of the royalties due, and shall be accompanied by payment to BC of the royalties due. The first such royalty report shall be due within [**] days of the Effective Date and shall cover the period
beginning on August 8, 2002 and ending on the day immediately prior to the Effective Date. 
 b) A sub-license income report for each
sub-license granted by MATERIA. Each report shall state the income received from the sub-licensee and provide a calculation of the royalties due to BC, and shall be accompanied by payment to BC of the royalties due. 

 

	 	6.4	In the case of a Product which is marketed, the term “Net Sales” shall mean the combined amount received by MATERIA and its Affiliates from the sale to unrelated third parties of Products, less the
following deductible expenses incurred in connection with sales of Products to the extent paid or allowed by MATERIA or an Affiliate and included in accordance with generally accepted accounting principals (GAAP) in the gross sales price billed:
(i) sales, use or turnover taxes; (ii) excise, value added or other taxes, custom duties or consular fees; (iii) transportation, freight, and handling charges, and insurance on shipments to customers; (iv) trade, cash or quantity
discounts or rebates to the extent actually granted (including Medicaid and other government-mandated rebates); (v) agent fees or commissions; and (vi) rebates, refunds, and credits for any rejected or returned Products or because of
retroactive price reductions, rebates or chargebacks. 

  
 - 8 - 

	 	6.5	For the purpose of calculating royalties under this clause, a Product shall be regarded as sold or leased by MATERIA when invoiced, or if not invoiced, when shipped or delivered by MATERIA. If a Product marketed by
MATERIA is re-marketed by an Affiliate, the royalty on each such Product so re-marketed shall be calculated on the highest of the prices at which it is marketed and re-marketed: provided, however, that in no
event shall royalty be paid more than once on each Product. 

  

	 	6.6	All payments provided for under this clause shall be made to BC in US Dollars without any deductions. Any exchange of currency made to calculate sales for the purpose of this clause shall be determined as at the last
business day of each quarter, using the average of the average daily buying and selling rates quoted by the Wall Street Journal during that quarter. 

  

	 	6.7	In the event that full payments of any amount due from MATERIA to BC under this Agreement is not made by any of the dates stipulated, MATERIA shall be liable to pay interest on the amount unpaid at the rate of [**] per
cent ([**]%) from the date when payment was due until the date of the actual payment. 

  

	 	6.8	MATERIA and MATERIA’s sub-licensees and sub-sub-licensees shall keep accounts of all Products, used and marketed and will permit BC or its agents to audit such accounts solely for the purpose of determining the
accuracy of the royalty reports and payments. MATERIA’s obligation and that of MATERIA’s sub-licensees and sub-sub-licensees concerning audit of their accounts shall terminate as to any report [**] years after the date of that report.

  
 - 9 - 

	7.	DURATION AND TERMINATION 

  

	 	7.1	This Agreement shall take effect on the Effective Date and (subject to the remaining sub-clauses of this clause) shall continue in force for fifteen (15) years or until the expiry of such patents as may be granted
directed to the Technology, whichever shall be later. 

  

	 	7.2	If either party commits a material breach of any of the provisions of this Agreement, and the breach is not remedied (where remediable) within the period allowed by notice given by the other party in writing calling on
the party in breach to effect such remedy (such period being not less than [**] days), the other party may by further written notice terminate this Agreement immediately. 

 

	 	7.3	MATERIA will use all reasonable efforts to develop and exploit the Technology, in order to maximize the financial return for both parties. Within [**] days after the end of each calendar year, MATERIA shall provide
BC with a report detailing the progress made and steps taken during the calendar year in: 

  

	 	7.3.1	taking legal action against any misappropriation or infringement of the Technology of which MATERIA becomes or is made aware: 

  

	 	7.3.2	developing the Technology in order to facilitate its commercial exploitation; and 

  

	 	7.3.3	promoting and marketing products. 

 Any failure by MATERIA or BC to provide a report as
required under clause 6.3 or 7.3 during the [**]-day period shall be regarded as a material breach of the provisions of this Agreement, for the purpose of clause 7.2. Furthermore, if either party, on reasonable and demonstrable grounds, concludes
from any such report that the progress made and steps taken by the other party are insufficient or inadequate; that party may initiate good faith discussions between the Chief Executive Officer of MATERIA and the Director, Office for Research
Compliance and Intellectual Property Management of BC to determine a plan to rectify the 

  
 - 10 - 

 
insufficient or inadequate progress. In the event that they are unable to reach agreement, the initiating party may terminate this Agreement by serving notice on the other party, the notice to
expire not less than [**] days after the termination of discussions. 
  

	 	7.4	MATERIA may terminate this Agreement, either in its entirety or as to any jurisdiction or any part of the PATENT RIGHTS, by [**] days’ written notice at any time, provided that MATERIA can and does bring all
sub-licenses and sub-sub-licensees to an end on the same date, including by the transfer of any such sublicense(s) to BC under terms acceptable to BC. Furthermore, any such termination shall not absolve MATERIA of its obligation to accrue and pay
royalties and provide reports under the provisions of clause 6 of this Agreement. 

  

	 	7.5	If MATERIA takes steps to terminate its existence or is required to do so for any reason or takes such steps to reorganize its efforts and priorities in such a way as BC may determine to jeopardize BC’s interests,
then BC shall have the right to terminate this Agreement by serving written notice on MATERIA. Such notice may terminate this Agreement either immediately or at the end of such period as BC shall select. 

 

	 	7.6	Clauses 6.7, 6.8, 7.6, 8, 10, and 11 shall survive the termination or expiration of this Agreement, for whatever reason. 

  

	8.	LIABILITY 

  

	 	8.1	To the extent that MATERIA engages in any activity permitted under this Agreement, MATERIA indemnifies and holds harmless BC from and against any and all claims, liability, expenses, damages and costs due to injury to
persons or damage to property arising or resulting from the manufacture, use or sale of any Product, or the practice of any process that is made, used or practiced using information provided by BC to MATERIA pursuant to this Agreement.

  

	 	8.2	 MATERIA shall defend, indemnify and hold BC harmless from and against all suits, claims, judgments and costs of any kind and character whatsoever
instituted, made or recovered against BC by any person or persons on the ground that the 

  
 - 11 - 

	 	
manufacture, use or sale of any Product by or on behalf of MATERIA or any sublicensees of MATERIA under this Agreement constitutes an infringement of a patent of any country, or the breach,
misuse, violation or infringement of any trade secret, confidential information, or other proprietary right. BC shall give MATERIA prompt notice in writing of the institution of any such suit and of each threat of suit or claim against BC, and BC
further agrees that MATERIA shall have full authority to defend such suit and that BC will provide to MATERIA information and reasonable assistance to enable MATERIA to do so. At it sole election and at its own expense, BC may be represented by its
own counsel in any action to which this clause applies. 

  

	 	8.3	WARRANTY AND DAMAGES DISCLAIMERS. BC represents and warrants: (i) it is the sole and exclusive owner of all right, title, and interest in the Technology; (ii) it has the right to grant the rights and
licenses granted herein, and the Technology is free and clear of any lien, encumbrance, security interest, or restriction on license; (iii) there are no threatened or pending actions, suits, investigations, claims, or proceedings in any way
relating to the Technology, and (iv) inventorship of the PATENT RIGHTS has been determined according to the patent laws applicable to any patent or patent application contained therein. BC MAKES NO OTHER REPRESENTATIONS OR WARRANTIES OF ANY
KIND CONCERNING THE PATENT RIGHTS, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF
LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. 

 IN NO EVENT SHALL BC, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES
AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER BC SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY OF THE FOREGOING. 

  
 - 12 - 

	 	8.4	BC makes no representation or warranty that advice given to MATERIA pursuant to this Agreement by any employee, student, agent or appointee of BC or the use of any information which they or BC provide in connection with
this agreement, will not result in infringement of third-party rights. 

  

	 	8.5	MATERIA undertakes to make no claim against any employee, student, agent or appointee of BC, being a claim which seeks to enforce against any of them any liability whatsoever in connection with this Agreement or the
subject-matter. 

  

	 	8.6	The liability of either party for any breach of this Agreement, or arising in any other way out of the subject-matter of this Agreement, will not extend to any incidental or consequential damages or losses including
(without limitation) loss of profits. 

  

	 	8.7	In any event, the maximum liability of BC to MATERIA under or otherwise in connection with this Agreement or its subject-matter shall not exceed the return of all monies paid by MATERIA under this Agreement.

  

	 	8.8	If any sub-clause of this clause 8 is held to be invalid or unenforceable under any applicable statute or rule of law, then it shall be deemed to be omitted, and if as a result any party becomes liable for loss or
damage which would otherwise have been excluded then such liability shall be subject to the remaining sub-clauses of this clause 8. 

  

	9.	FORCE MAJEURE 

 If the performance by either party of any of its obligations under
this Agreement (other than an obligation to make payment) shall be prevented by circumstances beyond its reasonable control, then such party shall be excused from performance of that obligation for the duration of the relevant event. 

  
 - 13 - 

	10.	NOTICES 

 BC’s representatives for the purpose of receiving payments and
notices shall until further notice be: 
 The Director, Office for Research Compliance and Intellectual Property Management 

Boston College 
 LCOB 550 

140 Commonwealth Avenue 
 Chestnut
Hill 
 MA 02167-3807 
 USA 

Facsimile: [**] 
 MATERIA’s
representative for the purpose of receiving notices shall until further notice be: 
 Materia, Inc. 

60 North San Gabriel Boulevard 

Pasadena, CA 91107 
 Attention:
President 
 Facsimile: [**] 

All notices shall be in writing sent by certified mail, courier or facsimile transmission. 

 

	11.	GENERAL 

  

	 	11.1	Clause headings are inserted in this Agreement for convenience only, and they shall not be taken into account in the interpretation of this Agreement. 

 

	 	11.2	Neither party shall use the name of the other or the other’s employees in any form of publicity, advertising or promotion without the prior written approval of the other. 

 

	 	11.3	Both parties shall be free to publicize the existence of this Agreement. Both parties undertake not to publicize the details of this Agreement except: 

 

	 	?	where required by governmental authority; or 

  

	 	?	where required to investors according to stock exchange rules; or 

  

	 	?	where the parties have agreed a mutually acceptable scope of a particular disclosure in advance. 

  

	 	11.4	This Agreement is personal to MATERIA and no rights or obligations may be assigned by MATERIA without the prior written consent of BC. 

  
 - 14 - 

	 	11.5	Nothing in this Agreement shall create, imply or evidence any partnership or joint venture between BC and MATERIA or the relationship between them of principal and agent. 

 

	 	11.6	This Agreement constitutes the entire agreement between the parties with regard to the Technology. Specifically, but without limitation, this Agreement does not impose or imply any obligation on BC to conduct
development work; any arrangements for such work shall be the subject of a separate agreement between the parties. Any variation of this Agreement shall be in writing and signed by authorized signatories for both parties. 

 

	 	11.7	This Agreement shall be governed by the laws of the Commonwealth of Massachusetts shall have exclusive jurisdiction to deal with any dispute which may arise of or in connection with this Agreement. 

 

	 	11.8	If any one or more clauses of sub-clauses of this Agreement would result in this Agreement being prohibited pursuant to Article 85(1) of the Treaty of Rome, then it or they shall be deemed to be omitted and the
Agreement shall be subject to termination at the option of either party. 

  

	12.	DEFINITIONS 

 The following terms as used herein shall have the meanings set forth
below: 
 “Affiliate” shall mean, with respect to a party to the Agreement, any entity directly or indirectly controlling or
controlled by or in common control with such party, where “control” is defined as the ownership of at least fifty percent (50%) of the equity or beneficial interests of such entity, or the right to vote for or appoint a majority of
the board of directors or other governing body of such entity. 
 “Provisional Rights Period” shall mean the period
beginning on the date of publication of a United States patent application under 35 U.S.C. 122(b) or of an international patent application filed under the treaty defined in 35 U.S.C. 351(a) designating the United States under Article 21(2)(a) of
such treaty and ending on the date the patent is issued or the patent application is abandoned or receives a final rejection from the USPTO. 

  
 - 15 - 

 “Sub-licensee Revenues” shall mean fees, payments, royalties or other license
revenues that MATERIA receives from sub-licensees, other than Affiliates, for the sale of Products or the conduct of services which are related to Products covered by one or more valid claims of the PATENT RIGHTS 

“USPTO” shall mean the United States Patent and Trademark Office. 

“WIPO” shall mean the World Intellectual Property Organization. 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their authorized representatives and delivered in duplicate originals
as of the Effective Date. 
  

									
		 	BC	 		 		 	MATERIA
					
	By:	 	 /s/ Stephen Erickson
	 		 	By:	 	 /s/ Mark S. Trimmer

	Name:	 	Stephen Erickson	 		 	Name:	 	Mark S. Trimmer
	Title:	 	Director Compliance and Intellectual Property Mgt. Boston College	 		 	Title:	 	Executive Vice President
					
	Date:	 	7/11/03	 		 	Date:	 	7/17/03

  
 - 16 -EX-10.14

 Exhibit 10.14 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

AMENDED AND RESTATED LICENSE AGREEMENT 

This Amended and Restated License Agreement (this “Agreement”) is entered into as of the 19th day of February, 2010 (the “Effective Date”), for the purpose of amending and replacing the License Agreement dated August 2, 2006 (the “Original Agreement”), by and among:
Aileron Therapeutics, Inc. (formerly Renegade Therapeutics, Inc.), a Delaware corporation, having a principal place of business at 840 Memorial Drive, 2nd Floor, Cambridge, MA 02142
(“Licensee”); President and Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”); and Dana-Farber Cancer Institute, Inc., 44 Binney Street, Boston, MA (“DFCI”).
Harvard and DFCI shall be referred to together as “Licensors”. 
 WHEREAS, Licensors and Licensee entered into the Original
Agreement, pursuant to which Licensors granted Licensee a license under the Original Patent Rights (as defined below), all in accordance with the terms and conditions of the Original Agreement; and 

WHEREAS, Licensee wishes to license from Licensors certain additional patent rights related to the Original Patent Rights; and 

WHEREAS, Licensors desire to have products based on these additional patent rights and the Original Patent Rights developed and commercialized
to benefit the public and are willing to grant licenses under the additional patent rights and Original Patent Rights; and 
 WHEREAS,
Licensee has represented to Licensors that it will use diligent efforts (as set forth below) to develop, obtain regulatory approval for and commercialize products based on these additional patent rights, as well as products based on the Original
Patent Rights; and 
 WHEREAS, the parties wish to add these additional patent rights to the scope of the licenses, and make several other
changes to the terms of, the Original Agreement by reforming, restating and replacing the Original Agreement with this Agreement, such that the terms of this Agreement shall be deemed to apply from and after the Effective Date. 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

 

	1.	Definitions. 

 Whenever used in this Agreement with an initial capital letter, the terms
defined in this Section 1 and elsewhere in this Agreement, whether used in the singular or the plural, shall have the meanings specified herein. 

1.1. “Affiliate” shall mean, with respect to any person, organization or entity, any other person, organization or entity
controlling, controlled by or under common control with, such first person, organization or entity. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing,
control shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding voting stock or other ownership 

  
 - 1 - 

 
interest of the other organization or entity, or (ii) possesses, directly or indirectly the power to elect or appoint fifty percent (50%) or more of the members of the governing body of
the organization or other entity. The parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may
be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence. 
 1.2.
“[**] Patent Rights” shall mean, in each case to the extent owned and controlled by DFCI: (a) the patent applications and patents listed in Exhibit 1.2 (including any PCT and/or U.S. utility applications claiming priority to any
such provisional applications that are filed on or before the one year conversion date thereof); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or
extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or
extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and covers subject matter described in, at least one of the patents or patent applications identified in (a),
(b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric
exclusivity periods, any other patent term extensions and exclusivity periods and the like and any equivalents anywhere in the world of any patents and patent applications identified in (a) through (e). 

1.3. “Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 
 1.4.
“Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial. 
 1.5.
“Combination Product” shall mean a Licensed Product which incorporates (a) one or more Covered Peptides and (b) at least one other Independent Active Ingredient. 

1.6. “Covered Peptide” shall mean any peptide (including poly-peptides) the production, making, use, sale or importation of
which falls within the scope of a Valid Claim. 
 1.7. “Development Milestones” shall mean: 

(a) “General Development Milestone” which shall mean the development milestone set forth in Section A of Exhibit 1.7 hereto
for the development of a Licensed Product. 
 (b) “[**] Development Milestones” which shall mean the development milestones
set forth in the table in Section D of Exhibit 1.7 hereto for the development of a Licensed Product that is covered by a Valid Claim of the [**] Patent Rights; 

(c) “[**] Development Milestone” which shall mean the development milestone set forth in Section B of Exhibit 1.7 hereto for
the development of a Licensed Product that is covered by a Valid Claim of the Licensors Patent Rights; 

  
 - 2 - 

 (d) “[**] Development Milestones” which shall mean the development milestones
set forth in the table in Section D of Exhibit 1.7 hereto for the development of a Licensed Product that is covered by a Valid Claim of the [**] Patent Rights; 

(e) “p53 Development Milestones” which shall mean the development milestones set forth in the table in Section D of Exhibit
1.7 hereto for the development of a Licensed Product that is covered by a Valid Claim of the p53 Patent Rights; and 
 (f) “[**]
Development Milestones” which shall mean the development milestones set forth in Section C of Exhibit 1.7 hereto for the development of a Licensed Product that is covered by a Valid Claim of the [**] Poly Peptide Patent Rights. 

For clarity, for purposes of evaluating whether a particular Development Milestone has been met by a particular Licensed Product the
applicable Valid Claim(s) shall be as existing in the U.S. patent application or patent (i.e., as then prosecuted or issued) as of the date the occurrence of the activity giving rise to the accomplishment of the Development Milestone. 

1.8. “Development Plan” shall mean the plan for the development of Licensed Products attached hereto as Exhibit 1.8, as such
plan may be amended from time to time pursuant to Sections 5.2. 
 1.9. “DFCI Inventions” shall mean any inventions or
discoveries made or developed solely by Dr. Loren Walensky in the performance of services for Licensee with respect to stabilized peptides, including without limitation methods of making, the composition of, and new uses for, stabilized
peptides. 
 1.10. “DFCI Patent Rights” shall mean any U.S. or foreign patents or patent applications that claim DFCI
Inventions, but only with respect to those claims that claim the subject matter of such DFCI Inventions. 
 1.11. “FDA”
shall mean the United States Food and Drug Administration. 
 1.12. “Field” shall mean all applications, except any use as
a research tool. 
 1.13. “First Commercial Sale” shall mean the first sale of a Licensed Product by Licensee, an Affiliate
of Licensee or a Sublicensee to an unaffiliated third party after Regulatory Approval has been achieved in the country in which such Licensed Product is sold. Sales for purposes of testing the Licensed Product and samples purposes shall not be
deemed First Commercial Sale. 
 1.14. “Harvard Inventions” shall mean any inventions or discoveries made or developed
solely by Dr. Greg Verdine in the performance of services for Licensee with respect to stabilized peptides, including without limitation methods of making, the composition of, and new uses for, stabilized peptides. 

1.15. “Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard; (a) the patent
applications and patents listed in Exhibit 1.15 (including any PCT and/or U.S. utility applications claiming priority to any such provisional applications that are 

  
 - 3 - 

 
filed on or before the one year conversion date thereof); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination,
substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b), including any reissues, renewals, reexaminations,
substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and covers subject matter described in, at least one of the patents or patent applications
identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); (f) any U.S. or foreign patents or patent
applications that claim Harvard Inventions, but only with respect to those claims that claim the subject matter of such Harvard Inventions; and (g) any supplementary protection certificates, pediatric exclusivity periods, any other patent term
extensions and exclusivity periods and the like and any equivalents anywhere in the world of any patents and patent applications identified in (a) through (f). 

1.16. “IND” shall mean an investigational new drug application, clinical study application, clinical trial exemption or
similar application or submission for approval to conduct human clinical investigations filed with a Regulatory Agency in any country. 

1.17. “Independent Active Ingredient” shall mean any compound or substance other than a Covered Peptide which (a) is
contained in a product and (b) when administered to a patient independently of any other active ingredient has a therapeutic clinical effect. 

1.18. “Initiation” or “Initiate” shall mean, with respect to a Clinical Trial, the administration of the first dose
to a patient in such Clinical Trial. 
 1.19. “Joint Inventions” shall mean all inventions and discoveries made jointly by
(a) one or more employees (or others on behalf) of Licensee, and (b) Dr. Greg Verdine and/or Dr. Loren Walensky in the performance of services for Licensee, with respect to stabilized peptides, including without limitation
methods of making, the composition of, and new uses for, stabilized peptides. 
 1.20. “Joint Patent Rights” shall mean any
patent or patent application that claims Joint Inventions. 
 1.21. “Licensed Patent Rights” shall mean, individually and
collectively, the Original Patent Rights, the [**] Patent Rights, the [**] Patent Rights, the p53 Patent Rights and the [**] Poly Peptide Patent Rights. 

1.22. “Licensed Product” shall mean any [**] Product or [**] Product. 

1.23. “Licensors Inventions” shall mean all inventions and discoveries (excluding any Joint Inventions) made jointly by
Dr. Verdine and Dr. Loren Walensky in the performance of services for Licensee with respect to stabilized peptides, including without limitation methods of making, the composition of, and new uses for, stabilized Peptides. 

1.24. “Licensors Patent Rights” shall mean, in each case to the extent owned and controlled by Licensors, as applicable:
(a) the patent applications and patents listed in Exhibit 1.24 (including any PCT and/or U.S. utility applications claiming priority to any such provisional 

  
 - 4 - 

 
applications that are filed on or before the one year conversion date thereof); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue,
renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b), including any reissues,
renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and covers subject matter described in, at least one of the patents
or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); (f) any U.S. or foreign
patents or patent applications that claim Licensors Inventions, but only with respect to those claims that claim the subject matter of such Licensors Inventions; and (g) any supplementary protection certificates, pediatric exclusivity periods,
any other patent term extensions and exclusivity periods and the like and any equivalents anywhere in the world of any patents and patent applications identified in (a) through (f). 

1.25. “Net Sales” shall mean the gross amount billed or invoiced or received (whichever occurs first) by or on behalf of
Licensee, its Affiliates and Sublicensees (in each case, the “Invoicing Entity”) on sales, leases or other transfers of Licensed Products (whether made before or after the First Commercial Sale of the Product), less the following to the
extent applicable to Licensed Products sold, leased or transferred: (a) customary trade, quantity, or cash discounts to the extent actually allowed and taken; (b) amounts repaid or credited by reason of rejection or return and
uncollectible portions of billed or invoiced amounts; (c) refunds, chargebacks and allowances actually given that effectively reduce the net selling price; (d) rebates paid or credited to any governmental agency (or branch thereof) or to
any third party payor, administrator or contractee; (e) discounts mandated by wholesalers, or granted to meet the requirements of, applicable state, provincial or federal law, including required retroactive price reductions; and (f) any
sales, value added or similar taxes, custom duties or other similar governmental charges levied on the production, sale, transportation, delivery, or use of a Licensed Product which is paid by or on behalf of Licensee or such Invoicing Entity;
provided that: 
 (i) In any transfers of Licensed Products between an Invoicing Entity and an Affiliate of such Invoicing Entity not for
the purpose of resale by such Affiliate (i.e., where such Affiliate is the end user of such Licensed Products for commercial purposes), Net Sales shall be equal to the fair market value of the Licensed Products so transferred, assuming an arm’s
length transaction made in the ordinary course of business; and 
 (ii) In the event that an Invoicing Entity receives non-monetary
consideration for any Licensed Products or in the case of transactions not at arm’s length with a non-Affiliate of Invoicing Entity, Net Sales shall be calculated based on the fair market value of such consideration or transaction, assuming an
arm’s length transaction made in the ordinary course of business. 
 Sales of Licensed Products by an Invoicing Entity to an Affiliate
of such Invoicing Entity, for resale by such Affiliate, shall not be deemed Net Sales and Net Sales shall be determined based on the total amount invoiced or billed by such Affiliate on resale to an independent third party purchaser. 

  
 - 5 - 

 With respect to sales of Combination Products, Net Sales shall be calculated as follows: 

(A) If the Covered Peptide(s) and all other Independent Active Ingredient(s) included in such Combination Product are available separately
(i.e. without any other active ingredients) in the country of sale, then Net Sales for purposes of royalty payments will be calculated by multiplying the Net Sales of the Combination Product by the fraction [**] where [**] is the gross invoice price
of the Covered Peptide(s) in the Combination Product during the royalty period in question, and [**] is the gross invoice price for all other Independent Active Ingredient(s) in the Combination Product during the royalty period in question. 

(B) Otherwise, the parties shall negotiate, in good faith, other means of calculating Net Sales with respect to such Combination Product. 

1.26. “[**] Patent Rights” shall mean, in each case to the extent owned and controlled by Licensors: (a) the patent
applications and patents listed in Exhibit 1.26 (including any PCX and/or U.S. utility applications claiming priority to any such provisional applications that are filed on or before the one year conversion date thereof); (b) any patent or
patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of
the patent applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority
date of, and covers subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a),
(b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like and any equivalents anywhere in the
world of any patents and patent applications identified in (a) through (e). 
 1.27. “Original Patent Rights” shall
mean the Harvard Patent Rights, the Licensors Patent Rights, the DFCI Patent Rights and the Joint Patent Rights. 
 1.28. “p53
Patent Rights” shall mean, in each case to the extent owned and controlled by Licensors; (a) the patent applications and patents listed in Exhibit 1.28 (including any PCT and/or U.S. utility applications claiming priority to any such
provisional applications that are filed on or before the one year conversion date thereof); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or
extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or
extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the priority date of, and covers subject matter described in, at least one of the patents or patent applications identified in (a),
(b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric
exclusivity periods, any other patent term extensions and exclusivity periods and the like and any equivalents anywhere in the world of any patents and patent applications identified in (a) through (e). 

  
 - 6 - 

 1.29. “Phase I Clinical Trial” shall mean a human clinical trial in any country
that would satisfy the requirements of 21 CFR 312.21(a). 
 1.30. “Phase II Clinical Trial” shall mean a human
clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b). 
 1.31. “Phase III Clinical
Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c). 
 1.32.
“Regulatory Agency” shall mean the FDA or equivalent agency or government body of another country. 
 1.33.
“Regulatory Approval” shall mean approval by the relevant Regulatory Agency permitting commercial sale of a Licensed Product in a particular country. 

1.34. “[**] Poly Peptide Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) the
patent applications and patents listed in Exhibit 1.34 (including any PCT and/or U.S. utility applications claiming priority to any such provisional applications that are filed on or before the one year conversion date thereof); (b) any patent
or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent applications identified in (a); (c) any patents issuing on any
of the patent applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent, which claim is entitled to the
priority date of, and covers subject matter described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a),
(b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like and any equivalents anywhere in the
world of any patents and patent applications identified in (a) through (e). 
 1.35. “Sub-contractor” shall
mean an independent third party whom Licensee or a Sublicensee contracts to perform, on behalf of Licensee or Sublicensee, as applicable, one or more of Licensee’s obligations or rights under this Agreement, or in the case of a Sublicense, one
or more of Sublicensee’s obligations or rights under the Sublicense agreement; provided that the term “Sub-contractor” shall not include any person or entity that pays Licensee, Sublicensee or any of their Affiliates any consideration
(in any form) with respect to such services (including without limitation any co-marketing or co-distribution partners). 
 1.36.
“Sublicense” shall mean any right granted, license given or agreement entered into, by Licensee to or with any other person or entity, under or with respect to or permitting any use of any of the Licensed Patent Rights or otherwise
permitting the development, manufacture, marketing, distribution and/or sale of Licensed Products (regardless of whether such grant of rights, license given or agreement entered into is referred to or is described as a sublicense). For clarity,
“Sublicense” does not include a grant by Licensee as part of a sale of a Licensed Product to an independent third party of the implied license (a) to use such Licensed Product or (b) to resell such Licensed Product, provided that
the only consideration (whether monetary or non-monetary) 

  
 - 7 - 

 
received by Licensee, or any Affiliate of Licensee, in connection with such grant is the fair market value of the Licensed Product sold. Notwithstanding anything expressed or implied in this
Agreement to the contrary, the following shall not be considered a Sublicense: any agreement in which Licensee grants its Affiliate the right to perform or exercise some or all of Licensee’s rights and/or obligations under Sections 4.1, 4.2 or
4.3, as contemplated in Section 4.1.5, as long as such Affiliate does not pay Licensee any consideration (in any form) actually for such grant. 

1.37. “Sublicense Receipts” shall mean any payments or other consideration that Licensee or any of its Affiliates receives in
connection with a Sublicense (including any fees or consideration for the grant of an option to obtain a Sublicense), including without limitation license fees, milestone payments and license maintenance fees, but specifically excluding:
(a) any royalties attributable to sales of Licensed Products (provided that such sales form the basis of royalties paid to Harvard under Section 6.5), (b) any profit share amounts attributable to sales of Licensed Products (provided
that such sales form the basis of royalties paid to Harvard under Section 6.5), (c) payments specifically committed to cover costs to be actually incurred by Licensee (including equipment purchases and full-time equivalent personnel
actually provided by Licensee) in the research and development of Licensed Products which are the subject matter of the Sublicense, (d) reimbursement of milestone payments paid by Licensee for milestones in Section 6.4 hereunder or amounts
incurred with respect to the filing, prosecution or maintenance of any Licensed Patent Rights, (e) loans or other debt obligations (any amounts of which are forgiven shall be deemed Sublicense Receipts), (f) amounts received from any third
party for the purchase of equity at fair market value (any amounts paid in excess of fair market value shall be deemed Sublicense Receipts), (g) securities of an Affiliate received from an Affiliate that are not provided in exchange for the
grant of a Sublicense, (h) amounts received for the fair market value of Licensed Products supplied by or on behalf of Licensee or its Affiliates and sold by the recipient Sublicensee to third parties, and (i) amounts received in
consideration of the sale of substantially all of the business or assets of Licensee or any of its Affiliates to which this Agreement pertains. 

In the event that Licensee or an Affiliate of Licensee receives non-monetary consideration in connection with a Sublicense, or the grant of an
option to obtain a Sublicense (excluding the attributed value of any cross-license granted to a third party in good faith, after arm’s length negotiations, to settle any actual or prospective claim of infringement by a Licensed Product of such
third party intellectual property rights, but not excluding any consideration actually received from such third party on account of such cross-license), or in the case of transactions not at arm’s length, Sublicense Receipts shall be calculated
based on the fair market value of such consideration or transaction, assuming an arm’s length transaction made in the ordinary course of business. 

1.38. “Sublicensee” shall mean any person or entity granted a Sublicense. 

1.39. “Third Party License” shall mean a license obtained by Licensee or its Affiliates from an unaffiliated third party to
one or more patents that have not been held invalid or unenforceable issued in the United States or any other jurisdiction, the claims of which cover the use, manufacture, sale or importation of a Covered Peptide in the country in which it is
manufactured or sold, or of one or more other functional components of a Licensed Product that is essential for the efficacy of such Licensed Product. 

  
 - 8 - 

 1.40. “Third Party Proposed Product” shall mean an actual or potential Licensed
Product that (a) is aimed at an indication for which [**], (b) does not present [**] with any Licensed Product that is being (or within a [**] year period is planned to be, as demonstrated by [**], and (c) does not contain
substantially the same [**] in any Licensed Product [**]. 
 1.41. “[**] Product” shall mean any product for use in
the Field [**]. 
 1.42. “[**] Product” shall mean any product for use in the Field [**]. 

1.43. “Valid Claim” shall mean (a) a pending claim of a patent application within the Licensed Patent Rights, which
(i) has been asserted in good faith, (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling, and (iii) does not remain pending more than [**] years from the date of issuance of the first
substantive patent office action considering the patentability of such claim by the relevant patent office in such country or territory; (b) a claim of an issued or granted and unexpired patent within the Licensed Patent Rights, which has not
been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, which has not been rendered unenforceable through disclaimer or
otherwise, which has not been abandoned, and which has not been lost through an interference proceeding. Notwithstanding the foregoing, the limitation of subsection (iii) above shall not apply to any patent application within the Joint Patent
Rights that is being prosecuted by Licensee, 
  

	2.	Title. 

 2.1. Subject to the licenses granted to Licensee pursuant to
Section 4 below, all rights, title and interest in and to the Harvard Patent Rights, the [**] Poly Peptide Patent Rights and the Harvard Inventions are and shall be owned solely and exclusively by Harvard. 

2.2. Subject to the licenses granted to Licensee pursuant to Section 4 below, all rights, title and interest in and to the
Licensors Patent Rights, [**] Patent Rights, p53 Patent Rights and Licensors Inventions are and shall be owned jointly and exclusively by Licensors. 

2.3. Subject to the licenses granted to Licensee pursuant to Section 4 below, all rights, title and interest in Joint Inventions
and Joint Patent Rights shall be owned jointly by (i) Harvard and/or DFCI, as applicable and (ii) Licensee. 
 2.4.
Subject to the licenses granted to Licensee pursuant to Section 4 below, all rights, title and interest in and to the [**] Patent Rights, the DFCI Patent Rights and DFCI Inventions shall be owned solely and exclusively by DFCI. 

2.5. All determinations of inventorship under this Agreement shall be made in accordance with United States patent law. In case of
dispute between Harvard (and/or DFCI) and Licensee over inventorship, a mutually acceptable outside patent counsel shall make the determination of the inventor(s) by applying the standards contained in United States patent law. 

2.6. Harvard or DFCI, as applicable, shall disclose to Licensee in writing the development, making, conception or reduction to practice
of any invention within the Harvard Inventions, DFCI Inventions or Joint Inventions of which it becomes aware, promptly after its receipt of an invention disclosure form from Dr. Greg Verdine or Dr. Loren Walensky, as applicable, in each
case that is not disclosed to Harvard or DFCI by Licensee pursuant to Section 2.7. 

  
 - 9 - 

 2.7. Licensee shall disclose to Harvard’s Office of Technology Development (or its
successor) and DFCI’s Office of Research and Technology Ventures in writing the development, making, conception or reduction to practice of any invention within the Harvard Inventions, DFCI Inventions or Joint Inventions of which it becomes
aware, promptly after it becomes aware of such invention, in each case that is not disclosed to Licensee by Harvard and/or DFCI pursuant to Section 2.6. 
  

	3.	Patent Filing, Prosecution and Maintenance. 

 3.1. Responsibility. 

3.1.1. Harvard. Subject to Article 8, Harvard shall be responsible for the preparation, filing, prosecution, protection and maintenance
of all Harvard Patent Rights and [**] Poly Peptide Patent Rights (collectively, the “Harvard Prosecuted Patent Rights”), using patent counsel reasonably acceptable to Licensee and will instruct such patent counsel to furnish
Licensee with copies of all correspondence relating to the Harvard Prosecuted Patent Rights from the United States Patent and Trademark Office and any other patent office as well as copies of all proposed responses to such correspondence in time for
Licensee to review and comment on such response. Harvard shall prepare, file, prosecute, protect and maintain the Harvard Prosecuted Patent Rights in good faith. Subject in each case to Licensee’s prior agreement to cover the relevant costs in
accordance with Section 3.2, Harvard shall file national phase applications in all countries requested by Licensee. Harvard shall consult with Licensee as to the preparation, filing, prosecution, protection and maintenance of the Harvard
Prosecuted Patent Rights reasonably prior to any deadline or action with the U.S. Patent & Trademark Office or any other patent office, and shall take into reasonable consideration all comments reasonably requested by Licensee, and (subject
in each case to Licensee’s prior agreement to cover the relevant costs in accordance with Section 3.2) add claims reasonably requested by Licensee, and shall furnish Licensee with copies of all relevant documents reasonably in advance of
such consultation. Without limiting the generality of the foregoing, Harvard agrees: (a) to give Licensee an opportunity to review the text of each patent application within the Harvard Prosecuted Patent Rights before filing; (b) consult
with Licensee with respect thereto; (c) supply Licensee with a copy of any application within the Harvard Prosecuted Patent Rights as filed, together with notice of its filing date and serial number; (d) keep Licensee advised of the status
of the actual and prospective patent filings within the Harvard Prosecuted Patent Rights; and (e) provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings. 

3.1.2. Licensee. Subject to the terms and conditions of this Article 3 and Article 8, Licensee shall have the first right to prepare,
file, protect, prosecute and maintain all Joint Patent Rights, [**] Patent Rights, [**] Patent Rights, P53 Patent Rights, Licensors Patent Rights and DFCI Patent Rights (collectively, the “Licensee Prosecuted Patent Rights”) at
Licensee’s expense, but Licensee may elect not to do so as set forth in Section 3.3. As of the Effective Date, Harvard and DFCI shall transfer the responsibility for preparing, filing, protecting, prosecuting and maintaining the Licensors
Patent Rights, [**] Patent Rights, [**] Patent Rights and P53 Patent 

  
 - 10 - 

 
Rights to Licensee. Licensee shall prepare, file, prosecute, protect and maintain the Licensee Prosecuted Patent Rights in good faith. Licensee shall, with respect to the preparation, filing,
protection, prosecution and maintenance of the Licensee Prosecuted Patent Rights: (a) use independent patent counsel reasonably acceptable to the other parties (i.e., Harvard and/or DFCI) hereto who have an ownership interest in the applicable
patent rights (each, an “Interested Party”) and instruct such patent counsel to furnish the Interested Party(ies) with copies of all correspondence relating to the Licensee Prosecuted Patent Rights from the United States Patent and
Trademark Office and any other patent office as well as copies of all proposed responses to such correspondence in time for the Interested Party(ies) to review and comment on such response; (b) give the Interested Party(ies) an opportunity to
review the text of each patent application before filing; (c) consult with the Interested Party(ies) with respect thereto; (d) supply the Interested Party(ies) with a copy of any application within the Licensee Prosecuted Patent Rights as
filed, together with notice of its filing date and serial number; (e) keep the Interested Party(ies) advised of the status of the actual and prospective patent filings within the Licensee Prosecuted Patent Rights; and (f) provide advance
copies of any papers related to the filing, prosecution and maintenance of such patent filings. Licensee shall give the Interested Party(ies) the opportunity to provide comments on and make requests of the filing party concerning the prosecution,
filing and maintenance of the Licensee Prosecuted Patent Rights, and shall take into reasonable consideration such comments and requests. Licensee acknowledges that Harvard will retain its own patent counsel to review Licensee’s preparation,
filing, protection, prosecution and maintenance of Licensee Prosecuted Patent Rights in which Harvard has an ownership interest. 
 3.2.
Expenses. Subject to Section 3.3 below, Licensee shall reimburse Harvard for all documented patent-related expenses incurred by Harvard pursuant to Section 3.1.1 within [**] days after Harvard invoices Licensee. Also, within [**] days
following the receipt of each invoice from Harvard, Licensee shall reimburse Harvard for amounts paid by Harvard to its patent counsel with respect to review of Licensee’s preparation, filing, protection, prosecution and maintenance of Licensee
Prosecuted Patent Rights in which Harvard has an ownership interest. In addition, within [**] days following the receipt of an invoice from Harvard and/or DFCI, Licensee shall reimburse Harvard and DFCI, as appropriate, for expenses incurred by
Licensors prior to the Effective Date, and in connection with the transfer of responsibility to Licensee as described in Section 3.1.2, with respect to the preparation, filing, prosecution and/or maintenance of the Licensors Patent Rights, [**]
Poly Peptide Patent Rights, [**] Patent Rights, [**] Patent Rights and p53 Patent Rights. 
 3.3. Abandonment. Should Licensee decide
that it does not wish to pay for the filing or prosecution of a patent application, or the maintenance of a patent, on any invention or claim included in the Licensed Patent Rights, in any country (an “Abandoned Country”), Licensee shall
provide Harvard and/or DFCI, as applicable based on ownership, with written notice of such election at least [**] days prior to the effective date of such abandonment (and in no event less than [**] days prior to the date on which any pending action
needs to be taken to preserve the relevant Licensed Patent Rights). Upon the effective date of such abandonment, Licensee shall be released from its obligation to pay for the prosecution of, or to reimburse Harvard for the expenses incurred by
Harvard thereafter in conjunction with, such Licensed Patent Rights in such Abandoned Country; provided that expenses for work or filing fees authorized prior to the receipt by Harvard and/or DFCI of such notice shall be deemed incurred prior to the
notice. 

  
 - 11 - 

 3.3.1. Effect of Abandonment of Harvard Patent Rights, [**] Poly Peptide Patent Rights, [**]
Patent Rights, [**] Patent Rights, P53 Patent Rights, Licensors Patent Rights and/or DFCI Patent Rights. In the event of Licensee’s abandonment of any Harvard Patent Rights, [**] Poly Peptide Patent Rights, [**] Patent Rights, [**] Patent
Rights, P53 Patent Rights, Licensors Patent Rights and/or DFCI Patent Rights, any license granted by Harvard and/or DFCI to Licensee hereunder with respect to such Licensed Patent Rights will terminate in the relevant Abandoned Country, and Licensee
will have no rights whatsoever to exploit such abandoned Licensed Patent Rights in such Abandoned Country. Harvard and/or DFCI shall then be free, without further notice or obligation to Licensee, to grant rights in and to such abandoned Licensed
Patent Rights in such Abandoned Country to third parties. 
 3.3.2. Effect of Abandonment of Joint Patent Rights. In the event of
Licensee’s abandonment of any Joint Patent Rights, Harvard (and/or DFCI, if DFCI is the joint owner of such Patent Rights with Licensee) may assume responsibility for paying for the preparation, filing, prosecution, protection and/or
maintenance of such Joint Patent Rights in such Abandoned Country, in its sole discretion. In such event, such paying Licensor(s) may choose, at its sole discretion, to terminate any license granted by such Licensor to Licensee hereunder with
respect to such Joint Patent Rights in such Abandoned Country. If such Licensor exercises its right to terminate: (a) the license granted hereunder with respect to such Joint Patent Rights in such Abandoned Country shall terminate and
(b) such Licensor(s) thereafter shall be free, without further notice or obligation to Licensee, and Licensee hereby grants such Licensor(s) an exclusive license (subject to the provisions of this Section 3.3.2) under its interest in such
Joint Patent Rights in such Abandoned Country, to grant rights in and to such Joint Patent Rights in such Abandoned Country to third parties; provided, however, that such third party licenses shall be subject to Licensee retaining the right, without
further notice or obligation to Harvard, to practice and otherwise exploit its interest in such Joint Patent Rights in such Abandoned Country in connection with any development or commercialization of a Licensed Product by or on behalf of Licensee
or its Affiliates, and to grant rights to third parties in and to its interest in such Joint Patent Rights in such Abandoned Country in connection with a license of a Licensed Product developed by or on behalf of Licensee, its Affiliates or any
Sublicensee. The claims of any Joint Patent Rights to which Licensee’s license is terminated in an Abandoned Country pursuant to this Section 3.3.2 shall cease to constitute Valid Claims for purposes of this Agreement. 

3.4. No Warranty. Nothing contained herein shall be deemed to be a warranty by Licensors that they can or will be able to obtain
patents on patent applications included in the Licensed Patent Rights, or that any of the Licensed Patent Rights will afford adequate or commercially worthwhile protection. 

3.5. Small Entity Designation. If Licensee, any Sublicensee and/or any holder of an option to obtain a Sublicense does not qualify, or
at any point during the term of this Agreement ceases to qualify, as a “small entity” as provided by the United States Patent and Trademark Office (USPTO), Licensee immediately shall so notify the USPTO (with respect to Licensed Patent
Rights for which Licensee has prosecution responsibility under the terms of this Agreement), as well as Licensors in order to enable Licensors to comply with USPTO regulations regarding payment of fees with respect to Licensed Patent Rights.

  
 - 12 - 

	4.	License Grant. 

 4.1. Licenses. 

4.1.1. Harvard Grants. Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants to Licensee an exclusive
(except as set forth in Sections 4.1.4 and 5.5.3 below), worldwide, royalty-bearing license under the Harvard Patent Rights and [**] Poly Peptide Patent Rights solely (a) to develop, make, have made, market, offer for sale, sell and import
Licensed Products for use solely in the Field and (b) to use Licensed Products in the development and manufacture of the Licensed Products described in clause (a). 

4.1.2. Licensors Grant. Subject to the terms and conditions set forth in this Agreement, each of the Licensors hereby grants to
Licensee an exclusive (except as set forth in Section 4.1.4 below), worldwide, royalty-bearing license under its interest in and to the Licensors Patent Rights, the [**] Patent Rights, the p53 Patent Rights and the Joint Patent Rights, solely
(a) to develop, make, have made, market, offer for sale, sell and import Licensed Products for use solely in the Field and (b) to use Licensed Products in the development and manufacture of the Licensed Products described in clause (a).

 4.1.3. DFCI Patent Rights. Subject to the terms and conditions set forth in this Agreement, DFCI hereby grants to Licensee an
exclusive (except as set forth in Section 4.1.4 below), worldwide, royalty-bearing license under the DFCI Patent Rights and [**] Patent Rights solely to develop, make, have made, use, market, offer for sale, sell and import Licensed Products in
the Field. 
 4.1.4. Limitations. The licenses granted under Sections 4.1.1, 4.1.2 and 4.1.3 shall be subject to the following
limitations: 
 4.1.4.1. Reserved Rights. Licensors retain the right under their interests in the Licensed Patent Rights to make and
use Licensed Products, and to license other not-for-profit research organizations to make and use Licensed Products, all of the foregoing solely for internal research, teaching and other educational purposes and not for the purpose of any commercial
manufacture, distribution or provision of services for a fee; 
 4.1.4.2. Government Rights. The U.S. federal government retains
rights in the Licensed Patent Rights pursuant to 35 USC §§200-212, 37 CFR §401 et seq. and applicable governmental implementing regulations, and any right granted in this Agreement greater than that permitted under 35 USC
§§200-212 or 37 CFR §401 et seq. shall be subject to modification as may be required to conform to the provisions of those statutes; and 

4.1.4.3. HHMI Rights. Licensee acknowledges that it has been informed that the [**] Patent Rights listed in Exhibit 1.2, Licensor
Patent Rights listed in Exhibit 1.24, and the p53 Patent Rights listed in Exhibit 1.28 were developed, at least in part, by employees of HHMI and that HHMI has a paid-up, non-exclusive, irrevocable license to use the [**] Patent Rights, the Licensor
Patent Rights (other than those described in Section 1.24 (f)) and the p53 Patent Rights for HHMI’s research purposes, but with no right to assign or sublicense (the “HHMI License”). This license is explicitly made subject to the
HHMI License. 

  
 - 13 - 

 4.1.4.4. Third Party Proposed Products. 

(a) If, at any time after August 2, 2011, a third party makes a bona fide proposal to either Licensor for developing a Third Party
Proposed Product and Harvard is interested in having such Third Party Proposed Product developed and commercialized, Harvard shall notify Licensee of such Third Party Proposed Product, and shall provide Licensee with information regarding the third
party proposal. Within [**] days of the receipt of such notification from Harvard, [**]. 
 (b) If Licensee notifies Harvard within
such [**] day period that [**], the parties will agree upon [**] with respect to such Third Party Proposed Product, which [**], subject to necessary adjustments, and will include reasonable [**]. In such case, Licensee shall be obligated (i) to
use commercially reasonable efforts to [**] in accordance with such new [**] and (ii) to [**] with respect to the Third Party Proposed Product. 

(c) If Licensee notifies Harvard that [**] (consistent with the considerations set forth in the following sentence) [**] with such
third party or another party. Bona fide business concerns of Licensee as well as the goal of ensuring that Licensed Products are developed and commercialized to benefit the public will be considered by Licensee in its determination of [**]. Licensee
shall have no obligation to license or sublicense any other intellectual property (i.e. [**]) to a prospective sublicensee. If Licensee has not entered into a [**] within a reasonable time after its notice to Harvard, at Harvard’s request, it
shall notify Harvard (in person or by telephone) the [**] shall be deemed Confidential Information of Licensee in accordance with Section 12.6. 

(d) If Licensee does not notify Harvard within the [**] day period described in (a) above or notifies Harvard [**] to
(A) [**] or to (B) enter into [**] with such third party or another party for such product, Harvard shall be [**] to such third party and otherwise consistent with the rights granted to Licensee herein. From all amounts received by Harvard
under [**], (i) Harvard shall first deduct [**] and (ii) all remaining amounts shall be distributed as follows: [**]. Harvard shall notify Licensee when it commences negotiations with such third party, and shall provide a copy of any such
license to Licensee, the terms of which shall be deemed Confidential Information of Harvard in accordance with Section 12.6. 
 4.1.5.
Affiliates and Sub-contractors. The licenses granted to Licensee under Sections 4.1.1, 4.1.2 and 4.1.3 shall include the right to have some or all of Licensee’s rights or obligations under such licenses performed or exercised by one or more
of its Affiliates and/or through Sub-contractors; provided that: (a) no such Affiliate or Sub-contractor shall be entitled to grant, directly or indirectly, to any person or entity any Sublicense; and (b) any acts taken by any such
Affiliate or Sub-contractor (or assignee thereof as described in the next sentence) in accordance with the rights granted under this Section 4.1.5 shall be deemed an act taken by Licensee under this Agreement. For clarity, the assignment of
such rights by an Affiliate or Subcontractor in connection with the sale of its business or assets to which such rights pertain or otherwise to a successor-in-interest as a result of a merger or reorganization or otherwise shall not be deemed to be
a Sublicense prohibited by this Section 4.1.5. 

  
 - 14 - 

 4.2. Sublicense. 

4.2.1. Sublicense Grant. Licensee shall be entitled to grant Sublicenses to third parties under the licenses granted pursuant to
Section 4.1 on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. 
 4.2.2. Sublicense
Agreements. Sublicenses shall only be granted pursuant to written agreements, which shall be subject and subordinate to the terms and conditions of this Agreement. Such Sublicense agreements shall contain, among other things, provisions to the
following effect; 
 4.2.2.1. All provisions necessary to ensure Licensee’s ability to perform its obligations under this
Agreement, including without limitation its obligations under Sections 7.1, 7.3 and 12.1; 
 4.2.2.2. A clause substantially the
same as the provisions of Section 10 (Indemnification) that shall also state that Harvard, DFCI and HHMI are intended third party beneficiaries of such Sublicense agreement for the purpose of enforcing such indemnification and insurance
provisions. 
 4.2.2.3. Upon any termination of this Agreement, all Sublicenses shall terminate. However, in recognition of the
substantial investment made by Sublicensees in commercializing the Licensed Patent Rights, and to avoid future negotiation over the terms of a Sublicensee’s continued exercise of the Licensed Patent Rights in the field and scope enjoyed
pursuant to its Sublicense Agreement, Licensors will, at the request of a Sublicensee after such termination, grant a direct license under the Licensed Patent Rights to such Sublicensee (effective as of the date of the termination of this Agreement)
for the Licensed Products and the field specified in its Sublicense Agreement and under the same terms and conditions (except as set forth in (c) and (d) below) as those granted to Licensee under this Agreement, provided that: 

(a) such Sublicensee is not in material default under the Sublicense Agreement at the time of termination of this Agreement; 

(b) such Sublicensee assumes all unsatisfied past, current, and future obligations of Licensee under this Agreement, including under
Section 3.2 and 6, with respect to the Licensed Products and field covered by its Sublicense; 
 (c) such Sublicensee agrees:
(i) with respect to Original Patent Rights covered by such Sublicense, to use commercially reasonable efforts, and/or cause its Affiliates to use commercially reasonable efforts (x) to develop Licensed Products, the making, using or
selling of which is covered by a Valid Claim of the Original Patent Rights, (y) to introduce such Licensed Products into the commercial market and (z) to market such Licensed Products following such introduction into the market (including
undertaking in such direct license to meet all applicable diligence milestones as set forth in the Sublicense agreement), in which event Sublicensee shall not be obligated to meet the original General Development Milestone within the time period set
forth in this Agreement; and (ii) with respect to all of the other Licensed Patent Rights covered by such Sublicense, to meet the relevant Development Milestones (e.g. [**] Development Milestone, [**] Development Milestone, [**] Development
Milestone, p53 Development Milestone and/or [**] Poly Peptide Milestone) within the time periods set forth in this Agreement, in which event such Sublicensee shall be obligated to meet such Development Milestones with such time periods; and 

  
 - 15 - 

 (d) (i) the terms contained in such direct license agreement do not impose any
representation, warranties, obligations or liabilities on Licensors or the Sublicensee which are not included in this Agreement and includes limitations of liability provisions identical to those set forth in Sections 9.2 and 9.3,
(ii) Sublicensee assumes all of Licensee’s obligations under Sections 5.3, 7.1.1, 7.3, 9.1, 10, 12.1, 12.4 and 12.7 with respect to the Licensed Products or field covered by its Sublicense, (iii) the royalty rates and milestone
payments contained in such new agreement shall be equivalent to the royalty rates and milestone payments specified in Sections 6.4 and 6.5 of this Agreement), (iv) Licensors shall not be entitled to any stock or equity payment or issuance from
the Sublicensee on account of such direct license, (v) the obligations to reimburse of patent prosecution expenses and pay license maintenance fees contained in the direct license agreement shall not be less favorable to Licensors than those
set forth in Sections 3 and 6.3 of this Agreement, respectively; provided, however, that such prosecution expenses and license maintenance fees shall be prorated among all former Sublicensees to whom Licensors grant a direct license
under this Section 4.2.2.3 and whose such direct licenses are in effect on the date payments are due. 
 4.2.2.4. The
Sublicensee shall not be entitled to sublicense its rights under such Sublicense agreement. However, Sublicensee shall be entitled to have some or all of its rights or obligations under such Sublicense performed or exercised by one or more of its
Affiliates and/or through Sub-contractors; provided that any acts taken by any such Affiliate or Sub-contractor (or assignee thereof as described in the next sentence) in accordance with the rights granted under this Section 4.2.2.4 shall be
deemed an act taken by Sublicensee under the Sublicense agreement. For clarity, the assignment of a Sublicense agreement by a Sublicensee in connection with the sale of its business or assets to which the Sublicense agreement pertains or otherwise
to a successor-in-interest as a result of a merger or reorganization or otherwise shall not be deemed to be a Sublicense prohibited by this Section 4.2.2.4. 

4.2.2.5. The Sublicense agreement may not be assigned by Sublicensee without the prior written consent of Harvard, except that
Sublicensee may assign the Sublicense agreement without the consent of Harvard (i) to an Affiliate of such Sublicenses or (ii) to a successor-in-interest in connection with the merger, consolidation, or sale of all or substantially all of
its assets or that portion of its business or assets to which the Sublicense agreement relates; provided that any such assignee agrees in writing in a manner reasonably satisfactory to Harvard to be bound by the terms of such Sublicense agreement.

 4.2.3. Delivery of Sublicense Agreement. Licensee shall furnish Licensors with a fully executed copy of any such Sublicense
agreement promptly after its execution. Licensors shall keep any such copies of Sublicense agreements in its confidential files and shall use them solely for the purpose of monitoring Licensee’s and Sublicensees’ compliance with their
obligations hereunder and enforcing Licensors’ rights under this Agreement. Any such Sublicense agreement shall be deemed Confidential Information of Licensee in accordance with Section 12.6. 

4.2.4. Breach by Sublicensee. Any act or omission by a Sublicensee, which would have constituted a breach of this Agreement had it been
an act or omission by Licensee, 

  
 - 16 - 

 
shall constitute a breach of this Agreement. Licensee shall indemnify Licensors and HHMI for, and hold them harmless from, any and all damages or losses caused to Licensors and HHMI as a result
of any such breach by a Sublicensee. For clarity, Licensee shall have the right to cure any such breach in the same manner as it has the right to cure its own breaches. 

4.3. No Other Grant of Rights. Nothing in this Agreement shall be construed to confer any rights upon Licensee by implication,
estoppel, or otherwise as to any technology or patent rights of Licensors or any other entity other than the rights granted herein with respect to Licensed Patent Rights, regardless of whether such technology or patent rights shall be dominant,
subordinate or otherwise related to any Licensed Patent Rights. 
  

	5.	Development and Commercialization. 

 5.1. Diligence. Licensee shall use
commercially reasonable efforts, and/or shall cause its Affiliates or Sublicensees to use commercially reasonable efforts: (i) to develop Licensed Products in accordance with the Development Plan, (ii) to introduce Licensed Products into
the commercial market and (iii) to market Licensed Products following such introduction into the market. In addition, Licensee, by itself or through Affiliates or Sublicensees, shall meet each of the Development Milestones within the time
periods set forth therein. Without limiting Licensors’ rights under any other provision of this Agreement, Licensors’ sole and exclusive remedy and Licensee’s sole and exclusive liability for any breach of the obligations set forth in
this Section 5.1 shall be the termination rights set forth in Section 5.5. For clarity, it is contemplated that Licensee, its Affiliate or Sublicensee can achieve the General Development Milestone simultaneously upon achieving a milestone
described in any of Sections 1.7 (b)-(f) with the same Licensed Product. For further clarity, if a Licensed Product is covered by a Valid Claim of two or more categories of Licensed Patent Rights, it is possible that it can meet the Development
Milestone in each such category if applicable. For example, if a Licensed Product is covered by Valid Claims within both the [**] Patent Rights and the [**] Poly Peptide Patent Rights, and Licensee files an IND for such Licensed Product within the
time periods required for the IND [**] Development Milestone and the IND [**] Development Milestone, then both such Development Milestones will be deemed to have been met by such IND filing. 

5.2. Development Plan. Licensee shall be entitled, from time to time, to make such adjustments to the then applicable Development Plan
including the timelines therein as Licensee believes, in its good faith judgment, are needed in order to improve Licensee’s ability to meet the Development Milestones. 

5.3. Reporting. Within [**] days after the end of each calendar year, Licensee shall furnish Harvard with a written report on the
progress of its, its Affiliate’s and Sublicensees’ efforts during the prior year to develop and commercialize Licensed Products, including without limitation research and development efforts and marketing efforts. The report shall also
contain a discussion of intended efforts and sales projections for the then current year. 
 5.4. Failure. The parties agree
that timely achievement of Development Milestones is subject to considerable uncertainty, given the novelty of the technology embodied in the Licensed Patent Rights, territorial or legal restrictions on the use of biotechnology products, the
regulatory climate and approval process, and pricing or other government restrictions on certain 

  
 - 17 - 

 
pharmaceutical products. Accordingly if Licensee fails to achieve any Development Milestone, the parties agree to discuss and, if appropriate, revise said milestone upon Licensee’s written
notice to Harvard and explanation for the reasons for such failure. If Licensee does not provide Harvard with a reasonable basis for its failure to meet a Development Milestone (and lack of finances shall not constitute reasonable basis), Harvard
shall notify Licensee in writing of Licensee’s failure and shall allow Licensee [**] days to cure its failure; provided that Harvard agrees to consider in good faith a reasonable extension to such [**]-day period if such failure occurs despite
Licensee’s (itself or through one or more Affiliates or Sublicensees) use of commercially reasonable efforts to meet such Development Milestone. 

5.5. Remedy for Failure. 

5.5.1. General Development Milestone. If a failure to meet a Development Milestone as described in Section 5.4 relates to the
General Development Milestone, Licensee’s failure to cure such delay within such [**]-day period (as may be extended) set forth in Section 5.4 shall constitute a material breach of this Agreement and Harvard shall have the right to
terminate this Agreement forthwith. 
 5.5.2. Other Development Milestones. If a failure to meet a Development Milestone as described
in Section 5.4 relates to a Development Milestone that is not the General Development Milestone (i.e., [**] Development Milestone, [**] Development Milestone, [**] Development Milestone, p53 Development Milestone or [**] Poly Peptide
Milestone), Licensee’s failure to cure such delay within such [**]-day period set forth in Section 5.4 shall entitle Harvard (or in the case of a failure to achieve a [**] Development Milestone, DFCI) to terminate Licensee’s license
with respect to the Licensed Patent Rights solely related to such Development Milestone (“Terminated Patent Rights”). For example, if the failure to meet a Development Milestone as described in Section 5.4.2 relates to a [**]
Development Milestone, Harvard will be entitled to terminate the license granted under Section 4.1.2 with respect to the [**] Patent Rights. For clarity, the termination of the license with respect to any Terminated Patent Rights under this
Section 5.5.2 will terminate any Sublicense granted with respect to such Terminated Patent Rights (and Licensors will not be required to grant any licenses with respect to such Terminated Patent Rights to any Sublicensee). For further clarity,
Licensee’s rights and obligations under Sections 3 and 8 with respect to any Terminated Patent Rights shall terminate. 
 5.5.3.
Background for Terminated Patent Rights. Notwithstanding the terms of Section 4.1.1, if any Licensed Patent Rights become Terminated Patent Rights, Harvard will be entitled to grant to third party licensees of such Terminated Patent Rights non-exclusive, worldwide, licenses (with the right to grant sublicenses) under the Harvard Patent Rights and [**] Poly Peptide Patent Rights in the Field solely for the purpose of and to the extent needed to
develop, make, have made, use, market, offer for sale, sell and import products, the making, using or selling of which falls within the scope of a Valid Claim of such Terminated Patent Rights. 

  
 - 18 - 

	6.	Consideration for Grant of License 

 6.1. License Issuance Fee. 

6.1.1. Original Patent Rights. The parties acknowledge that Licensee paid Harvard the license issuance fee and issued equity to
Licensors as partial consideration for the grant of the licenses under the Original Patent Rights in accordance with the terms of the Original Agreement. The rights and obligations of the parties with respect to such equity are set forth in the
Stock Purchase Agreements dated November 19, 2007, between Harvard and Licensee and the Stock Purchase Agreements dated November 19, 2007, between DFCI and Licensee. 

6.1.2. Additional Patent Rights. 

6.1.2.1. [**] Poly Peptide Patent Rights. In partial consideration for the license granted to Licensee pursuant to Section 4.1.1
above with respect to the [**] Poly Peptide Patent Rights, Licensee shall pay Harvard a license issuance fee of [**] US Dollars ($[**]). Such amount will be paid in three installments, as follows; (a) [**] US Dollars ($[**]) will be paid within
[**] business days after the Effective Date; (b) fifteen thousand US Dollars ($[**]) will be paid within [**] business days after the [**] of the Effective Date; and (c) [**] US Dollars ($[**]) will be paid within [**] business days after
the [**] of the Effective Date. 
 6.1.2.2. [**] Patent Rights. In partial consideration for the license granted to Licensee
pursuant to Section 4.1.2 above with respect to the [**] Patent Rights, Licensee shall pay Harvard a license issuance fee of [**] US Dollars ($[**]). Such amount will be paid in three installments, as follows; (a) [**] US Dollars ($[**])
will be paid within [**] business days after the Effective Date; (b) [**] US Dollars ($[**]) will be paid within [**] business days after the [**] of the Effective Date; and (c) [**] US Dollars ($[**]) will be paid within [**] business
days after the [**] of the Effective Date. 
 6.1.2.3. p53 Patent Rights. In partial consideration for the license granted to
Licensee pursuant to Section 4.1.2 above with respect to the p53 Patent Rights, Licensee shall pay Harvard a license issuance fee of [**] US Dollars ($[**]). Such amount will be paid in three installments, as follows: (a) [**] US Dollars
($[**]) will be paid within [**] business days after the Effective Date; (b) [**] US Dollars ($[**]) will be paid within [**] business days after the [**] of the Effective Date; and (c) [**] US Dollars ($[**]) will be paid within [**]
business days after the [**] of the Effective Date. 
 6.1.2.4. [**] Patent Rights. In partial consideration for the license granted
to Licensee pursuant to Section 4.1.3 above with respect to the [**] Patent Rights, Licensee shall pay Harvard a license issuance fee of [**] US Dollars ($[**]). Such amount will be paid in three installments, as follows: (a) [**] US
Dollars ($[**]) will be paid within [**] business days after the Effective Date; (b) [**] US Dollars ($[**]) will be paid within [**] business days after the [**] of the Effective Date; and (c) [**] US Dollars ($[**]) will be paid within
[**] business days after the [**] of the Effective Date. 
 For clarity, Licensee shall be obligated to pay the full amount of each
installment set forth in this Section 6.1.2 on the due date therefore regardless of whether, at the time the relevant installment is due, (i) this Agreement is still in effect or (ii) the relevant Licensed Patent Rights are still
licensed under this Agreement (or have become Terminated Patent Rights). 
 6.2. [Intentionally omitted] 

  
 - 19 - 

 6.3. License Maintenance Fee. 

6.3.1. Original Patent Rights. The parties acknowledge that Licensee paid Harvard the annual license maintenance fee amounts that were
due on January 1, 2008 and January 1, 2009 with respect to the Original Patent Rights in accordance with the terms of the Original Agreement. In addition, Licensee shall pay Harvard annual license maintenance fees for the license with
respect to the Original Patent Rights as follows: 
 6.3.1.1. On each of [**] business days after the Effective Date,
January 1, 2011 and January 1, 2012, Licensee shall pay Harvard an annual license maintenance fee of [**] US Dollars ($[**]); and 

6.3.1.2. On January 1, 2013 and on January 1 of each year thereafter until the expiration of the last to expire of the
Original Patent Rights, Licensee shall pay Harvard an annual license maintenance fee of [**] US Dollars ($[**]). 
 Each payment made
pursuant to this Section 6.3.1 shall be creditable against royalties due under Section 6.5 for sales made during the year following the due date of such payment of Licensed Products, the making, using or selling of which falls within the
scope of a Valid Claim of the Original Patent Rights. 
 6.3.2. [**] Poly Peptide Patent Rights. Licensee shall pay Harvard annual
license maintenance fees for the license with respect to the [**] Poly Peptide Patent Rights as follows: 
 6.3.2.1. On each of [**]
business days after the Effective Date and January 1, 2011, Licensee shall pay Harvard an annual license maintenance fee of [**] US Dollars ($[**]); 

6.3.2.2. On each of January 1, 2012, 2013 and 2014, Licensee shall pay Harvard an annual license maintenance fee of [**] US
Dollars ($[**]); and 
 6.3.2.3. On January 1, 2015 and on January 1 of each year thereafter until the expiration of the
last to expire of the [**] Poly Peptide Patent Rights or the earlier termination of the license with respect to the [**] Poly Peptide Patent Rights pursuant to Section 5.5.2, Licensee shall pay Harvard an annual license maintenance fee of [**]
US Dollars ($[**]). 
 Each payment made pursuant to this Section 6.3.2 shall be creditable against royalties due under
Section 6.5 for sales made during the year following the due date of such payment of Licensed Products, the making, using or selling of which falls within the scope of a Valid Claim of the [**] Poly Peptide Patent Rights. 

6.3.3. [**] Patent Rights. Licensee shall pay Harvard annual license maintenance fees for the license with respect to the [**] Patent
Rights as follows: 
 6.3.3.1. On each of [**] business days after the Effective Date and January 1, 2011, Licensee shall pay
Harvard an annual license maintenance fee of [**] US Dollars ($[**]); 

  
 - 20 - 

 6.3.3.2. On each of January 1, 2012, 2013 and 2014, Licensee shall pay Harvard an
annual license maintenance fee of [**] US Dollars ($[**]); and 
 6.3.3.3. On January 1, 2015 and on January 1 of each
year thereafter until the expiration of the last to expire of the [**] Patent Rights or the earlier termination of the license with respect to the [**] Patent Rights pursuant to Section 5.5.2, Licensee shall pay Harvard an annual license
maintenance fee of [**] US Dollars ($[**]). 
 Each payment made pursuant to this Section 6.3.3 shall be creditable against royalties
due under Section 6.5 for sales made during the year following the due date of such payment of Licensed Products, the making, using or selling of which falls within the scope of a Valid Claim of the [**] Patent Rights. 

6.3.4. p53 Patent Rights. Licensee shall pay Harvard annual license maintenance fees for the license with respect to the p53 Patent
Rights as follows: 
 6.3.4.1. On each of [**] business days after the Effective Date and January 1, 2011, Licensee shall pay
Harvard an annual license maintenance fee of [**] US Dollars ($[**]); 
 6.3.4.2. On each of January 1, 2012, 2013 and 2014,
Licensee shall pay Harvard an annual license maintenance fee of [**] US Dollars ($[**]); and 
 6.3.4.3. On January 1, 2015 and
on January 1 of each year thereafter until the expiration of the last to expire of the p53 Patent Rights or the earlier termination of the license with respect to the p53 Patent Rights pursuant to Section 5.5.2, Licensee shall pay Harvard
an annual license maintenance fee of [**] US Dollars ($[**]). 
 Each payment made pursuant to this Section 6.3.4 shall be creditable
against royalties due under Section 6.5 for sales made during the year following the due date of such payment of Licensed Products, the making, using or selling of which falls within the scope of a Valid Claim of the p53 Patent Rights. 

6.3.5. [**] Patent Rights. Licensee shall pay Harvard annual license maintenance fees for the license with respect to the [**] Patent
Rights as follows: 
 6.3.5.1. On each of [**] business days after the Effective Date and January 1, 2011, Licensee shall pay
Harvard an annual license maintenance fee of [**] US Dollars ($[**]); 
 6.3.5.2. On each of January 1, 2012, 2013 and 2014,
Licensee shall pay Harvard an annual license maintenance fee of [**] US Dollars ($[**]); and 
 6.3.5.3. On January 1, 2015 and
on January 1 of each year thereafter until the expiration of the last to expire of the [**] Patent Rights or the earlier termination of the license with respect to the [**] Patent Rights pursuant to Section 5.5.2, Licensee shall pay
Harvard an annual license maintenance fee of [**] US Dollars ($[**]). 
 Each payment made pursuant to this Section 6.3.5 shall be
creditable against royalties due under Section 6.5 for sales made during the year following the due date of such payment of Licensed Products, the making, using or selling of which falls within the scope of a Valid Claim of the [**] Patent
Rights. 

  
 - 21 - 

 6.4. Milestone Payments. 

6.4.1. Therapeutic Products. In addition, Licensee shall pay Harvard the following milestone payments with respect to each Licensed
Product being developed or commercialized for the prevention or treatment of [**] (a “Therapeutic Product”) to reach the relevant milestone, regardless of whether such milestone is achieved by Licensee or a Sublicensee: 

6.4.1.1. $50,000 (fifty thousand US Dollars) upon Initiation of the first Phase I Clinical Trial with respect to such Therapeutic
Product; 
 6.4.1.2. $[**] US Dollars) upon [**]; 

6.4.1.3. $[**] US Dollars) upon [**]; 

6.4.1.4. $[**] US Dollars) upon [**]; 

6.4.1.5. $[**] US Dollars) upon the achievement of cumulative worldwide sales of the first Therapeutic Product of $[**] US Dollars);
and 
 6.4.1.6. $[**] US Dollars) upon the achievement of cumulative worldwide sales of the first Therapeutic Product of $[**] US
Dollars). 
 Licensee shall notify Harvard in writing within [**] days following the achievement of each milestone described in this
Section 6.4.1, and shall make the appropriate milestone payment within [**] days after the achievement of such milestone. Each milestone payment shall be payable only upon the initial achievement of such milestone with respect to a Therapeutic
Product and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone with respect to such Therapeutic Product. For clarity, the milestones set forth in Section 6.4.1 are successive and, upon achievement of any
milestone by a Therapeutic Product, all prior milestones for such Therapeutic Product shall be deemed achieved and, to the extent any payments were not made with respect thereto, the corresponding payments shall be due. For purposes of the milestone
payments in this Section 6.4.1 all Licensed Products incorporating the same Covered Peptide shall be deemed to be the same Therapeutic Product. 

If development of a Therapeutic Product is abandoned after one or more of the milestone payments set forth in Sections [**] have been made
with respect to such Therapeutic Product (“Abandoned Therapeutic Product”), but before the [**] of such Abandoned Therapeutic Product, then such milestone payments shall be credited against any milestone payments that subsequently become
due pursuant to Sections [**] for any other Therapeutic Product that is intended to prevent or treat the same indication, is directed to the same biological target(s) and has substantially the same mechanism of action as the Abandoned Licensed
Product (a “Back-Up Product”), until such amounts have been fully credited. The above notwithstanding, if Licensee thereafter revives development efforts with respect to such Abandoned Therapeutic Product and such efforts lead to the
attainment of the milestone described in Section [**], as applicable, that follows the last milestone for which payment was made prior to abandonment, Licensee shall be required to reimburse Harvard the full amount credited pursuant to this
paragraph upon reaching such milestone. For purposes of illustration, [**]. 

  
 - 22 - 

 6.4.2. Diagnostic Products. In addition, Licensee shall pay Harvard the following
milestone payments with respect to each Licensed Product being commercialized for the diagnosis of [**] (a “Diagnostic Product”) to reach the relevant milestone, regardless of whether such milestone is achieved by Licensee or a
Sublicensee: 
 6.4.2.1. $[**] US Dollars) upon the earlier of [**]; and 

6.4.2.2. $[**] US Dollars) upon the achievement of cumulative worldwide sales of the first Diagnostic Product of $[**] US Dollars).

 Licensee shall notify Harvard in writing within [**] days following the achievement of each milestone described in this
Section 6.4.2, and shall make the appropriate milestone payment within [**] days after the achievement of such milestone. Each milestone payment shall be payable only upon the initial achievement of such milestone with respect to a Diagnostic
Product and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone with respect to such Diagnostic Product. 

6.5. Royalties on Net Sales. 

6.5.1. Licensee shall pay Harvard royalties on Net Sales as follows: 

 

	 	(a)	An amount equal to [**]% of all Net Sales of [**] Products; and 

  

	 	(b)	An amount equal to [**]% of all Net Sales of [**] Products; and 

  

	 	(c)	An amount equal to [**]% of all Net Sales of Combination Products (with Net Sales as determined in Section 1.25) in which the Covered Peptide would be considered a [**] product if sold with no Independent Active
Ingredient; and 

  

	 	(d)	An amount equal to [**]% of all Net Sales of Combination Products (with Net Sales as determined in Section 1.25) in which the Covered Peptide would be considered a [**] product if sold with no Independent Active
Ingredient. 

 6.5.2. Notwithstanding the foregoing, in the event that Licensee or an Affiliate of Licensee is required
to make royalty payments, at fair market terms after arms’ length negotiations, under a Third Party License as a result of the sale of a Licensed Product in a certain country, Licensee may offset an amount equal to [**]% of such third-party
payments with respect to such sale of such Licensed Product against the royalty payments that are due to Licensors pursuant to Section 6.5.1 with respect to sales of such Licensed Product in such country; provided that in no event, shall the
royalty payments to Licensors under Section 6.5.1 with respect to such Licensed Product be reduced by more than [**]% of the amount otherwise due with respect to such Licensed Product. 

  
 - 23 - 

 6.5.3. With respect to each Licensed Product, royalties will be payable on a
country-by-country basis, so long as the making, using or selling of the Licensed Product falls within the scope of a Valid Claim in the country in which such Licensed Product is made, used or sold. 

6.5.4. If the use, manufacture, sale or importation of any Licensed Product is covered by more than one Valid Claim of the Licensed
Patent Rights, multiple royalties shall not be due. Accordingly, no more than one royalty shall be due with respect to any unit of Licensed Product. Further no royalty shall be due with respect to reasonable quantities of units of Licensed
Product used solely for clinical trials, other internal research or development purposes or as samples or promotional goods. 
 6.6.
Sublicense Receipts. 
 6.6.1. General. In addition, Licensee shall pay Harvard an amount equal to [**] percent ([**]%) of all
Sublicense Receipts. Notwithstanding the foregoing, if a Sublicense is part of a transaction in which Licensee also conveys rights to technology or intellectual property other than the Licensed Patent Rights that is reasonably necessary for, or
directed to, the discovery, development, manufacture, sale or importation of a Licensed Product, then Licensee will propose in good faith by written notice to Harvard a basis for allocation of the consideration received by Licensee and its
Affiliates for such transaction between the Licensed Patent Rights and such other technology and intellectual property based on the relative value to be attributed to the Sublicense as part of the overall transaction. Such notice shall describe in
reasonable detail the rationale for such allocation. If Harvard disputes the proposed allocation, then the provisions of Section 6.6.2 shall apply. The amount payable to Harvard under this Section 6.6 with respect to Sublicense Receipts
received in connection with such transaction shall be determined by the following equation: 
 [**]. 

If Licensee receives Sublicense Receipts that are creditable against amounts payable by the relevant Sublicensee with respect to sales of Licensed Products,
then any amount paid by Licensee to Harvard under this Section 6.6.1 on account of such Sublicense Receipts shall be creditable against any amounts payable by Licensee to Harvard under Section 6.5 with respect to such sales. 

6.6.2. Disputes. In the event that Harvard disputes Licensee’s proposed allocation of Sublicense Receipts with respect to a
particular transaction, Harvard shall notify Licensee within [**] days of receipt of the proposed allocation (the “Allocation Dispute Notice”), in which case senior executives of Licensee and Harvard shall promptly meet in an attempt to
resolve such matter in good faith. If Licensee and Harvard are unable to so resolve such matter within [**] days of the Allocation Dispute Notice, then either Licensee or Harvard may by written notice to the other have such dispute referred for
resolution by an independent expert with substantial experience in valuing biopharmaceutical transactions. The parties shall agree upon the appointment of such independent expert. Licensee shall bear the costs of such expert in making such
resolution. Licensee and Harvard shall instruct the expert to provide a written allocation of the Sublicense Receipts for the particular transaction between the Licensed Patent Rights and the other relevant technology and intellectual property
licensed or sublicensed in connection therewith 

  
 - 24 - 

 
in such transaction within [**] days of the date of appointment. Each of Licensee and Harvard shall promptly provide to the expert in confidence such information in its possession and control as
the expert may reasonably request in connection with such resolution. The written allocation of the expert, absent clear error, shall be binding upon the parties. 
  

	7.	Reports; Payments; Records. 

 7.1. Reports and Payments. 

7.1.1. Reports. Within [**] days after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which Net
Sales are generated or Sublicense Receipts received, Licensee shall deliver to Licensors a report containing the following information: 

(a) the number of units of Licensed Products sold by Licensee, its Affiliates and Sublicensees for the applicable Calendar Quarter,
broken down by Licensed Products (i.e. [**] Products and [**] Products) and the Licensed Patent Rights covering such Licensed Products; 

(b) the gross amount billed for Licensed Products sold by Licensee, its Affiliates and Sublicensees during the applicable Calendar
Quarter, broken down by Licensed Products (i.e. [**] Products and [**] Products) and the Licensed Patent Rights covering such Licensed Products; 

(c) a calculation of Net Sales for the applicable Calendar Quarter, broken down by type of Licensed Product (i.e. [**] Products and
[**] Products) and the Licensed Patent Rights covering such Licensed Products, including an itemized listing of applicable deductions; 

(d) the amount of Sublicense Receipts received for the applicable Calendar Quarter; and 

(e) the total amount payable to Harvard in U.S. dollars on Net Sales and Sublicense Receipts for the applicable Calendar Quarter,
together with the exchange rates used for conversion. 
 If no amounts are due to Harvard for any Calendar Quarter, the report shall so
state. 
 7.1.2. Payment for Net Sales and Sublicense Receipts. Within [**] days of end of each Calendar Quarter, Licensee shall pay
Harvard all amounts due with respect to Net Sales and Sublicense Receipts for the applicable Calendar Quarter. 
 7.2. Payment Currency.
All payments due under this Agreement shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in The Wall Street Journal
U.S. Internet edition at www.wsj.com) on the last working day of the applicable Calendar Quarter. Such payments shall be without deduction of exchange, collection, or other charges. 

  
 - 25 - 

 7.3. Records. Licensee shall maintain, and shall cause its Affiliates and Sublicensees to
maintain, complete and accurate records of Licensed Products that are sold under this Agreement, any amounts payable to Harvard in relation to such Licensed Products and all Sublicense Receipts received by Licensee and its Affiliates, which records
shall contain sufficient information to permit Harvard to confirm the accuracy of any reports or notifications delivered to Licensors under Section 7.1. The relevant party shall retain such records relating to a given Calendar Quarter for at
least [**] years after the conclusion of that Calendar Quarter, during which time Harvard shall have the right (except as provided below), at its expense, to cause an independent, certified public accountant to inspect such records during normal
business hours for the sole purpose of verifying reports and payments delivered under this Agreement. Such accountant shall execute a confidentiality agreement reasonably acceptable to Licensee, and shall not disclose to Harvard any information
other than information relating to the accuracy of reports and payments delivered under this Agreement. The parties shall reconcile any underpayment or overpayment within [**] days after the accountant delivers the results of the audit. In the event
that any audit performed under this Section 7.3 reveals an underpayment in excess of [**] percent ([**]%) in any calendar year, the audited party shall bear the full cost of such audit. Harvard may exercise its rights under this
Section 7.3 only [**] per audited party and only with reasonable prior notice to the audited party. Notwithstanding the foregoing, to the extent that Licensee does not have the right to grant Harvard the right to audit the records of any of its
Sublicensees hereunder, Licensee shall obtain for itself such right and, at the request of Harvard, Licensee shall exercise such inspection right with respect to such Sublicensees, using an independent, certified public accountant acceptable to
Harvard, and provide the results of such inspection for inspection by Harvard pursuant to this Section 7.3. In such event, Licensee shall bear the full cost of such audit regardless of whether an underpayment of any amount is revealed.

 7.4. Late Payments. Any payments by Licensee that are not paid on or before the date such payments are due under this
Agreement shall bear interest at the lower of (a) [**] percent ([**]%) per month and (b) the maximum rate allowed by law. Interest shall accrue beginning on the first day following the due date for payment and shall be compounded
quarterly. Payment of such interest by Licensee shall not limit, in any way, Harvard’s right to exercise any other remedies Harvard may have as a consequence of the lateness of any payment. 

7.5. Payment Method. Each payment due to Harvard under this Agreement shall be paid by check or wire transfer of funds to
Harvard’s account in accordance with written instructions provided by Harvard. If made by wire transfer, such payments shall be marked so as to refer to this Agreement. 

7.6. Withholding Tax. If laws, rules or regulations require withholding of income taxes or other taxes imposed upon payments set forth
in this Section 7, Licensee shall make such withholding payments as may be required and shall subtract such withholding payments from the payments set forth in this Section 7. Licensee shall explain the justification for withholding and
shall promptly submit appropriate proof of payment of the withholding taxes and any other information as may be necessary for tax credit purposes to Licensors. 

7.7. Payment Responsibility to DFCI. Harvard shall be solely responsible for making payments due to DFCI, if any, in respect of the
rights and licenses granted to Licensee hereunder with respect to the DFCI Patent Rights, [**] Patent Rights, [**] Patent Rights, p53 Patent Rights, 

  
 - 26 - 

 
as well as the Joint Patent Rights and Licensors Patent Rights in which Dr. Walensky is an inventor. In no event shall Licensee have any obligation to DFCI for any amounts remitted hereunder
to Harvard. 
 7.8. Confidentiality of Records. All materials and information disclosed to or reviewed by Harvard or DFCI, or the
appointed agents of either pursuant to this Article 7 shall be considered Confidential Information in accordance with Section 12.6. 
  

	8.	Enforcement of Patent Rights. 

 8.1. Notice. In the event either Harvard or DFCI
(on one hand) or Licensee (on the other) becomes aware of any possible or actual infringement of any Licensed Patent Rights relating to Licensed Products (collectively, an “Infringement”), that party shall promptly notify the other party
(provided that Licensee shall notify Harvard) and provide it with details regarding such Infringement. 
 8.2. Suit by Licensee.
Licensee shall have the first right, but not the obligation, to take action in the prosecution, prevention, or termination of any Infringement. Before Licensee commences an action with respect to any Infringement, Licensee shall consider in good
faith the views of Harvard and potential effects on the public interest in making its decision whether to sue. Should Licensee elect to bring suit against an infringer, Licensee shall keep Harvard reasonably informed of the progress of the action
and shall give Harvard a reasonable opportunity in advance to consult with Licensee and offer its views about major decision affecting the litigation. Licensee shall give careful consideration to those views, but shall have the right to control the
action, provided, however, that if Licensee fails to defend in good faith the validity and/or enforceability of the Licensed Patent Rights in the action or, or if Licensee’s license to a Valid Claim in suit terminates, Harvard may elect to take
control of the action pursuant to Section 8.3. Should Licensee elect to bring suit against an infringer and either or both Licensors are joined as party plaintiff in any such suit, such Licensor(s) shall have the right to withhold approval of
counsel selected by Licensee only upon its reasonable determination that a conflict of interest exists with such counsel. If a joined Licensor withholds such approval due to a reasonable determination that a conflict of interest exists with the
counsel selected by Licensee, then Licensee shall have the option to keep such counsel selected by Licensee and to provide separate counsel for such Licensor at Licensee’s expense. The expenses of such suit or suits that Licensee elects to
bring, including any reasonable out-of-pocket expenses of Licensors incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Licensee and Licensee shall hold Licensors free, clear and
harmless from and against any and all costs of such litigation, including attorney’s fees, in each case incurred at the request of Licensee. Licensee shall not compromise or settle any such litigation that purports to limit the scope or
validity of any Licensed Patents without the prior written consent of Harvard, which consent shall not be unreasonably withheld or delayed. In the event Licensee exercises its right to sue pursuant to this Section 8.2, it shall first reimburse
itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorney’s fees, reasonably incurred in the prosecution of any such suit. If, after such
reimbursement, any funds shall remain from said recovery, then Harvard shall receive an amount equal to [**]% of such funds and the remaining [**]% of such funds shall be retained by Licensee. 

  
 - 27 - 

 8.3. Suit by Harvard. If Licensee does not take action in the prosecution, prevention, or
termination of any Infringement pursuant to Section 8.2 above, and has not commenced negotiations with the infringer for the discontinuance of said Infringement, within the earlier of (a) [**] days after receipt of notice to Licensee by
Harvard of the existence of an Infringement and (b) [**] days prior to the last date by which any Infringement action may be filed against the infringer, Harvard may elect to do so; provided that Harvard shall consider in good faith the
grounds, if any, that Licensee may have had for not taking such action and any request by Licensee to delay or forego such action. Should Harvard elect to bring suit against an infringer and Licensee is joined as party plaintiff in any such suit,
Licensee shall have the right to withhold approval of counsel selected by Harvard only upon its reasonable determination that a conflict of interest exists with such counsel. If Licensee withholds such approval due to a reasonable determination that
a conflict of interest exists with the counsel selected by Harvard, then Harvard shall have the option to keep such counsel selected by Harvard and to provide separate counsel for Licensee at Harvard’s expense. The expenses of such suit or
suits that Harvard elects to bring, including any expenses of Licensee incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Harvard and Harvard shall hold Licensee free, clear and
harmless from and against any and all costs of such litigation, including attorney’s fees, in each case incurred at the request of Harvard. Harvard shall not compromise or settle such litigation that purports to limit the scope or validity of
any Licensed Patents without the prior written consent of Licensee, which consent shall not be unreasonably withheld or delayed. In the event Harvard exercises its right to sue pursuant to this Section 8.3, it shall first reimburse itself out
of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorney’s fees, reasonably incurred in the prosecution of any such suit. If, after such reimbursement, any
funds shall remain from said recovery, then Licensee shall receive an amount equal to [**]% of such funds and the remaining [**]% of such funds shall be retained by Harvard. 

8.4. Own Counsel. Each party shall always have the right to be represented by counsel of its own selection and at its own expense in
any suit instituted under this Section 8 by another party for Infringement. 
 8.5. Cooperation. Each party agrees to
cooperate fully in any action under this Section 8 which is controlled by another party, provided that the controlling party reimburses the cooperating parties promptly for any costs and expenses incurred by the cooperating parties in
connection with providing such assistance. 
 8.6. Standing. If a party lacks standing and another party has standing to bring
any such suit, action or proceeding, then such other party shall do so at the request of and at the expense of the requesting party. If a party determines that it is necessary or desirable for another party to join any such suit, action or
proceeding, the other party shall execute all papers and perform such other acts as may be reasonably required in the circumstances. 

8.7. Declaratory Judgment. If a declaratory judgment action is brought as an independent action naming Licensee and/or any of its
Affiliates or Sublicensees as a defendant and alleging invalidity or unenforceability of any claims within the Licensed Patent Rights (except Joint Patent Rights), Licensee shall promptly notify Licensors in writing and Harvard and/or DFCI, as
relevant based on ownership of the subject Licensed Patent Rights, may elect, upon 

  
 - 28 - 

 
written notice to Licensee within [**] days after Licensors receive notice of the commencement of such action, to take over the sole defense of the invalidity or unenforceability aspect of the
action at its/their own expense. If neither Harvard nor DFCI elect to take over the action, Licensee (and/or any of its Affiliates or Sublicensees, as applicable) shall have the right to control such action in its entirety at its own expense, in
which case it shall keep Harvard and/or DFCI, as relevant, reasonably informed of the progress of the action and shall give Harvard and/or DFCI, as relevant, a reasonable opportunity in advance to consult and offer its/their views about major
decisions affecting such defense, which views Licensee (and/or any of its Affiliates or Sublicensees, as applicable) shall consider in good faith. Licensee may elect to retain sole responsibility for defense of the invalidity and/or unenforceability
aspect of any action alleging invalidity or unenforceability with respect to Joint Patent Rights at its own expense. No party responsible for handling the defense of a declaratory judgment action as specified in this Section 8.7 shall
compromise or settle such litigation in any manner that purports to limit the scope or validity of any Licensed Patent Rights without the prior written consent of the owner(s) of such Licensed Patent Rights, which consent shall not be unreasonably
withheld or delayed. 
 8.8. Paragraph IV Certification. Harvard and DFCI each shall inform Licensee of any certification regarding
any Licensed Patent Rights received by it pursuant to 21 U.S.C. §§ 355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or successor provisions, or any similar provisions in a country other than the United States, and shall make reasonable efforts to
provide Licensee with a copy of such certification within [**] business days of receipt. Licensors’ and Licensee’s rights with respect to the initiation and prosecution of any legal action in connection with such certification or any
recovery obtained as a result of such legal action shall be as defined in Sections 8.2 though 8.4 above. Regardless of which party has the right to initiate and prosecute such action, the parties shall, as soon as practicable after receiving notice
of such certification, convene and consult with each other regarding the appropriate course of conduct for such action. The initiating party shall keep the other parties fully informed and provide them with an opportunity to participate in decisions
regarding the appropriate course of conduct for such action, as well as the right to join and participate in such action. 
  

	9.	Warranties; Limitation of Liability. 

 9.1. Compliance with Law. Licensee warrants
that it will comply, and ensure that its Affiliates and Sublicensees comply, with, all local, state, and international laws and regulations relating to the development, manufacture, use, and sale of Licensed Products. Without limiting the foregoing,
Licensee represents and warrants that it shall, and shall ensure that its Affiliates and Sublicensees shall, comply with all United States export control laws and regulations with respect to Licensed Products. 

9.2. No Warranty. 

9.2.1. Harvard warrants and represents that, to the best of its knowledge, it owns all rights in the Harvard Patent Rights listed in
Exhibit 1.15 necessary to grant the licenses set forth in this Agreement. Licensors warrant and represent that, to the best of their knowledge, they own all rights in the Licensor Patent Rights listed in Exhibit 1.24 necessary to grants the licenses
set forth in this Agreement. Licensors make no warranties whatsoever as to the commercial or scientific value of the Licensed Patent Rights or the inventions disclosed therein. Licensors make 

  
 - 29 - 

 
no representation that the practice of the Licensed Patent Rights or the manufacture, use or sale of any Licensed Product, or any element thereof, will not infringe the patent or proprietary
rights of any third party. 
 9.2.2. Except as otherwise expressly provided in this Agreement, no party makes any warranty with
respect to any technology, patents, goods, services, rights or other subject matter of this Agreement and hereby disclaims warranties of merchantability, fitness for a particular purpose and noninfringement with respect to any and all of the
foregoing. 
 9.3. Limitation of Liability. 

9.3.1. Subject to Section 10, none of the parties will be liable to any other with respect to any subject matter of this Agreement
under any contract, negligence, strict liability or other legal or equitable theory for (i) any indirect, incidental, consequential or punitive damages or lost profits or (ii) cost of procurement of substitute goods, technology or
services. 
 9.3.2. Licensors’ aggregate liability for all damages of any kind arising out of or relating to this Agreement or
its subject matter shall not exceed the amounts paid to Licensors under this Agreement. 
  

	10.	Indemnification. 

 10.1. Indemnity. 

10.1.1. Licensee shall indemnify, defend and hold harmless Licensors and their current or former directors, governing board members,
trustees, officers, faculties, medical and professional staffs, employees, students, and agents and their respective successors, heirs and assigns (collectively, the “Indemnitees”) from and against any third party claim, liability, cost,
expense, damage, deficiency, loss or obligation of any kind or nature (including, without limitation, reasonable attorney’s fees and other costs and expenses of litigation) (collectively, “Claims”), based upon, arising out of, or
otherwise relating to the practice of any right or license under this Agreement by or on behalf of Licensee, any of its Affiliates, or any of its Sublicensees, including without limitation any cause of action relating to product liability concerning
any product, process, or service made, used or sold pursuant to any right or license granted under this Agreement, except to the extent any such Claim is based on the gross negligence or willful misconduct of any Indemnitee. 

HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”) will be indemnified, defended by counsel
acceptable to HHMI, and held harmless by the Licensee from and against any Claim, based upon, arising out of, or otherwise relating to this Agreement, including without limitation any cause of action relating to product liability. The previous
sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. 

As a condition of indemnification under this Section 10, (a) the Indemnitees shall provide Licensee with prompt written notice of
any claim, suit or action for which indemnification is sought (provided that the failure of Indemnitees so to notify Licensee will relieve Licensee from 

  
 - 30 - 

 
liability for indemnification only to the extent Licensee is prejudiced by such delay); (b) the Indemnitees shall provide Licensee with the exclusive right to control the defense and
settlement of such Claims, and Licensee shall not be obligated to indemnify any Indemnitee in connection with any settlement for any Claim unless Licensee previously consents in writing to such settlement; and (c) the Indemnitees shall
cooperate fully with Licensee in such defense, at Licensee’s expense, and will permit Licensee to conduct and control such defense and the disposition of any such claim, suit, or action for which Licensee acknowledges it is fully responsible;
provided that Licensee shall not settle any such claim, suit or action by admitting fault or liability on the part of the Licensors, or that would limit the scope or validity of any of the Licensed Patent Rights, without the prior written consent of
Licensors, which consent shall not be unreasonably denied or delayed. 
 Notice of any claim for which indemnification may be sought
pursuant to this Agreement shall be given reasonably promptly by HHMI following actual receipt of written notice thereof by an officer or attorney of HHMI. Notwithstanding the foregoing, the delay or failure of any HHMI Indemnitee to give reasonably
prompt notice to Licensee of any such claim shall not affect the rights of such HHMI Indemnitee unless, and then only to the extent that, such delay or failure is prejudicial to or otherwise adversely affects Licensee. Licensee agrees not to settle
any Claim against an HHMI Indemnitee without HHMI’s written consent, where (a) such settlement would include any admission of liability on the part of any HHMI Indemnitee, (b) such settlement would impose any restriction on any HHMI
Indemnitee’s conduct of any of its activities, or (c) such settlement would not include an unconditional release of all HHMI Indemnitees from all liability for claims that are the subject matter of the settled Claim. 

10.1.2. Licensee shall, at its own expense, provide attorneys reasonably acceptable to Harvard to defend against any actions brought or
filed against any Indemnitee hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. Licensee shall, at its own expense, provide attorneys reasonably acceptable to HHMI to defend
against any actions brought or filed against any HHMI Indemnitee hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. 

10.2. Insurance. 

10.2.1. Beginning at the time any Licensed Product is being commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by Licensee, or by an Affiliate, Sublicensee or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[**] per incident and $[**]
annual aggregate and naming the Licensors and HHMI as additional insureds. During clinical trials of any Licensed Product, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such equal or
such lesser amount as Harvard shall require, naming the Licensors and HHMI as additional insureds. Such commercial general liability insurance shall provide; (a) product liability coverage and (b) broad form contractual liability coverage
for Licensors’ and HHMI’s indemnification under this Agreement. 
 10.2.2. If Licensee elects to self-insure all or part of
the limits described above in Section 10.2.1 (including deductibles or retentions which are in excess of $[**] annual aggregate) such self-insurance program must be acceptable to Harvard and the Risk Management Foundation

  
 - 31 - 

 
of the Harvard Medical Institutions, Inc. in their sole discretion. The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with
respect to its indemnification under this Agreement. 
 10.2.3. Licensee shall provide Harvard with written evidence of such
insurance upon request of Licensors. Licensee shall provide Licensors with written notice at least [**] days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing
comparable coverage within such [**] day period, Licensors shall have the right to terminate this Agreement effective at the end of such [**] day period without notice or any additional waiting periods. 

10.2.4. Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement
during: (a) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by Licensee, or an Affiliate, Sublicensee or agent of Licensee; and (b) a
reasonable period after the period referred to in (a) above which in no event shall be less than [**] years. 
  

	11.	Term and Termination. 

 11.1. Term. The term of this Agreement shall commence on
the Effective Date and, unless earlier terminated as provided in this Section 11, shall continue in full force and effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last-to-expire Valid
Claim covering the making, using or selling of such Licensed Product in such country. 
 11.2. Termination. 

11.2.1. Termination Without Cause. Licensee may terminate this Agreement upon thirty (30) days prior written notice to
Licensors. 
 11.2.2. Termination for Default. 

11.2.2.1. In the event that either Licensor commits a material breach of its obligations under this Agreement and fails to cure that
breach within [**] days after receiving written notice thereof from Licensee, Licensee may terminate this Agreement immediately upon written notice to Licensors. 

11.2.2.2. In the event that Licensee commits any material breach of its obligations under this Agreement (other than any breach
specifically described in Sections 11.2.2.3 or 11.2.2.4 below, or any material breach of Section 5.1) and fails to cure that breach within [**] days after receiving written notice thereof, Licensors may terminate this Agreement immediately upon
written notice to Licensee. 
 11.2.2.3. In the event Licensee fails to pay any amounts due and payable to Harvard hereunder, and
fails to make such payments within [**] days after receiving written notice of such failure, Harvard may terminate this Agreement immediately upon written notice to Licensee; provided that, if a Bona Fide Dispute exists between the parties as to
whether such amounts are due or owing, the [**] day period shall be tolled pending resolution of such dispute in 

  
 - 32 - 

 
accordance with the procedure set forth in clauses (i) through (iv) below. For the purposes of this Section 11.2.2.3, a “Bona Fide Dispute” shall be deemed to exist if
Licensee believes in good faith that it is not required to pay the sums in dispute and has placed the sums in dispute or other sufficient collateral in escrow in a manner reasonably acceptable to Harvard until the dispute is resolved. 

(i) In the event of a Bona Fide Dispute, upon written request by either party to the other party, the parties shall promptly negotiate in
good faith to appoint a mutually acceptable, disinterested, conflict-free individual not affiliated with either party to resolve such dispute (an “Arbitrator”). If the parties are not able to agree within [**] business days after the
receipt of the written request in the immediately preceding sentence, either party may request the appointment of an arbitrator on a expedited basis by the American Arbitration Association, sitting in Boston, with relevant commercial experience,
from its panel of arbitrators. Arbitration shall be conducted in Boston, MA under the commercial Arbitration Rules of the American Arbitration Association. Subject to clause (iv) below, the fees and costs of the Arbitrator shall be shared
equally (50%) by the parties. 
 (ii) Within [**] days after the designation of the Arbitrator, the parties shall each simultaneously
submit to the Arbitrator and to each other a written statement of their respective positions on such disagreement. Each party shall have [**] days from receipt of the other party’s statement to submit a written response, which shall include any
technical information in support of such response. The Arbitrator shall have the right to meet with the parties, either alone or together, as necessary to make a determination. 

(iii) No later than [**] days after the designation of the Arbitrator, the Arbitrator shall render his/her decision, and s/he shall provide
the parties with a written statement setting forth the basis of the decision. 
 (iv) In the event that the Arbitrator rules in favor of
Harvard, Licensee shall reimburse Harvard in full for Harvard’s share of the fees and costs of the Arbitrator and for all of Harvard’s reasonable out-of-pocket expenses (including attorneys fees) incurred in connection with the arbitration
proceedings. In addition, Licensee shall pay Harvard interest on the amount awarded, if any, in accordance with Section 7.4. 

11.2.2.4. If Licensee defaults in its obligations under Section 10.2 to procure and maintain insurance or, if Licensee has in any
event failed to comply with the notice requirements contained therein, then Licensors may terminate this Agreement if Licensee has not cured such default or failure within [**] days of written notice thereof from Licensors. 

11.2.3. Diligence. Harvard shall have the right to terminate this Agreement in accordance with the provisions of Section 5.5. 

11.2.4. Bankruptcy. Licensors may terminate this Agreement upon notice to Licensee if Licensee is adjudged insolvent or bankrupt,
applies for judicial or extra-judicial settlement with its creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy appointed by reason of its
insolvency, or in the event an involuntary bankruptcy action is filed against Licensee and not dismissed within ninety (90) days, or if Licensee becomes the subject of liquidation or dissolution proceedings or otherwise discontinues doing
business generally. 

  
 - 33 - 

 11.3. Effect of Termination. 

11.3.1. Termination of Rights. Upon termination of this Agreement by any party pursuant to any of the provisions of Section 11.2:
(a) the rights and licenses granted to Licensee under Section 4 shall terminate and all rights in and to and under the Licensed Patent Rights shall revert to Harvard, DFCI or Licensors (as applicable); (b) Licensee, its Affiliates and
Sublicensees shall not be entitled to make any further use whatsoever of or practice the Licensed Patent Rights nor shall Licensee, its Affiliates or Sublicensees develop, make, have made, use, offer to sell, sell, have sold, import, export,
otherwise transfer physical possession of or otherwise transfer title to Licensed Products; and (c) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense; provided, however, that, for
each Sublicensee that meets the requirements of Section 4.2.2.3(a), upon termination of the Sublicense agreement with such Sublicensee, each such Sublicensee shall have the right to obtain a direct license from Licensors as set forth in
Section 4.2.2.3. 
 11.3.2. Accruing Obligations. Termination of this Agreement shall not relieve the parties of obligations
occurring prior to such termination, including obligations to pay amounts accruing hereunder up to the date of termination. 
 11.4.
Survival. The parties’ respective rights, obligations and duties under Sections 4.2.2.3, 6.1.2, 7.3, 7.8, 9, 10, 11, 12.3, 12.4, 12.6, 12.7, 12.11, 12.12, 12.14, 12.16 (for the period set forth therein) and 12.17, together with any accrued
but unpaid payment obligations shall survive any expiration or termination of this Agreement. In addition, Licensee’s obligations under Section 6.6 (and its corresponding obligations under Section 7.1.1) with respect to Sublicenses
granted prior to termination of the Agreement shall survive termination. 
  

	12.	Miscellaneous. 

 12.1. Preference for United States Industry. During the period of
exclusivity of this license in the United States, Licensee shall, to the extent required by law, cause any Licensed Product produced for sale in the United States to be manufactured substantially in the United States. If Licensee notifies Licensors
that Licensee desires to seek a waiver of the preference for United States industry from the applicable agency of the United States government, Licensors shall reasonably cooperate with Licensee, at Licensee’s expense, in seeking such waiver.

 12.2. No Security Interest. Licensee shall not enter into any agreement under which Licensee grants to or otherwise creates in any
third party a security interest in this Agreement or any of the rights granted to Licensee herein. Any grant or creation of a security interest purported or attempted to be made in violation of the terms of this Section 12.2 shall be null and
void and of no legal effect. 
 12.3. Disclosure of Agreement. Neither party will make any public announcement regarding this
Agreement without the prior written approval of the other party, provided that each party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of its legal counsel, to comply with applicable laws, or in
confidence to its current or prospective partners, investors, accountants and agents. 

  
 - 34 - 

 12.4. Use of Name. Licensee shall not, and shall ensure that its Affiliates and
Sublicensees shall not, use the name or insignia of Harvard or DFCI or the name of any of Harvard’s or DFCI’s officers, faculty, other researchers or students, or any adaptation of such names, in any advertising, promotional or sales
literature, including without limitation any press release or any document employed to obtain funds, without the prior written approval of Harvard or DFCI, as applicable. This restriction shall not apply to any information required by law to be
disclosed to any governmental entity. 
 12.5. Supersedes Original Agreement; Entire Agreement. The parties acknowledge and
agree that the Original Agreement is hereby terminated in its entirety as of the Effective Date. As of the Effective Date, this Agreement replaces and supersedes the Original Agreement in its entirety. Accordingly notwithstanding anything in the
Original Agreement to the contrary none of the terms or conditions of the Original Agreement shall survive such termination. Notwithstanding the foregoing, any of Licensee’s obligations under the Original Agreement which accrued prior to the
Effective Date will survive termination of the Original Agreement. This Agreement is the sole agreement with respect to the subject matter hereof and, except as expressly set forth herein, supersedes all other agreements and understandings between
the parties with respect to the same. 
 12.6. Notices. Unless otherwise specifically provided, all notices required or
permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by facsimile 

  
 - 35 - 

 
or certified mail, return receipt requested, to the following addresses, unless the parties are subsequently notified of any change of address in accordance with this Section 12.6: 

 

			
	If to Licensee:	  	 Aileron Therapeutics, Inc.
 840 Memorial
Drive, 2nd Floor
 Cambridge, MA 02142

 
 Attn: Chief Executive Officer

		
	If to Harvard:	  	 Office of Technology Development
 Harvard
University
 Holyoke Center 727
 1350 Massachusetts Avenue

Cambridge, Massachusetts 02138
  

Attn.: Chief Technology Development Officer

		
	If to DFCI:	  	 Office of Research and Technology Ventures

Dana-Farber Cancer Institute, Inc.
 44 Binney Street, BP304E

Boston, MA 02115
  

Attn: Vice President, Research and Technology Ventures

 Any notice shall be deemed to have been received as follows: (i) by personal delivery, upon receipt;
(ii) by facsimile, one business day after transmission or dispatch; (iii) by airmail, seven (7) business days after delivery to the postal authorities by the party serving notice. If notice is sent by facsimile, a confirming copy of
the same shall be sent by mail to the same address. 
 12.7. Governing Law and Jurisdiction. This Agreement will be governed by, and
construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined
by the law of the country in which the patent shall have been granted. Any dispute will be resolved by the state courts of the Commonwealth of Massachusetts or the federal courts of the District of Massachusetts, without restricting any right of
appeal. 
 12.8. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
legal representatives, successors and permitted assigns. 
 12.8. Headings. Section and subsection headings are inserted for
convenience of reference only and do not form a part of this Agreement. 
 12.9. Counterparts. This Agreement may be executed
simultaneously in two or more counterparts, each of which shall be deemed an original. 
 12.10. Amendment; Waiver. This Agreement
may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of any party at any

  
 - 36 - 

 
time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce the same. No waiver by either party of any condition or of the breach
of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of
this Agreement. 
 12.11. No Agency or Partnership. Nothing contained in this Agreement shall give any party the right to bind
another, or be deemed to constitute the parties as agents for each other or as partners with each other or any third party. 
 12.12.
Assignment and Successors. This Agreement may not be assigned by Licensee without the consent of Harvard, which consent shall not be unreasonably withheld, except that Licensee may, without such consent, assign this Agreement and the rights,
obligations and interests of such party to any of its Affiliates, to any purchaser of all or substantially all of its assets or business to which the subject matter of this Agreement relates, or to any successor entity resulting from any merger or
consolidation of Licensee with or into such entity. Except pursuant to a written agreement wherein such assignee acknowledges the terms and conditions of this Agreement and agrees to be bound by the applicable terms hereof and with prior written
notice to Licensee identifying the proposed assignee, neither Licensor shall assign any of its rights to the Licensed Patent Rights to any third party. 

12.13. Force Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party,
including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement
with reasonable dispatch whenever such causes are removed. 
 12.14. Interpretation. The parties hereto acknowledge and agree that:
(i) each party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting
party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to both parties hereto and not in favor of or against either party, regardless of which party
was generally responsible for the preparation of this Agreement. 
 12.15. Severability. If any provision of this Agreement is or
becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected. 

12.16. Confidentiality. The following provisions are intended to protect any confidential or proprietary information disclosed by
Licensee in writing to Harvard or DFCI pursuant to Section 4.2.3, 5.3 or 7 (collectively, “Confidential Information”). 

12.16.1. Obligations. For a period of [**] years after disclosure of any portion of Confidential Information, the receiving party shall
(i) maintain such Confidential Information in strict confidence, except that the receiving party may disclose or permit disclosure of any Confidential Information to those persons who are obligated to maintain the confidential

  
 - 37 - 

 
nature of such Confidential Information and who need to know such Confidential Information for the purposes of this Agreement: (ii) use such Confidential Information solely for the purposes
of this Agreement; and (iii) allow its trustees or directors, officers, employees, consultants, auditors, and advisors to reproduce the Confidential Information only to the extent necessary for the purposes of this Agreement with all such
reproductions being considered Confidential Information. 
 12.16.2. Exceptions. The obligations of the receiving party under
Section 12.16.1 above shall not apply to the extent that the receiving party can demonstrate that certain Confidential Information (i) was generally available to the public prior to the time of its disclosure under this Agreement;
(ii) was generally available to the public after the time of its disclosure under this Agreement through means other than an unauthorized disclosure resulting from an act or omissions by the receiving party, (iii) was independently
developed or discovered by the receiving party without use of the Confidential Information; (iv) is or was disclosed to the receiving party at any time, whether prior to or after the time of its disclosure under this Agreement, by a third party
having no fiduciary relationship with the disclosing party and having no obligation or confidentiality with respect to such Confidential Information to disclosing party; or (v) is required to be disclosed to comply with applicable laws or
regulations, or with a court or administrative order provided that the disclosing party receives reasonable prior written notice of such disclosure. 

12.17. Third Party Beneficiary Status. 

12.17.1. HHMI is not a party to this Agreement and has no liability to any licensee, sublicensee, or user of anything covered by this
Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

12.17.2. Each Sublicensee is an intended third-party beneficiary of Section 4.2.2.3 with the right to enforce the same. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 - 38 - 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above. 
  

									
	President and Fellows of Harvard College	 		 	Dana Farber Cancer Institute
					
	By:	 	 /s/ Isaac T. Kohlberg
	 		 	By:	 	 /s/ Anthony A. del Campo

	Name:	 	Isaac T. Kohlberg	 		 	Name:	 	Anthony A. del Campo, M.B.A.
	Title: 	 	 Senior Associate Provost
 Chief Technology
Development Officer
 Office of Technology Development
 Harvard
University
	 		 	Title:	 	 Vice President
 Research and Technology
Ventures
 Dana Farber Cancer Institute
 4/5/2010

		
	Aileron Therapeutics, Inc.	 	
					
	By:	 	 /s/ Joseph A. Yanchik III
	 		 		 	
	Name:	 	Joseph A. Yanchik III	 		 		 	
	Title:	 	CEO	 		 		 	
		 	Aileron Therapeutics, Inc.	 		 		 	

  
 - 39 - 

 EXHIBIT 1.2 

[**] PATENT RIGHTS 
 [**] 

  
 - 40 - 

 EXHIBIT 1.7 

DEVELOPMENT MILESTONES 
  

	A.	General Development Milestone 

 [**]. 

 

	B.	[**] Development Milestone 

 [**]. 

 

	C.	[**] Development Milestones 

 [**] 

  
 - 41 - 

	D.	[**] Development Milestones, [**] Development Milestones and p53 Development Milestones 

[**] 

  
 - 42 - 

 EXHIBIT 1.8 

DEVELOPMENT PLAN 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of two pages were omitted. [**]. 

  
 - 43 - 

 EXHIBIT 1.15 

HARVARD PATENT RIGHTS 
 [**] 

  
 - 44 - 

 EXHIBIT 1.24 

LICENSORS PATENT RIGHTS 
 [**] 

  
 - 45 - 

 EXHIBIT 1.26 

[**] PATENT RIGHTS 
 [**] 

  
 - 46 - 

 EXHIBIT 1.28 

p53 PATENT RIGHTS 
 [**] 

  
 - 47 - 

 EXHIBIT 1.34 

[**] POLY PEPTIDE PATENT RIGHTS 

[**] 

  
 - 48 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]